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Abstract 
Background 
Glioblastoma Multiforme (GBM) is the most commonly occurring tumour of the central nervous 
system (CNS). Currently GBM is considered an incurable malignancy with patients 
experiencing abysmal life expectancies. Lack of progress in the discovery of novel treatments 
has led to the repurposing of existing licenced medication as a possible alternative option. 
Metformin is from the biguanide family of drugs and is the most common medication used in 
the treatment of type 2 diabetes. Clinical studies have reported that, in type 2 diabetic 
patients, metformin might reduce cancer incidence and severity. Currently, metformin is being 
assessed in clinical trials as a treatment for a range of cancer types including GBM. The 
antineoplastic mechanisms utilized by metformin and other biguanides have not been fully 
elucidated.  
Methods 
The effects of metformin were evaluated, alone and in combination with other agents, on a 
panel of GBM cell cultures. Functional analysis of metformin mechanism of action was 
assessed through measurement of apoptosis, depolarisation of the mitochondria membrane, 
caspase pathway activation, cell cycle progression and the expression levels of micoRNAs.  
Results 
Analysis of fourteen GBM cell cultures showed a cytotoxic response to metformin that was 
significantly linked to the P53 status (p=0.0024). In combination drug testing, one of the four 
drugs showed a synergistic pairing with metformin. The kinase inhibitor sorafenib, showed 
synergism (CI ≤ 1) in eight GBM cell cultures. Flow cytometry of metformin treated GBM cells 
showed no significant increase (p>0.005) in apoptotic cell populations. Caspase 3/7 levels 
showed no significant increase post metformin treatment (p>0.005). Metformin caused 
depolarisation of the mitochondrial membrane in six GBM cell cultures. Four microRNAs were 
shown to have expression levels changes post-metformin treatment. Upregulation of 
expression was identified in miR-140, miR-192, let-7c. Downregulation was identified in miR-
222.  
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Conclusions  
Metformin was shown to have cytotoxic effect on a GBM cell cultures and has potential as 
GBM therapeutic agent and possible treatment synergy with sorafenib. The significance of P53 
status to metformin sensitivity may suggest that its use should be directed to a sub-set of 
GBM patients. Mechanism for cell death by metformin was shown not to rely on apoptotic 
pathways but caspase 3/7 independent depolarization of mitochondrial cell membranes and 
cell cycle arrest. Investigations into autophagy may help to further define the pathways 
metformin is utilising to promote cell death. The impact of metformin on the expression profile 
of miR-222, miR-192 and let-7c is in line with clinical studies of other cancer types.  This 
shows possible insight into the cancer independent actions of metformin.  The interplay 
recorded between glucose availability and cell death indicates a possible key factor in the 
utilisation of metformin as a therapeutic agent. This finding may warrant the addition of 
dietary control regimes in clinical trials to maximise metformin efficacy.  This work highlights 
the strong potential for biguanides in the development of new drug treatments and in 
expanding our knowledge of cancer metabolism.  
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1 Introduction 
1.1 Cancer 
Cancer is one of the leading causes of morbidity and mortality in the world 
(Siegel et al., 2016). It is a disease that affects all ages and all populations. 
The data published in 2014 by the WHOs international Agency for Research 
on Cancer (IARC) estimated, that at current rates, approximately 14 million 
new cases of malignant tumours would be reported, and 6.2 million people 
will die of cancer annually (McGuire, 2016). The figures have increased in 
recent years however this can be partially attributed to the development of 
newer, more reliable methods of cancer detection (Christopher et al., 2014; 
Torre et al., 2015; Siegel et al., 2016; Philips et al., 2018). 
1.2 Brain tumours  
Tumours of the brain and the CNS constitute some of the rarest cancer types, 
in 2015 CNS tumours represented 1.4% of all new cancer diagnosis, however 
they were also the cause of 2.6% of cancer related mortalities (Howlader et 
al., 2016). Recent studies indicate a sustained and significant rise in GBM 
prevalence across all ages that cannot be attributed to any one risk factor, 
and which also suggests the cause maybe with widespread environmental 
and/or lifestyle factors (Philips et al., 2018). Cancer mortality is especially 
important in relation to children, which account for 30% of cancer deaths 
(McNeill et al., 2016). For adolescents in the USA (aged birth-19 years) from 
2016 onwards, brain tumours surpassed leukaemia as the leading cause of 
cancer death (Rebecca et al., 2016).  
Glioma are CNS tumours that originate from glial cells and categorized with 
grades I through IV based on the severity. Grades I-III are “low grade” 
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gliomas and are characterized by slower growth rates. Grade IV are high grade 
tumours that are aggressive and malignant commonly described as 
glioblastoma multiforme (GBM) (Eckel-Passow et al., 2015).  
1.2.1 GBM 
Though the diagnosis of a GBM is rare, it is the most common type of brain 
tumour (69%) with poor patient outcomes (Ohgaki and Kleihues, 2007; 
Howlader et al., 2016). Acquisition of a GBM is universally and rapidly fatal. 
The expected median survival for a GBM patient is around 15 months, with 2 
years survival less than 35% (Bleeker et al., 2012). GBM cells show a high 
amount of morphological variation. The cell silhouette can vary from spindle-
shaped to polygonal with an overly pigmented chromatin (Schultz et al., 2005. 
Nuceli are distinct but have irregular membranes and are typically elongated. 
Binucleated and multinucleated cells can also be found within a GBM tumour 
(Schultz et al., 2005). A main pathological feature that separates GBM from 
lower grade astrocytoma are necrotic foci normally with peripheral pseudo-
palisading cellular areas (Kleihues and Sobin, 2000; Brat and Van Meir, 2004).  
1.2.2 GBM subtyping  
Historic methods of classification relied primarily on pathologists staining and 
identifying histological appearance from a surgical dissection, the techniques 
date back almost 100 years (Bailey and Cushing, 1925). Modern classification 
of CNS tumours follows WHO guidelines, the first edition of which was released 
in 1979. An update to the fourth edition guidelines was released in May 2016. 
This update relied more on molecular subtyping to characterise different sub 
groups (Arevalo et al., 2017). The methodology of this categorization is 
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demonstrated in figure 1.1. The key attribute for determination within the GBM 
sub-group is now based on molecular analysis, focusing on tumours IDH 
mutation status. The majority of GBM (>90%) present as primary tumours in 
adults (Ohgaki and Kleihues, 2007).  GBM are labelled as primary or secondary 
based on the source of origination. Primary GBM are tumours that develop de 
novo, without any sign of developing from a prior tumour. Secondary GBM are 
generated through development of a lower grade astrocytoma. 
However, GBM tumours are highly heterogeneous entities with a range of 
possible mutations and molecular markers. Isocitrate dehydrogenase (IDH) 
catalyses the oxidative decarboxylation of isocitrate and is one of the major 
modern determinants in glioma stratification and identification. IDH mutations 
are primarily found in secondary GBM and rarely in primary (Hai et al., 2009; 
Korshunov et al., 2017). Identification of the mutation is a good prognostic 
marker but not an overall predictive marker for patient survival (van den Bent 
et al., 2010). Tumour protein (TP53) is a 53-kilodalton tumour suppressor 
protein. It is primary function is regulation of DNA binding proteins that 
prevent the acquisition of mutations (Kandoth et al., 2013). TP53 is further 
discussed in 1.3.3. Phosphatase and tensin homolog (PTEN) is a tumour 
suppressor protein that regulates the AKT pathway controlling cell growth, 
survival and cell cycle progression. In GBM PTEN deficiency has been linked 
to promoting malignant growth through macrophage recruitment, and 
therapeutic resistance through histone regulation (Benitez et al., 2017; Chen 
et al., 2018). Epidermal growth factor receptor (EGFR) is a transmembrane 
protein that is often found to be mutated in GBM, leading to the promotion of 
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more aggressive phenotypes and uncontrolled cell division (Monga et al., 
2017; Xu et al., 2017).  1p/19Q co-deletion is referring to the loss of the short 
arm on chromosome 1 and the long arm of chromosome 19. It is a genetic 
hallmark of oligodendrogliomas, but the loss of these regions has also been 
proven prognostically favourable for GBM patients (Hill et al., 2003). O6-
methylguanine–DNA methyltransferase (MGMT), further discussed in 1.3.2.1, 
is an important predictive marker in clinical settings that is linked to the 
effectiveness of the key GBM, treatment temozolomide (TMZ) (Molenaar et 
al., 2014). 
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Figure 1.1 WHO methodology for the classification of adult gliomas. New WHO classification 
flow chart for the intracranial adult gliomas. Primary stratification based on histological separation 
followed by IDH mutation status. Diffuse glioma then segregated based off co-deletion present on 
chromosome 1p/19q or the mutation of ATRX/TP53.  
Oligoastrocytomas were omitted due to rarity. 
DDx, Differential diagnosis; IDH, Isocitrate dehydrogenase; ATRX, TP-dependent helicase ATRX; 
TP53, Tumour protein p53; NOS, not otherwise specified (Arevalo et al., 2017). 
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1.3 Treatment of GBM 
1.3.1 Treatment methods 
Primary treatment method for GBM is a multi-modal response including 
surgical resection, whole brain radiation therapies (60Gy as standard) and 
chemotherapy (Stupp et al., 2015). The main chemotherapeutic agent used in 
the treatment is TMZ, an alkylating agent. First introduced in 2005 as part of 
the STUPP protocol; TMZ when combined with standard radiotherapy 
increased 2-year-survival from 10.4% to 26.5% in GBM patients (Stupp et al., 
2005). In addition to TMZ, other actively used chemotherapy agents include 
platinum compounds; irinotecan and etoposide, nitrosureas: carmustine 
(BCNU) and lomustine (CCNU) and vincristine, part of the PCV regimen 
(Alifieris et al., 2015). Many of the treatments are commonly linked to strong 
side effects that impair patient wellbeing including nausea and vomiting 
(Aapro and Alberts, 1981; Goldberg et al., 2004; Jordan et al., 2005; Hesketh, 
2008). 
1.3.2 Mechanisms of resistance in GBM  
GBM are characterized as having high genetic heterogeneity that normally 
leads them to have many intratumoral phenotypes (Meyer et al.,2015). Due 
to this non-homologous make up of GBM, the tumours are highly resistant to 
chemotherapy agents and have many mechanisms that act against successful 
treatment. 
1.3.2.1 DNA repair through MGMT methylation  
The DNA management and repair gene MGMT has been heavily linked with 
GBM cell survival (Bell et al., 2018). MGMT functions by removing the O6 
position of guanine, this can limit the effectiveness of alkylating agents for 
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example TMZ (Esteller et al., 2000). Methylation of MGMT is common in GBM 
(approximately 45%) and this is linked with more favourable patient survival 
(Hegi et al., 2005). The methylation and silencing of MGMT has been long 
proposed as a prognostic marker. However, the accuracy of this as the 
independent predictive factor for GBM has often been debated (Fietkau et al., 
2013). Recent methods combing Isocitrate dehydrogenase 1 (IDH1) data with 
MGMTs has shown improvements in predictive accuracy (Remco et al., 2014).  
1.3.2.2 Angiogenesis  
As with most tumour cells, GBM cells are very resource intensive, requiring 
large amounts of energy to maintain a functional metabolism (Zhao et al., 
2011). The primary resource for tumour cells is glucose, used as fuel for 
glycolysis and leads to an over production of lactate (Goodwin et al., 2015). 
This is part of a reprogramming of cellular metabolism to produce a system 
defined as the Warburg effect (Poteet et al., 2013). To maintain high rates of 
tumour growth, increased blood supply though vascularisation is needed. GBM 
are one of the most vascularised tumour types and so large amounts of VEGF 
is produced to induce angiogenesis in the surrounding tissue (Soda et al., 
2013). Bevacizumab is an anti-angiogenesis drug that has had success in 
reducing tumour growth and increasing progression-free survival (Narita, 
2015). However, patients go on to develop resistance to the drug after several 
treatments and so the impact on overall patient survival is minimal (Lu and 
Bergers, 2013). Anti-angiogenesis drugs are expected to play a role as part of 
combination therapies and are currently being combined with other treatments 
in future clinical trials (Schiff et al., 2018). 
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1.3.2.3 Blood brain barrier 
The blood brain barrier (BBB) is a key defence mechanism within the body 
designed to protect the flow of potentially hazardous agents from reaching the 
brain, but it is also often a hindrance to the ability to deliver drugs to a target 
tumour (Oberoi et al., 2015). Structurally the BBB is made up of several layers 
of cells, the core of which is capillary endothelial cells lined by basal lamina 
(Feustel et al., 2012). The specialised capillary cells possess multi-molecule 
complex structures built up of transmembrane and membrane associated 
proteins. The tight junctions (TJ) are built between adjacent cells, the 
complexes tightly control transport and signalling out of the capillary (Luissint 
et al., 2012). Supplementing the endothelial cells are astrocytes and pericytes. 
The end-feet of astrocyte cells sheath the BBB but do not act as barrier, 
instead they function by supporting the endothelial cells and TJs (Praveen et 
al., 2004; Hong et al., 2015). Pericytes are intricately linked into brain capillary 
endothelium and are vitally important in regulation of endothelial cell 
expression and polarisation of astrocyte end-feet (Lai et al., 2005; Armulik et 
al., 2010).  As one complete structure the BBB possess several transport 
mechanisms to move required molecules into the brain tissue, a list of 
mechanism is given in figure 1.3 (Wong et al., 2013).  
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Figure 1.2 Composition and structure of the BBB. The BBB is a multi-layered barrier, 
regulating all signalling and transport of molecules into brain tissue. All material exchange 
happens at the endothelial cells in capillaries which are protected by complex structures 
called tight junctions. Interspersed among the endothelial cells are pericytes that help 
regulate the expression levels of near-by endothelial and astrocytic cells. They also has a 
role in renewing the BBB. The BBB is then wrapped in the feet of astrocyte cells, the 
astrocytes regulate and maintain the BBB. (Yamazaki et al., 2017) 
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The development of a tumour in CNS can have an adverse effect of the 
structure and integrity of the BBB.  At the blood brain tumour barrier (BBTB) 
the blood vessels become “leaky” due to abnormal growth and potentially 
produce easier vascular access to the tumour site (Kemper et al., 2006). This 
is achieved by glioma cells invading perivascular space and displacing 
astrocytic end feet from the BBB (Watkins et al., 2014). As the barrier 
Figure 1.3 Transport mechanisms across the blood brain barrier. The BBB possess 
several mechanisms to help the exchange of required molecules into the brain tissue.  Small 
ions and water can cross the barrier through use of ion channels. Small lipid soluble molecules 
can cross through the phospholipid membranes of the BBB cells. All other molecules requiring 
transport in and out of the brain tissue require support from transport proteins and solute 
carrier systems.  (Wong et al., 2013) 
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degrades, pericyte numbers reduce, increasing permeability of the BBB to 
water and molecules by endothelial transcytosis (Armulik et al., 2010). This 
damage should be a boon to tumour drug delivery, but the invasive potential 
of GBM leads to cells migrating away from the BBTB. This forces cells into 
areas where protection from drugs is afforded by still functional sections of 
the BBB (Van Tellingen, 2015).  Gliomas also show up-regulation and 
expression of multidrug resistance protein-1 (MDR-1), part of the ATP-binding 
cassette transporter superfamily. The increased expression of this protein 
allows cancer cells to remove many chemotherapeutic agents from the cell 
(Munoz et al., 2014; Alifieris and Trafalis, 2015).   
1.3.3 Tumour genetics  
Tumours operate through a range of genetic mutations. The identification of 
tumour promoting genes and tumour suppressors has been and key in 
understanding the multifaceted impacts and progression of diffuse glioma.  
1.3.3.1 GBM Genome project 
GBM, like all human cancer cells, possesses multiple chromosomal 
abnormalities, nucleotide substitutions and divergent epigenetic alterations 
(Cancer Genome Atlas Research Network, 2008). Long term research projects 
have been established with the goal of using large scale multi-dimensional 
analysis to understand and map the variations. The Cancer Genome Atlas 
(TCGA) is a public resource that collates and catalogues genetic data from 
human tumours (Kim et al., 2018). As part of the initial pilot study, the first 
tumour type analysed through TCGA was GBM (Tomczak et al., 2015). From 
this initial data analysis, key GBM features were determined. Deregulation of 
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several pathways including p53, retinoblastoma protein (RB) and 
RTK/RAS/PI3K. A summary of this data is shown in figure 1.4. Further analysis 
has highlighted alterations in the epidermal growth factor receptor (EGFR), 
neurofibromatosis type 1 gene (NF1) and isocitrate dehydrogenase 1 (IDH1) 
(Verhaak et al., 2010). Analysis of DNA methylation levels in GBM data has 
caused the creation of the glioma-CpG island methylator phenotype (G-CIMP). 
Promoter regions of genes can be rich in cytosine and guanine paired bases, 
referred to as 5'—C—phosphate—G—3' (CpG) islands and hyper methylation 
of them leads to gene silencing. G-CIMP was identified in a subgroup of 
gliomas with a specific DNA methylation status (Noushmehr et al., 2010).  
The analysis of the database has also identified other smaller subsets of GBM. 
Less than four percent of tumours displayed chromosomal translocation of 
tyrosine kinase domains of fibroblast growth factor receptor (FGFR) genes into 
coding domains of the transforming acidic coiled-coil (TACC) gene. This led to 
the creation of FGFR-TACC oncogenic fusion protein that localised to mitotic 
spindle of astrocytes causing aneuploidy (Singh et al., 2012).     
TCGA data has also identified microRNAs that regulate and control GBM 
development. Two miRNAs, miR-148a and miR-31 have been identified to 
promote tumour growth and regulate angiogenesis through meditation of 
hypoxia-inducible factor 1-alpha (Wong et al., 2015). 
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Figure 1.4 Key GBM signalling pathway dysregulation. Data on the genetic 
alteration in signalling pathways analysed by the TCGA. Three pathways were identified 
as having frequent aberration and signalling changes, (a) RTK/RAS/PI3K, (b) p53 and (c) 
CDKN2A. Red coloured objects signifies activating genetic alterations and blue signifies 
inactivating alterations. The darker the shade of the object, the high the 
frequency/percentage that the object was shown to be altered. Percentage chance of each 
section being altered is described alongside it. Each pathway shown has a box describing 
the overall percentage chance that pathway signalling was affected. (Cancer Genome Atlas 
Research Network, 2008). 
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1.3.3.2 Genetic mutations 
Tumour protein 53 (P53) was originally labelled as a proto-oncogene, this was 
until correct identification of the wild-type form (Finlay et al., 1989). Now P53 
is known as the most common mutation to be found in all human cancers 
(Kandoth et al., 2013). The gene is an important tumour regulator and 
suppressor. It functions through a range of mechanisms that include detection 
of DNA damage, G1/S cell cycle arrest and ultimately apoptosis. P53 
upregulation and activation occurs in the presence of DNA damage where P53 
will bind to DNA (Basu and Murphy, 2016).  Mutations of P53 can cause 
reductions in expression and prevent it binding to DNA (Muller and Vousden, 
2013). This then leads to a large gain of function for the tumour cell. The 
benefits can be cancer specific but are known to include increases in invasion, 
migration, proliferation, progression of cell cycle, drug resistance, colony 
formation, angiogenesis and overall cell survival (Muller and Vousden, 2014). 
In GBM, P53 is mutated 25-30% in primary tumours and 60-70% in secondary 
tumours but studies have yet to show an association with overall GBM 
prognosis (England et al., 2013). In addition to tumour suppression roles, in 
GBM P53 has been shown to be a regulator of the mevalonate metabolic 
pathway (Laezza et al, 2015). In a variety of cancers phosphatase and tensin 
homolog (PTEN) is a commonly mutated oncogene. In glioma, loss of PTEN is 
associated with immune-resistance and, alongside mutations in P53, it can 
have an impact on glioma cell survival and tumorigenesis (Parsa et al., 2007; 
Zheng et al., 2008). EGFR is a transmembrane protein that has key role in 
starting a signalling cascade that controls cell division (Delgado-Lopez and 
Corrales-Garcia, 2016). It is known to be amplified in 40% of GBM this leads 
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to increases in cellular proliferation and resistance to radiotherapy (Barker et 
al., 2001; William et al., 2017).  
1.4 Development of new treatments 
1.4.1 Clinical trials and drug development  
TMZ was first licensed for the treatment of GBM in 1999 and became a 
frontline treatment for GBM in 2005 where it remains to this day (Sansom, 
2009; Stupp et al., 2005). Currently novel drugs have to proceed through 
numerous clinical trials to prove safety and efficacy (Piantadosi, 2017). Only 
on completion of this can it be considered for mass deployment as an accepted 
treatment. Clinical trials and approval can take years and there is no guarantee 
a drug will gain successful approval.  Clinical trial design and execution in 
neuro-oncology has many challenging issues (Van Meir et al., 2010; Patrick et 
al., 2017). For GBM treatment there have been many clinical trial for a range 
of therapies, but none have achieved the levels of use and acceptance as TMZ. 
This issue may also have been compounded by the problem that in the last 
few decades, research and development productivity in drug discovery has 
been falling (Kola et al., 2004; Paul et al., 2010; Herper., 2012) This can be 
attributed partly to reductions in investment for high risk and low return drug 
development (Pammolli, et al., 2011).  Though modern invention of next 
generation sequencing the landscape of cancer trials has begun to change. 
Historically cancer has been solely categorized histologically by the site of 
origin, now the role of biomarkers relevant to different subtypes are being 
recognised and tumours are being acknowledged as heterogeneous entities 
requiring tailored treatments (Duffy et al., 2014; Korpanty et al., 2014; Tefferi 
et al., 2015). 
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1.4.2 Novel treatment methodologies 
New techniques are being developed to work alongside and augment existing 
treatments. The techniques have a variety of strategies to influence tumours 
ranging from utilizing electromagnetic energy fields to developing personalised 
patient treatments (Carlsson et al., 2014).  
1.4.2.1 Immunotherapy 
Immunotherapy models attempt to reprogram the patients innate immune 
system to enable it to target and combat the tumour. Due to the complex 
nature of immune responses, many potential effectors can be targeted. This 
includes cellular targets; adoptive and engineered T cell transfers, vaccination 
using both specific and non-specific antigens, and immunomodulation through 
pathway inhibitors (Reardon et al., 2014). DCVax-L is an example of an 
immunotherapy treatment methodology that is currently undergoing clinical 
trials. This a labour-intensive technique requires individual samples from a 
patient and involves presenting tumour biopsy to differentiated dendritic cells 
before returning them to the patient to induce T-Cell aggression (Prins et al., 
2011).  
1.4.2.2 Monoclonal antibodies 
The aim with monoclonal antibodies is to disrupt receptor signalling through 
targeting cell surface receptors and ligands. Inevitably this will prevent 
downstream pathway activation and further cellular signalling (Melstrom and 
sentovich, 2017). Avastin (Bevacizumab) is a monoclonal antibody that is 
designed to target VEGF and reduce angiogenesis at tumour sites. This 
strategy would produce a technique which would act independent of cancer 
type and cell profiling. Recent studies found however that adding avastin 
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added no benefit over the standard treatment regimen (Gilbert et al., 2014). 
In addition, the nutritional depletion caused by reduction of VEGF may trigger 
a tumour escape response and increase the number of invasive cells (de Groot 
et al., 2010).   
1.4.2.3 Small-molecule inhibitors 
Small-molecule inhibitors (SMI) are small structures designed to bind to or 
inhibit specific cellular pathways or act as epigenetic regulators. Several SMIs 
have been generated including caspase activating NSC-154829, Wnt Pathway 
inhibitor SEN461 and apoptotic inducer vacquionol-1 (Trembath et al., 2007; 
De Robertis et al., 2013; Kitambi et al., 2014). Due to expense and difficulty 
in construction, very few small-molecule inhibitors have made it to clinical trials 
and this limits further development on the molecules. However, the production 
and use of the materials was considered completely intractable twenty years 
ago. As technologies improve the development of new small-molecule 
inhibitors may produce new treatment options (Arkin et al., 2014). 
1.4.2.4 Mechanical solutions 
In addition to traditional medical drug developments future alternative 
therapies for brain tumours are being developed.  The Novocure Optune 
system is a wearable device that generates tumour treating fields (TTFields) 
within the patient’s brain. Tumour cells kept under high exposure to the anti-
mitotic electrical fields have a reduction in tumour cell division (Chaudhry et 
al., 2015). In GBM clinical trials TTFields have shown proven efficacy in 
management of tumours and the technology is now being developed for other 
tumour types (Burri et al., 2017). Thermotherapy utilises ferromagnetic 
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magnetic nanoparticles injected into a tumour to cause damage to surrounding 
cells. After injection into the patient, the nanoparticles are exposed to an 
alternating magnetic field that causes the production of heat at the tumour 
site (Jordan and Maier-Hauff, 2007). However, the future of this technology is 
unclear as the use of iron oxide nanoparticles is becoming increasingly 
controlled by regulating agencies to safeguard the use of the materials (Gobbo 
et al., 2015). Novel methods show possible new potential for GBM treatment 
however further testing and rigorous assessment is still required before it will 
be accepted as useable treatments by governing authorities.  
1.4.3 Repurposing existing medication 
The generation and approval of a new drug can take approximately $1-2 billion 
and take over 10 years to gain approval (Hong et al., 2011; Massey and 
Robertson, 2018).  Due to the length time that is required to complete rigours 
clinical trials for the approval of new medications, an alternative option is 
repurposing of existing licenced medication. The fact that a licenced 
medication is already deemed safe for human consumption and use the clinical 
trial process can be shortened. Repurposing of existing licenced drugs for the 
treatment of GBM is an alternative that could lead to faster implementation of 
new treatments (Abbruzzese et al., 2017). Two examples of approved 
repurposed medications include: sildenafil designed to treat angina but 
repurposed for erectile dysfunction and minoxidil a blood pressure medication 
now used to treat hair loss (Blume-Peytavi et al., 2016; Goldstein et al., 2016). 
For the treatment of GBM there are several candidates for potential 
 20 
   
repurposing, including ritanserin, disulfiram and metformin (Liu et al., 2012; 
Brenneman et al., 2016; Chae et al., 2016). 
1.5 Metformin 
Metformin, 1,1-dimethylbiguanide hydrochloride, is a biguanide drug that is 
used as the first-line medication in the treatment of type 2 diabetes (Maruthur 
et al., 2016). Currently metformin is the most commonly used oral 
antihyperglycemic agent in the US (Abdul-Ghani and Defronzo, 2017). Since 
2002, the WHO began listing metformin as an essential medication 
highlighting its efficiency and effectiveness (World Health Organization, 2002).  
1.5.1 History of metformin 
The origin of metformin lies in the chemical guanidine extracted from the plant 
Galega officinalis (Goats rue/French lilac). Historically it has been recorded 
that Galega officinalis was utilized to treat the symptoms of diabetes since 
1772 (Clifford, 2017). The guanidine extract was subsequently synthesised 
into a new chemical form called biguanide in the 1870s (Watanabe, 1918; 
Bailey and Clifford, 2004).  
The first synthesis of metformin from biguanide was in 1922 and experiments 
on animals occurred in 1929, where it was shown to reduce blood glucose 
levels of dogs and rabbits (Werner and James, 1922; Slotta and Tschesche, 
1929).  Metformin was later used for the treatment of diabetes in the United 
Kingdom from the 1950s (Hadden, 2005). Figure 1.2 displays the various 
biguanide molecular structures. It did not gain world-wide acceptance until 
the approval for clinical use in the USA in 1995. (Nattrass and Alberti, 1978; 
DeFronzo et al., 1995; Bailey and Turner, 1996). One of the delays for the 
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USA acceptance of biguanides was the risk of lactic acidosis, this was lessened 
only after phenformin and buformin became de-classified and removed from 
clinical use as diabetes medications in most countries (DeFronzo et al., 1995). 
The structures of the biguanide and similar compounds is shown in figure 1.5. 
To this day metformin is the only remaining legal biguanide for the treatment 
of type 2 diabetes worldwide that is also listed as a WHO essential medication 
(World Health Organization, 2017). In 2005, a study examining statistical data 
identified a possible link between type 2 diabetics using metformin and a 
reduced risk of cancer (Evans et al., 2005). In the following years, this link 
has been expanded to encompass a variety of tumour types (Pollak, 2012; 
Kasznicki et al., 2014). Currently, metformin is being tested in a range of 
clinical trials to assess its anti-cancer potential (Heckman-Stoddard et al., 
2017). This has led to the testing of metformin as a potential candidate to be 
repurposed for use in cancer treatment (Chae et al., 2016).   
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Figure 1.5 Structure of biguanides and similar classes of chemicals. Biguanide is the precursor 
molecule used in the development of all further biguanides that was originally made from the fusion 
of two guanidine. Guanidine was the original chemical extracted from plant Galega officinali, Mono-
guanidine and diguanidien are other derivatives of guanidine that were also used as potential diabetic 
treatments. Phenformin and Buformin have been banned for use in most countries. Proguanil is used 
as a treatment of malaria and metformin is used primarily to treat type 2 diabetes. (Bailey, 2017) 
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1.5.2 Safety and metformin 
1.5.2.1 Patient risks  
Metformin has had a long history of use and is used by millions on a daily basis 
(Bailey, 2017). However, metformin does have side effects and risks involved 
with its application.  The primary risk that has been established is lactic 
acidosis (DeFronzo et al., 2016). This was more prevalent in the two other 
clinically used biguanides phenformin and buformin (Ching et al., 2008, Bailey, 
2017). Comparatively, the risk of lactic acidosis following metformin treatment 
was the lowest of the three chemicals. Current measurements put cases of 
lactic acidosis caused by metformin at <10 per 100,00 patient-years 
(DeFronzo et al., 2016). The use of metformin is not advised for patients with 
even moderate renal impairment. Given the increased likelihood of excessive 
plasma metformin accumulation that could potentially trigger metformin 
induced lactic acidosis (DeFronzo et al., 2016). However, it has been noted 
the metformin-associated lactic acidosis may be inappropriate. The 
measurements of lactic acidosis and metformin blood concentration are not 
normally carried out immediately on patient admission and so the delay of the 
measurements resulting in a change of the patient’s metabolic status causing 
a potential bias on reporting actual numbers (Lalau and Kajbaf, 2014).  
1.5.2.2 Ecological impacts  
Metformin passes through and is excreted from the human body without being 
metabolised (Hassan and Carlton, 2018). The drug then enters the water 
supply still in the same form of which it was generated. The KWR research 
institute in Germany conducted a review on the prevalence of metformin in 
the surface water and found in rivers and lakes concentrations exceeding 
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1µg/L (Ter Laak and Baken, 2014). Metformin readily dissolves in water and 
sewage treatment plants are not currently set up to remove metformin. After 
passing through them it has been shown that microbial agents degrade 
metformin into guanylurea as shown in Figure 1.6 (Ter Laak and Baken, 2014). 
Kosma et al., (2015) reported levels of metformin were present in Greek waste 
waters but that levels of guanylurea were the higher ecological risk. The 
presence of both chemicals has been detected in the lakes, rivers and 
surrounding sea of Germany at ng/L doses (Trautwein et al 2014). Measurable 
concentrations of the levels indicate there is no natural process to degrade the 
elements further in the environment. Without treatment plants removing 
waste metformin from water supplies further could see metformin naturally 
enter food chains and become unknowingly consumed (Eggen and Lillo, 2012). 
The long-term risk of exposure to humans is minimal however varying effects 
have been seen in other species. Brassica napus cv. Sheik and Brassica rapa 
cv. Valo have shown a high affinity for metformin uptake in seeds (Eggen and 
Lillo, 2012). Carrots grown in soil concentrations of 6-10mg/kg dw saw 
negative effects on growth and development. Niemuth and Klapper (2015) 
showed that exposing fathead minnows to metformin concentrations in line to 
current post waste treatment effluents caused an increase in the generation 
of intersex organisms.  Hanisch et al., 2004 also evaluated the risk to the 
aquatic environment using the PEC/PNEC ratio and got a value above 1, 
indicating metformin as a low concern but potential risk compound for the 
environment. Currently there is no consensus as to the possible ecological 
ramification of metformin exposure to the environment. Data on acute and 
 25 
   
chronic guanylurea toxicity are very limited (Laak and Baken, 2014) and so 
further research will be needed before an overall conclusion can be gained.   
 
Figure 1.6 Breakdown of the chemical structure and attributes of metformin and 
guanylurea. Metformin is not metabolised within the human body. Guanylurea is generated 
in the environment by the breakdown of metformin.  (Thomas et al., 2010; Sheurer et al., 
2012; Laak and Baken, 2014; Christina et al., 2015).  
1.5.3 Advantages of repurposing metformin  
Metformin presents a low risk drug as a repurposed medication. It can be 
taken orally daily and will cause very little disruption to patients. The primary 
side effects of metformin use include: diarrhoea, nausea, vomiting, and 
flatulence, but are ameliorated through dose control and delivery mechanism 
(Legro, 2017). The BBB presents a major obstacle for the development of new 
anti-cancer drugs. Metformin has been shown to readily cross the blood brain 
barrier and reach brain tissue (Łabuzek et al., 2010).  In addition, metformin 
may have a protective effect for the brain, as it has been shown to upregulate 
the functions of the BBB, in rat studies. This demonstrated through activation 
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of AMP-activated protein Kinase (AMPK) metformin increased barrier tightness 
and reduced overall permeability. (Takata et al., 2013). Metformin in a 
medicinal form is readily available world-wide. The essential medication 
labelling from the WHO has meant that metformin availability even in less 
developed countries is still high (World Health Organization, 2017). This wide 
spread access and low cost has led to metformin being purposed as a potential 
adjunct to thrombolysis treatment for low to mid income economies (Bromage, 
and Yellon, 2015). Metformin has also already been successfully repurposed 
as a second line treatment for polycystic ovary syndrome (Velazquez et al., 
1994). POS is characterised by anovulation and irregular menstrual cycles 
leading to infertility (Lord et al., 2003). Metformin treatment has been 
demonstrated to increase ovulation and improves menstrual frequency (Legro, 
2017). 
1.5.4 Metformin cancer clinical trials 
Repurposing metformin as a cancer treatment is already being tested in a 
range of clinical trials for a variety of cancers. The results of these have shown 
a variety of outcomes.  
A phase II trial of stage IIc/III/IV ovarian, fallopian tube and primary 
peritoneal cancer, tested metformin alongside chemotherapy and debulking 
surgery on thirty-two patients. This translational study reported positive 
outcomes for patients receiving metformin and supported metformin in phase-
III trials (Buckanovich et al., 2017).  
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A phase III trial of 3256 women, who had completed standard therapy for 
early stage breast cancer, was conducted using metformin (Dowling et al., 
2018). The study focused on levels of the cancer antigen 15-3, an important 
biomarker for breast cancer progression and metastasis (Geng et al., 2014). 
The trial concluded that metformin significantly lowered cancer antigen 15-3 
levels (Dowling et al., 2018).  
A phase 0 clinical trial on 41 non-diabetic breast cancer patients focused on 
changes in metabolic markers and gene expression caused by doses of 
metformin up to 1500mg. The outcome was that metformin affected breast 
cancer metabolism at the clinical doses. Metformin inhibited fatty acid 
oxidation and mitochondrial gene expression in cancer tissue but not normal 
patient cells (Lord et al., 2016).     
I-SPY 2 is a phase II trial evaluating ganitumab and metformin alongside 
standard neoadjuvant therapies for high-risk breast cancer patients. It used a 
Bayesian predictive model with a ≥85% threshold for success. Two hundred 
and thirty-four patients took part in the trial. None of the treatment sub-types 
achieved the threshold level for success and were deemed not to show an 
impact in reducing patient’s tumour burden (Yee et al., 2017).   
Chae 2016 studied ongoing and completed, cancer based, metformin clinical 
trials. In several trials metformin was shown to reduce levels of tumour 
survival bio markers, but overall, it concluded that data on survival outcomes 
for patients was still lacking. There were only two studies with complete data, 
two phase II late stage pancreatic cancer clinical trials. Both trials saw no 
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improvement from adding metformin to the treatment regimen (Kordes et al., 
2015; Reni et al., 2015).  From the available data it is speculated that 
metformin maybe more suitable for earlier stages of cancer. However, more 
mature study data and survival rate assessments are required to ascertain 
metformin use as a therapeutic cancer treatment (Chae et al., 2016). 
1.6 Metformin mechanism of action  
The mechanisms of metformin anti-neoplastic activity are not fully understood 
(Rena et al., 2017). It is believed to operate indirectly through lowering insulin 
levels in patients with hyperinsulinemia and directly through inhibition of 
respiratory complex I of the electron transport chain in mitochondria (Pollak, 
2012).  
1.6.1 AMPK and mTOR 
Inhibition of mitochondrial complex I leads to activation of AMPK (Han et al., 
2015). This protein has been demonstrated to act as both tumour suppressor, 
through inhibition of mammalian target of rapamycin (mTOR), an oncogene 
facilitating cell division and has a role in aiding metabolic reprogramming (Jeon 
et al., 2012; Liu et al., 2013).  
mTOR functions as a kinase that regulates several downstream processes 
including protein synthesis, lipid synthesis cell survival, cell motility, autophagy 
and transcription (Hay et al., 2004). Control of downstream pathways is 
maintained by the creation of two different protein signalling complexes, 
mTOR complex (mTORC) 1 and 2 (Lipton et al., 2014; Saxton et al., 2017). 
The two complexes have variations in the proteins used but both utilize mTOR 
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as the core component (Kim et al., 2015). Figure 1.7 shows the full mTOR 
signalling network and pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
Metformin control and inhibition of mTORC has been reported through several 
pathways. In prostate cancer metformin increases expression of the regulated 
in development and DNA damage response 1 (REDD1) protein in a p53-
dependent manner (Sahra et al., 2011). REDD1 is an endogenous negative 
regulator of mTORC1 that can be activated through metabolic stress (McGhee 
et al., 2009; Tiwarekar et al., 2018).  
Figure 1.7 mTOR signalling complex and pathway. mTOR forms two separate 
complexes mTORC1 and mTORC2 to regulate multiple downstream effectors. mTORC1 
affects anabolic and catabolic pathways. mTORC2 affects cellular proliferation pathways 
including cell survival, metabolism and cytoskeletal organisation. mTORC1 is primarily 
inhibited by AMPK phosphorylation of RAPTOR and the AKT substrate PRAS40. mTORC1 
can also inhibit mTORC2 through the downstream effector S6K. (Kim et al., 2015) 
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In pancreatic cancer, metformin downregulates the transcription factors of 
specificity proteins 1, 3 and 4 leading to inhibition of downstream mTOR 
signalling (Nair et al., 2014). 
AMPK suppression of mTOR can also be achieved through phosphorylation of 
TSC2 and RAPTOR (Inoki et al., 2003; Gwinn et al., 2008). This inhibition 
impacts fatty acid synthesis and causes reduction in tumour proliferation and 
growth (Dowling et al., 2007). In GBM, AMPK is constitutively activated and 
upregulated (Liu et al., 2013).  Inhibition of the mTOR pathway by metformin 
has also been shown to be independent of AMPK activation (Kalender et al., 
2010). Metformin acts through increasing affinity of the protein kinase B (AKT) 
substrate PRAS40 binding to RAPTOR and negatively regulates mTOR complex 
1 (Liu et al.,2013). 
1.6.2 Micro RNA 
1.6.2.1 Overview 
Micro RNAs (miRNA) are short non-coding regions of RNA no longer than 
approximately 30 base pairs. Originally thought to be fragment translated 
products of non-coding “junk” DNA regions. However, now it is known that 
miRNA play a critically important role in post-transcriptional regulation and 
silencing of other RNAs. (Santa-Maria et al., 2015). Primarily miRNAs act within 
the cell but the extracellular effects of miRNAs have been well documented 
and the detection of circulating miRNAs in blood plasma as a biomarker is 
being developed for clinical applications (Pirola et al., 2015). The result of 
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miRNA regulation on cells can affect a range of biological process such as cell 
proliferation, differentiation, survival and motility (Christopher et al., 2016). 
1.6.2.2 Generation and function of miRNAs  
The formation of miRNAs occurs within the nucleus. RNA polymerase II (Pol 
II), this enzyme responsible for transcribing most miRNA. The resulting 
product is referred to as a primary-miRNA (pri-miRNA) and possess good self-
complimentary sequences that aid in self binding to form a hairpin stem-loop. 
Other features of pri-miRNA are poly A tails on the 3’ end.  This structure 
makes the pri-miRNA detectable by the proteins DGCR8 and Drosha, which 
together form a microprocessor complex (Gregory et al., 2004). This complex 
function is to remove the miRNA still connected at the hairpin loop of the pir-
miRNA and produce a double stranded sequence with a short nucleotide 
overhang on the 3’ end, now referred to as pre-miRNA (Denli et al., 2004). 
There is a small sub-group of pre-miRNAs that are generated through Drosha-
independent means, that bypass the microprocessor complex and are spliced 
out of introns (Berezikov et al., 2007).  Originally the mi-RNA variants were 
not believed to be present within mammalian organisms, however recently 
studies have identified the presence in human genomes. Variations in the 
expression profiles have also been linked to cancer and tumour cells, giving 
them a potential use as a diagnostic tool (Butkytė et al., 2016). Export out of 
the nucleus to the cytoplasm is handled by nuclear transmembrane protein 
exportin-5 (Wu et al., 2018). This protein is able to identify pre-miRNA due to 
the nucleotide overhand that was left post Drosha cleavage (Wilson et al., 
2013). Once in the cystol the pre-miRNA is cleaved by the RNasa III enzyme 
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Dicer. This removes the hairpin loop from one end of the pre-miRNA leaving 
a double strand RNA fragment that will eventually denature leaving the 
complete miRNA free. Though there are two complete nucleotide strands, 
referred, to as 5’ and 3’, both are not always used as functional miRNA to 
become incorporated in a miRNA-induced silencing complex (miRISC) (Eulalio 
et al., 2008, Fabian and Sonenburg, 2012). Any non-functional strands are 
degraded after separating from the other miRNA, post Dicer modification 
(Kawamata et al., 2015).   Figure 1.8 shows an overview of this process from 
gene to miRISC. The complete mIRISC is able to identify and bind to mRNA 
sequences in the cytoplasm by using the miRNA component as a template 
(Sheu-Gruttadauria et al., 2018). Once bound the mRNA is unable to be 
translated by ribosomes and is effectively silenced (Islam et al., 2017). This 
post transcriptional method of silencing then leads to the degradation of the 
mRNA and is shown in figure 1.9.   
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Figure 1.8 Schematic overview of miRNA biogenesis. Occurring within the nucleus miRNA are 
formed from both miRNA genes and from non-functional introns. Transcription of miRNA is moderated 
by Pol II. Within the nucleus miRNA take on structural changes due to modification by Drosha enzyme. 
The changes allow it to pass through the nuclear membrane through exportin 5 and enter the 
cytoplasm. Further changes and cleavage occur due to the Dicer protein leaving a miRNA duplex. One 
or both strands join into a completed protein complex (mIRISC) to enact mRNA transcriptional 
regulation. (Christopher et al., 2016) 
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Figure 1.9 Generation and function of miRNA. miRNA are generated in the nucleus 
and, post restructuring and modification, are released through the nuclear membrane as 
pre-miRNA. In the cytoplasm the miRNA is further modified by cleavage of the hairpin 
loop to produce miRNA duplexes. One strand is degraded and the other becomes 
mature miRNA. In this final state the miRNA can combine with proteins to form a RNA-
induced silencing complex (RISC). One the complex is fully formed; the miRNA 
component allows the RISC to bind to complimentary bases of mRNA in the cytoplasm. 
Depending on how complimentary the sequence between the miRNA and then mRNA 
determines the overall fate of the mRNA. Near or exact complimentary base sequences 
will allow the mRNA to become degraded. Non-specific binding allows the miRNA to bind 
to mRNA and block the translation of the mRNA sequence (Islam et al., 2017). 
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1.6.2.3 MiRNAs role in cancer  
As a cell progresses towards a cancerous state, the ability to control and 
regulate the expression of RNA, including miRNA, is often damaged or lost (Lin 
et al., 2015). This dysregulation in miRNA expression impacts a range of 
cellular process involved in preventing further tumour development, including 
cell cycle arrest, differentiation and apoptosis (Hata and Lieberman, 2015). 
The role each miRNA has in the progression of tumours varies, an individual 
miRNA can take on oncogenic or tumour suppressive affect. Distinguishing 
what effect an individual miRNA has on a cell is context dependent. An 
example of a strong oncogenic miRNA is miR-21. In most human cancers miR-
21 is found to be over expressed and acts as an oncogene by targeting and 
decreasing the expression of FBX011 tumour suppressor gene (Yang et al., 
2015). This oncogenic role is also in GBM, where miR-21 has an impact on 
P53, TGF-β and mitochondrial apoptosis tumour-suppression pathways (Chan 
et al., 2005; Papagiannakopoulos et al., 2008; Maachani et al., 2016). miR-
466 acts as a tumour suppressor in prostate cancer where it has a negative 
effect on cell proliferation and prevents metastasis by targeting bone-related 
transcription factor RUNX2 (Colden et al., 2017). Cancer type dependent 
variation have also been identified. MiR-222 is frequently upregulated in 
cancers, including GBM where it reduces apoptosis and aids in cell survival 
(Zhang et al., 2010). However, the inverse of this is demonstrated in prostate 
cancer where miR-222 acts as a tumour suppressor (Fuse et al., 2012) 
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1.6.2.4 Impact of metformin on micro-RNA expression 
There is growing evidence that metformin has an impact on the expression 
and modulation of a range of miRNAs. The changes have been linked to a 
range of metformin effects including anti-cancer properties. A review by Pulito 
et al. (2014) identified nine main miRNAs that were impacted by metformin 
treatment across a range of cancers (miR-26a, miR-33a, miR-140, miR-142, 
miR-192, miR-200, miR-205 miR-222 and let-7c). Metformin has been shown 
to induce apoptosis through increasing expression in miR-708-5p causing it to 
suppression expression of the endoplasmic reticulum membrane protein 
neuronatin in prostate cancer (Yang et al., 2015). It also induces 
mitochondrial-dependent cellular apoptosis in KB human oral cancer cells 
through increased expression of miR26a (Wang et al., 2016). Cell cycle arrest 
has also reported in a range of tumour types. In renal cancer cells metformin 
induces G0/G1 arrest and delayed entry into S phase through up regulation of 
miRNA34a. In pancreatic cancer cells a similar G1-phase arrest is seen from 
metformin treatment, but this is induced through down regulation of miR-221 
(Tanaka et al., 2015). 
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1.6.3 Cell Death 
1.6.3.1 Role of apoptosis 
Apoptosis, or programmed cell death, is an important cellular mechanism that 
functions to enable the destruction and removal of cells in a controlled manner. 
This mechanism utilizes a host of intracellular machinery to perform a range 
of functions within an organism including; embryonic development, structural 
development, immune response, hormone dependant atrophy and chemical-
induced cell death (Elmore, 2007). Once apoptosis has begun it is irreversible 
and ultimately ends in the breakdown of all cellular function. Many cellular 
pathways are involved in the activation and execution of the process. The main 
two mechanisms observed are the extrinsic pathway and intrinsic pathway 
(Budihardjo et al., 1999). Both pathways act through the function of various 
caspase proteins but are activated and regulated through different means. The 
pathways shown for both intrinsic and extrinsic apoptosis are shown in Figure 
1.10. The extrinsic pathway is mediated by cell surface death receptors that 
respond to death ligands normally presented by immune-effector cells (Lowe 
et al., 2000). This leads to the formation of a death-inducing signalling 
complex (DISC) that activates the cascade of caspase pathways within the 
cell. The intrinsic pathway centres around various functions of the 
mitochondria that can include activation of the caspase pathway and activation 
of APAF1 through release of cytochrome C (Fulda and Debtain, 2006).  
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Figure 1.10. Extrinsic and intrinsic apoptotic pathways. Apoptosis is a cellular 
process that utilises a range of signalling pathways. The two version of apoptosis vary 
based on the initial signalling trigger. Extrinsic apoptosis cascades down from an extra 
cellular signal that generates the creation of a DISC. Intrinsic apoptosis has several 
triggers relating to metabolic activity, DNA damage and cellular stress. Intrinsic and 
extrinsic pathways both utilise several caspase family proteins that eventually end in the 
activation of the execution effector caspases 3 and 7. (Lowe et al., 2000; Hunt, 2002). 
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Mitochondria have an important role in the intrinsic apoptotic pathway and 
regulate downstream caspase effectors through release of cytochrome C 
(Hunt, 2002). A key component of mitochondrial action is the mitochondrial 
membrane potential (Δψ) that powers the tricarboxylic acid cycle (Martínez-
Reyes et al., 2016). In some cells the depolarisation of the transmembrane 
potential, loss of oxidative phosphorylation and the release of apoptogenic 
factors by the mitochondria are key to intrinsic apoptotic progression. 
However, there is also data to show that the factors are not effectors of 
apoptosis and occur later in progression, as an end result of other components 
of the apoptotic-signalling pathway (Ly et al., 2003). Though the complete 
mechanisms are unknown, metformin has been shown to affect mitochondria 
through multiple pathways which could induce mitochondrial stress leading to 
apoptosis.  Biguanides can inhibit complex 1 of the mitochondrial respiratory 
chain and inhibit mitochondrial ATP synthase through accumulation within the 
mitochondria matrix (Owen et al., 2000, Bridges et al., 2014). Metformin can 
also lead to the inhibition of mitochondrial glycerophosphate, a redox shuttle 
enzyme, causing a reduction in lactate to glucose conversion and decreasing 
hepatic gluconeogenesis (Madiraju et al., 2014). In addition, metformin has 
been shown to reduce mitochondrial fragmentation and suppress 
mitochondrial fission by reducing dynamin-related protein 1 (Wang et al., 
2017). In prostate, lung and melanoma cancer cells, metformin has been 
shown to cause an increase in mitochondrial uptake of calcium through the 
mitochondrial calcium uniporter, causing mitochondria to swell. However, it 
simultaneously also inhibited the opening of the mitochondrial permeability 
 40 
   
transition pore and increased mitochondrial biogenesis, both protective 
measures against apoptosis (Loubiere et al., 2017).  
1.6.3.2 Disruption of apoptosis in cancer 
Cancer cells have evolved many ways to prevent and block cell death from 
apoptotic pathways. Extrinsic pathways can be blocked through increasing the 
concentration of anti-apoptotic molecules, blocking key activation receptors or 
by mutations that impair the function of pro-apoptotic genes. An example is 
mutations that cause loss or damage to cell surface receptors CD95 or TRAIL 
(Fulda and Debatin 2006). Loss of TRAIL has been found in head, neck, 
osteosarcoma (Pai et al, 1998; Dechant et al., 2004). The ability to control the 
activation of apoptosis is an important goal in the development of some 
treatments. However there has been limited progress in developing the 
extrinsic caspase pathway for clinical benefit. Due to the less specific nature 
of activating extracellular receptors of cells, non-specific binding has caused 
toxicity issues with treatments. The attempts include utilising tumour necrosis 
factor alpha (TNF-α) and targeting first apoptosis signal receptor CD95 (FAS) 
with antibodies (Ashkenazi, 2015). Clinical trials of TRAIL receptor agonists 
have had poor outcomes (Merchant et al., 2012, von Pawel et al., 2014). 
Recent novel information, understanding cancer cells resistance to TRAIL and 
potential mechanisms to counter the pro-tumorigenic effects of endogenous 
TRAIL, highlight that TRAIL based treatment methodologies could still be 
utilised effectively (von Karstedt et al., 2017).  
Mitochondria are key organelles that have a role in cell survival and 
proliferation through production of metabolites and ATP. Metformin has been 
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shown to induce apoptosis in multiple tumour types including, but not limited 
to: ovarian, prostate, gastric, lung, leukaemia and breast cancer cells (Han et 
al., 2015; Li et al., 2015; Moon et al., 2015; Rodríguez-Lirio et al., 2015;; Yang 
et al., 2015 Zhang., 2016).  
1.6.3.3 Autophagy 
Autophagy is an alternative method of cell destruction. It functions through 
use of autophagosomes. These are double membrane cytosolic vesicles that, 
once active, move around a cell absorbing macromolecules and organelles. 
Once material has been collected, the autophagosomes combine with 
lysosomes and become autolysosomes. The fused complex then breaks down 
all the absorbed phagosomes contents (Ramirez et al.,2013).  Trigger of 
autophagy in GBM has been identified as a potential therapeutic target 
(Palumbo et al. 2012). 
Self-degradation of cells can also occur through autophagy, a controlled 
cellular process in which the cells own lysosomes deconstruct other internal 
cellular structures (Xie et al., 2007). This process is used for a variety of 
roles including removal of damaged organelles, regulation of metabolism, 
cellular survival and as a method of programmed cell death (Parzych et al., 
2014; Kobayashi, 2015). An overview of the stages of autophagy are 
outlined in Figure 1.11. Autophagy is controlled by several upstream regular 
pathways, primarily through regulation of mTOR supplemented with 
regulatory signalling from Phosphoinositide 3-kinase (P13K) and AKT (Heras-
Sandoval et al., 2014). The relationship of the upstream elements is shown 
in Figure 1.12. 
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Metformin can induce autophagy through inducing cellular stress and 
decreasing mitochondrial ATP (Lindqvist et al., 2018).  For hepatocellular 
carcinoma, metformin induces autophagy through upregulation of tumour 
suppression protein CEBPD (Tsai, 2017). In colon cancer cells metformin 
induced autophagy in a P53 dependent manner, with wild type P53 displaying 
activation of autophagy due to metformin treatment (Buzzai et al., 2007). In 
lymphoma, metformin can induce autophagy in conjunction with the anti-
cancer drug doxorubicin leading to a reduction in cell growth (Shi et al., 2012). 
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Figure 1.11 Outline of autophagy. Autophagy begins with a double membraned structure 
gathering proteins, organelles and other cellular materials found with the cytoplasm. This leads 
to the formation of the autophagosome. This compact structure continues to fuse with a 
lysosome and occasionally, depending on the membrane bound cargo, an endosome. Once 
fusion of the membranes has completed the completed autolysosome degrades all contained 
materials to be recycled as molecules for other cellular processes. (Nakamura et al., 2017) 
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Figure 1.12 Autophagy regulation pathway. The primary mechanism controlling 
autophagy is mTOR. Inactivation of mTOR can occur from a range of cellular signalling relating 
to cellular stress, growth factors, glucose and amino acid levels. This leads to substrates 
produced by P13K complexes and the ULK Complex to move to be transported to the nascent 
phagophore. Further protein complexes are then recruited to create the complete 
autophagosome.  (Maier et al., 2012) 
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The suppression of autophagy is commonly associated with tumorigenic cell 
transformations, inferring that autophagy has an important role in tumour 
suppression (Gozuacik et al., 2004; Fulda et al., 2015). Metformin has also 
been seen to act through induction of autophagy in a range of tumours such 
as oesophageal squamous cell carcinoma, thyroid and endometrial cancer 
cells (Feng et al., 2014; Song et al., 2016; Gu et al., 2017). For GBM cell 
lines it has been shown that metformin, when used in combination with 
arsenic trioxide, can induce both apoptosis and autophagy (Carmignani et 
al., 2014). Primarily acting through concomitant activation of AMPK, REDD1 
and inhibition of the mTOR pathway (Sesen et al., 2015).  
1.6.4 Cell cycle 
Cell cycle and its regulation is critical to the maintenance of existing cell 
populations and the generation of new cells. Dysregulation of the cell cycle, 
leading to unchecked proliferation, is a common feature in cancer cell 
development (Evan and Vousden, 2001). Progression through the cell cycle is 
heavily controlled and regulated. To prevent the cellular process happening 
incorrectly there are several checkpoints in the cell cycle that must be passed 
before proceeding (Vermeulen et al., 2003). The checkpoints occur at key 
stages in cell division and are a failsafe to prevent DNA damage and aberrant 
cell behaviour. If checkpoint specific pre-requisites are not met at the 
checkpoint, then the cycle arrests and division is prevented (Bertoli et al., 
2014). The main two groups of molecules responsible for controlled 
progression through the check points are cyclins and cyclin-dependent kinases 
(CDK). CDK bind to form protein complexes that allow the cell to advance to 
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each subsequent step and inevitably complete cell division (Spoerri et al., 
2015). Table 1.1 contains a list of checkpoints and the linked cyclin Cdk 
complexes. A full summary of the cell cycle developmental checkpoints can be 
found in figure 1.13. 
 
Checkpoint Cyclin1 Cdk 
G1 phase checkpoint Cyclin D 
Cdk4 
Cdk6 
S phase checkpoint Cyclin E Cdk2 
G2 phase checkpoint Cyclin A 
Cdk2 
Cdk1 
Spindle checkpoint Cyclin B Cdk1 
 
 
 
 
 
 
 
Table 1.1 – Required cyclin CDK combination for cell cycle checkpoint progression 
1Cyclin required for cell cycle checkpoint progression. For G1 and G2 phase checkpoints cyclins must 
form relevant complex’s with both listed Cdk to enable progression through the checkpoint.  
(Spoerri et al., 2015) 
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Figure 1.13 Cell cycle developmental progression checkpoints. There are four 
main stages to cell cycle progression: G1, S, G2 and M phase. Controlling the cells 
movement through the phases are four main check points, G1 to S phase transition, S 
phase checkpoint, G2 phase checkpoint and the spindle assembly checkpoint. Each check 
point ensures that the cell has not suffered damage and that correct prerequisite stages 
have been completed. G1/S, S phase and G2 phase all check for DNA damage that would 
lead to mutation and errors post division. The three phases also possess an additional 
unique checkpoint assessment; G1/S asses that previous mitosis was completed correctly, 
S phase checks for duplication of genetic material and G2 assess the cell mitotic 
preparation. The spindle check point assesses correct establishment of mitotic spindle for 
correct allocation of chromosomes. Each stage is controlled by the creation of a specific 
cyclin Cdk protein complex (Schnerch et al., 2012). 
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 Metformin has been shown to induce cell cycle arrest in a cancer specific 
manner through a range of mechanisms. In lung cancer cells metformin has 
been shown to induce G1 cell cycle arrest through suppression of the atypical 
repressor E2F8. Expression of E2F8 has been linked with poor patient survival 
(Jin et al., 2017). G1 and G2/M cell cycle arrest was seen in separate prostate 
cells treated with metformin in separate experiments (Babcook et al., 2014; 
Gonnissen et al., 2017). In GBM cell lines LN18 and LN229 metformin has been 
shown to increase radio sensitivity and induce G2/M cell cycle arrest in 
conjunction with TMZ (Adeberg et al., 2017). In drug resistant leukaemia 
metformin arrests cells in S and G2/M phases through downregulation of cyclin 
A, cyclin B1 and cdc2 (Rodríguez-Lirio et al., 2015). Breast cancer cell respond 
to metformin by upregulating cyclin G2, cyclin G2 is a key regulator of the 
G2/M checkpoint through inhibition of CycB1-Cdc2 (Zimmermann et al., 2012, 
Zimmermann et al., 2016). 
1.6.5 Necrosis and Oncosis  
Necrosis is a cellular process that sometimes is associated with cell death. It 
is considered by some that necrosis should not be a true mechanism of cell 
death as it is merely the fate of a cell that has accidentally died. Instead the 
term oncosis leading to necrosis is the correct terminology (Elmore, 2007). 
However, necrosis is a similar but less regulated mechanism compared to 
apoptosis, in that the breakdown of the cell still happens but focuses on the 
breakdown of intracellular membranes. The materials released enter the 
extracellular milieu and cause the cells to promote response from nearby 
immune cells (Zong et al., 2004). Metformin is not normally associated with 
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cell death through necrosis. However, one study has shown that in prostate 
cancer cells the combination of simvastatin metformin is able to induce Ripk1- 
and Ripk3- dependent necrosis (Babcook et al., 2014).     
1.6.6 Other mechanisms  
The high mutation rate of cancerous cells leads to alterations in metabolism 
pathways (Lindgvist et al., 2018). In contrast to normal cells, that produce 
energy through oxidative phosphorylation, cancer cells primarily utilize 
glycolysis and lactic acid fermentation as energy sources (Vander Heiden et 
al., 2009). This behaviour is referred to as oxidative phosphorylation or the 
Warburg effect (Goodwin et al., 2015). This change in metabolism is driven 
by mutations and dysregulation in normal cellular pathways. The embryonic 
isoform of pyruvate kinase, M2, is exclusively expressed in tumour cells 
instead of normal pyruvate kinase M1 (Christofk et al., 2008). This is a key 
driver in the Warburg effect and aids in promoting mTORC1, boosting cell 
proliferation (Ye et al., 2012). Overexpression of phosphoglycerate 
dehydrogenase (PHGDH) blocks glucose metabolites becoming pyruvate to 
end the Krebs cycle and instead redirects them to produce serine (Locasale 
et al., 2011). Over expression has also been linked to glioma cell 
proliferation and invasion (Liu et al., 2013). Von Hippel-Lindau (VHL) tumour 
suppressor that can be suppressed in tumours, this cause redirection glucose 
away from the Krebs cycle to generate lactate (Lee et al., 2016). 
Degradation of VHL has also been shown to promote glioma genesis (Zhu et 
al., 2017). IDH1 allows tumour cells to generate lipids from citrate and is 
linked with aggression in GBM (Sun & Denko, 2014; Miroshnikova et al., 
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2016). Fumate-hydratase (FH) deficient cells accumulate fumarate that 
induces hypoxia-inducible factors (HIFs) that have been shown to aid in the 
regulation of GBM (Frezza et al., 2011; Yang et al., 2012). The interaction of 
cancer alteration to metabolic pathways is given in figure 1.14. 
There are suggestions that the mechanism of action of metformin is cancer 
type independent and acts through inhibiting mitochondrial complex 1 (NADH 
dehydrogenase) of cancer cells (Wheaton et al., 2014). Metformin has also 
been shown to be an inhibitor of hexokinase 2 blocking the first step in 
glycolysis (Salani et al., 2014)   The reprogrammed metabolism of cancer cells 
is a potential vulnerability that could be exploited to treat tumours while 
leaving normal cells unharmed (Würth et al., 2013, Weinburg et al., 2015).  
Regarding cancer stem cells (CSC), metformin has been shown to have a 
cytotoxic effect because of its ability to targets glioma CSCs (Mouhieddine et 
al., 2015). This possible mechanism will deprive the tumour cell population of 
its stem/progenitor cells preventing regrowth and possible resurgence. 
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Figure 1.14 Mutations and metabolism alterations in cancer. Metabolism pathways 
utilised by cancer cells. Colour coding indicates areas of effects from different mutations. 
Red – Embryonic pyruvate Kinase M2 is over expressed and drive the Warburg effect. 
Orange – PHGDH enables the generation of serine from glucose metabolites and promotes 
glioma proliferation. Blue – VHL deficiencies enables increased generation of lactate from 
glucose metabolites and promotes the generation of glioma cells. Purple – IDH1 enable 
tumour cells to generate lipids from citrate and promotes glioma aggression.  Green – 
Deficiency in FH leads to a build-up of fumarate that promote HIFs. 
Additions to the diagram show the target areas that metformin can impact. Black circle – 
Metformin inhibits hexokinase 2, an enzyme utilised at the start of glycolysis (Salani et al., 
2014). Black rectangle – Metformin can inhibit mitochondrial complex 1 (Wheaton et al., 
2014). 
PKM2, M2 isoform of pyruvate kinase; PHGDH, phosphoglycerate dehydrogenase; PDH, 
pyruvate dehydrogenase complex; PDK, pyruvate dehydrogenase kinase; ACO, aconitase; 
IDH, isocitrate dehydrogenase; SDH, succinate dehydrogenase complex (mitochondrial 
Complex II); FH, fumarate hydratase; HMOX, heme oxygenase. (Hiller et al., 2013). 
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1.6.7 Overview  
The mechanisms through which metformin induces anti-tumour effects 
remains unclear and varies based on cancer type and environment. Defining 
an outline to the actions of metformin is hindered by its ability to induce 
multiples forms of cell death. Studies in both melanoma and endometrial cells 
have identified that metformin can induce cell cycle arrest (in one or more 
phases), autophagy and apoptosis in the same cell population (Tomic et al., 
2011; Takahashi et al., 2014). The large variation in reported findings may 
highlight that metformin mechanism does not directly induce pathways of cell 
death and therefore all the observed result are potential side effects. Hence, 
it is probable that the mechanism of action for metformin is dependent on 
tumour type. 
1.7 Drug synergy 
1.7.1 Metformin  
The testing of metformin as a therapy for GBM comes with very little risk. The 
drug is readily available and is relatively stable. The drug is not metabolized 
by human cells and is normally excreted in the same form it is ingested in, 
indicating it is hydrophillic (Bailey, 2017). The drug does not bioaccumulate in 
human tissue unless renal function is impaired (Viollet et al., 2012). This 
makes an ideal candidate to test through In vitro and In vivo models. It can 
readily dissolve in water and DMSO so will be deliverable to cells in the culture 
media (Block et al., 2009; Sankar et al., 2013). Lactic acidosis (LAD) is the 
primary side effect of any risk however this is of a low incidence in patients 
and normally linked to an impairment in renal function (Salpeter et al., 2010). 
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Figure 1.15 Structure and hydrolysis of TMZ. TMZ must become hydrolysed into its 
reactive component form of a methydiazonium ion and an inactive AIC. The activation of 
hydrolysis is regulated by a pH greater than 7.  (Lopes, et al 2013) Formula: C6H6N6O2 
Molecular mass 194.151 g/mol 
 
Studying metformin in cell culture will help identify its mechanism of action 
and if it might have suitability to be repurposed as an anti-cancer agent.    
1.7.2 Combination treatments  
Metformin would never be used as a mono drug therapy for cancer treatment. 
Instead metformin would be used as part of a treatment regime involving 
several different drugs to increase overall efficacy. Identifying potential 
synergistic partners for metformin would further the possibility of use in 
treatment for GBM patients. Disulfiram and Sorafenib have already been 
identified as potential candidates to work synergistically with metformin for 
cancer treatments (Aldea et al., 2014, Jivan, et al., 2015).  
 
1.7.2.1 Temozolomide 
 
 
 
 
 
 
 
TMZ is part of the STUPP protocol and is the mainstay in standard treatment 
of GBM. The drug functions as an alkylating agent that damages DNA to trigger 
cell death (Lee et al., 2018).  The drug is administered orally and absorbed in 
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gastrointestinal tract. As soon as the drug is exposed to a pH>7 it will 
spontaneously hydrolyse into methytriazine (MTIC) (Lopes, et al 2013). This 
process is heavily mediated by pH and gives TMZ an in vitro half-life in serum 
of approximately 30 min (Andrasi et al., 2011). MTIC has an in vitro half-life 
of approximately 25 min before degrading to drugs final form of an inactive 4-
Amino-5-imidazole-carboxamide (5-AIC) and an active methydiazonium ion.  
AIC is a stable molecule in water at pH approximately 7 (Andrasi, et al., 2010). 
1.7.2.2 Sodium Oxamate 
 
 
 
Figure 1.16 – Structure of sodium oxamate. Formula: NH2COCOONa Molecular mass 
111.03 g/mol 
Sodium oxamate is a glycolysis inhibitor reducing the conversion of pyruvate 
to lactate in cystol through direct effect on lactate dehydrogenase (LDH). This 
results in a net reduction of the build-up of lactic acid and prevents the onset 
of lactic acidosis (LAD) in cells. The presence of LAD in cancer cells is linked 
to cancer proliferation and metastasis (Walenta, et al., 2004). Oxamate has 
been identified to have synergy with the metformin analogue phenformin 
(Miskimins, et al. 2014).  
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1.7.2.3 Disulfiram 
 
 
 
Figure 1.17 – Structure of the anti-alcohol-dependency drug disulfiram. The primary 
target of disulfiram is the enzyme acetaldehyde dehydrogenase.   Formula: C10H20N2S4. 
Molecular mass 296.539 g/mol 
Disulfiram (DSF) has been used as an anti-alcohol-dependency drug for over 
60 years (Johanson, et al., 1992). In recent years DSF when combined with 
copper has been assessed for it potential repurposing as an anti-tumour agent 
(Cvek et al., 2011). It impacts tumour cells primarily through inhibition of the 
ALDH and NF-kB pathway (Liu et al., 2012, Liu et al., 2014). A study has also 
shown that DSF efficacy can be enhanced by metformin in oesophageal 
squamous cell carcinoma (OSCC) (Jivan, et al., 2015). The mechanism of 
disulfiram action requires the presence of copper chloride to work at optimum 
levels and GBM cell lines DSF combined with copper has been shown to have 
cytotoxic effect (Liu et al., 2012). 
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1.7.2.4 Sorafenib 
 
 
 
Fig. 1.18 – Structure of sorafenib. Sorafenib is a kinase inhibitor drug primarily used in 
the treatment of kidney, liver and thyroid cancer. The drug functions by inactivating B-Raf 
protein through binding to its kinase domain.  Formula: C21H16ClF3N4O3. Molecular mass 
464.825 g/mol. 
Sorafenib is a multi-kinase inhibitor currently used for the treatment of renal 
cell carcinoma that primarily acts by blocking receptor tyrosine kinase 
signalling in VEGFR, PDGFR, C-Kit and RET (Wilhelm et al., 2006). The net 
downstream effect is reduction in tumour proliferation, anti-angiogenic and an 
increase in apoptotic effects. Since the drugs approval in 2007, the prospective 
range of therapeutic targets has been expanded to include liver and thyroid 
cancer (Escudier et al., 2007; Llovet et al., 2008; Brose et al., 2013).  Sorafenib 
has shown potential as a repurposed therapeutic agent against the tropical 
disease Schistosoma mansoni (Keiser, et al., 2015) and the Rift Valley fever 
virus (Kehn-Hall, et al., 2017).  Sorafenib use on GBM is still not fully explored, 
though it has been seen to work synergistically with TMZ for in vitro studies 
(Robert B et al., 2013). However, the drug efficacy at improving radio-
sensitivity seems disputed (Sherman et al., 2014) (Riedel et al., 2016).  It has 
been in at least one cell line that metformin acts synergistically with sorafenib 
(Aldea et al., 2014). Sorafenib is also being tested as part of GBM clinical trials 
as an anti-angiogenesis VEGFR-2 inhibitor (Schiff et al., 2018).   
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1.8 Cell culture models 
1.8.1 Tissue culturing and micro-environment  
In vitro cancer study is primarily carried out using tissue culturing methods to 
generate suitable micro environments for growing cells. However, tissue 
culturing produces only a facsimile of a cells natural environment and can lead 
to genetic and phenotypic changes over time (Bara et al., 2014, Nestor et al., 
2015). EGFR amplification is common in GBM but upon transfer to cell culture 
this amplification is rapidly lost (William et al., 2017). Cell culturing micro 
environments can create false reproductions of the original growing conditions 
for the cultured cells, for example the availability of glucose.  The average 
healthy, non-diabetic, adult has circulating glucose levels around 5-6mmol/l 
and an adult diabetic has blood glucose levels around 7 mmol/L to 10mmol/L 
(Menendez et al., 2012). The average tissue culture media uses glucoses 
concentration in the 10-25 mmol/l range. The three most common cell culture 
media are DMEM (25mM glucose), RPMI 1650 (11.11mM glucose) and DME/F-
12 (17.50mM glucose). Alternative media formulation can better represent 
normal tumour growing conditions. Hams F-10 is a media originally designed 
for the culturing of Chinese hamster ovary cells (Ham, 1963). This media 
utilises 6mM glucose and is closer to resting circulating blood glucose of the 
human body. The overabundance of glucose in growth media has been 
demonstrated to reduce metformin efficacy in both breast and ovarian cancer. 
(Menendez et al., 2012; Wahdan-Alaswad, et al., 2013; Litchfield, et al., 
2015).  
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1.8.2 Culture models 
All tumours consist of a large heterogenous collection of cells (Reya et al., 
2001). Experimenting on the cells has always been a difficult process. Only a 
small amount of material from biopsy is available for use and then not all of 
the remaining tissue is viable for tissue culturing and investigation. Exclusively 
working solely on such finite samples makes consistent longevity of such work 
a logistical problem. The main alternative method is the creation of in vitro cell 
cultures.  
The act of culturing cells for experimentation has become an important model 
for modern molecular biology, but most modern culturing techniques have 
origins from plant culture systems modernised during the 1940s (Thorpe, 
2007). Culturing animal and cancer cells is a more complex process. The first 
successfully created immortalized human cancer cell line was generated from 
cervical cancer in 1951, now referred to as Hela cells (Lucey, et al., 2009). 
Since then many GBM cell lines have also been derived from human tumours, 
including U251MG, U87MG and U373MG (Ponten et al., 1968, Westermark et 
al., 1973; Ponten et al., 1978). All these cultures are readily available 
worldwide. However, since the initial production, the introduction and use of 
these cell lines has caused several problems. In 1999, a cross contamination 
of U251 and U373 has occurred. Though the full extent of the mix up will 
probably never be fully ascertained, a great deal of work will have been 
completed and published under incorrect assumptions (Torsvik et al. 2014).  
The use of cell cultures has been a mainstay as a biological system since its 
inception, however now under more modern assessment techniques, its 
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reliability and use are being scrutinized. When compared to its original 
progenitor sample, U251MG cell cultures no longer retain genotypic and 
phenotypical features that were present 60 years ago. Comparison of high and 
low passage U251MG showed that, over time, the cell line loses its typical GBM 
signature while also gaining many genetic deletions and duplications (Torsvik 
et al., 2014). This highlights the need for embracing more relevant biological 
models of cell culture. A middle ground between experimenting directly on 
biopsy material and using immortal cell lines are short term cell cultures. Short 
term cell cultures are cells processed in the same manner to a regular cell line 
but are not used above a fixed passage (Speirs et al., 1998; Roberts et al., 
2017). The use of cells in this manner should prevent the culture from, 
phenotypically and genetically, deviating to heavily from its original source. 
This allows the cultures to remain a good representative model of the original 
tumour, that it was generated from, while at the same time also providing an 
ample supply of cellular material to serve as a functional system. 
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1.9 Summary  
GBM possess a genetically variable phenotype and currently has limited 
treatment options with positive outcomes. Developing new treatment solutions 
for sub-sets of GBM could generate targeted treatment possibilities. Metformin 
has potential as an anti-tumour therapy and can potentially synergistically 
work with other treatments. Research and clinical trials are already 
investigating metformin use in several tumour types. Investigations into the 
use of metformin on GBM are limited and the mechanisms of action through 
which metformin can act are not understood. The mechanism, inducing cell 
death, effects on tumour metabolism and regulation of miRNA, are all areas 
where further knowledge is needed before metformin can be assessed as a 
GBM treatment option and utilized for clinical trials. The limitations of immortal 
cell lines combined with the inherent genetic variability of GBM do not make 
the cultures a suitable assessment model. Understanding the effect metformin 
has on a diverse range of GBM short term cell cultures will generate a unique 
response profile and identify potential target sub-groups.   
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1.10 Aim and objectives 
Metformin has been identified as a possible candidate for repurposing as a 
cancer therapeutic. The underlying anti-tumour mechanisms of metformin are 
not well understood. This study hypothesises that metformin can be 
demonstrated to act as an anti-GBM agent in vitro. The aim of this study was 
to utilise characterised patient derived short term cell cultures to investigate 
the potential of metformin as repurposed GBM treatment. The objectives of 
this study were:  
•  To investigate the efficacy of biguanides to inhibit proliferation of GBM 
cells in vitro under a range of physiological conditions.  
• To determine whether metformin acts synergistically with other drugs 
including disulfiram, TMZ, sodium oxamate and sorafenib. 
•  To analyse the effect of glucose availability on metformin sensitivity 
and levels of induced cell death  
• To understand the role of metformin in inducing cell death in GBM 
cultures. Identifying the mechanism of action and potential pathways utilised 
including apoptosis, caspase analysis and mitochondrial membrane potential. 
• To identify and evaluate candidate miRNAs with expression changes 
affected by metformin.    
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Chapter 2 Materials and methods 
This study was conducted under ethical approval granted by the Life Science 
Ethics Committee, University of Wolverhampton, LSEC/22/0909 
2.1 Cell culture 
2.1.1 Cell Cultures 
All patient-derived short-term cell cultures had been previously established 
from fresh GBM biopsy material obtained during surgical resection at the 
National Hospital for Neurology and Neurosurgery between 1980 and 2008 
(Professor John Darling). All tumour tissues were classified according to WHO 
criteria (Louis et al., 2007). Tumour samples used for cell culture were surplus 
to diagnostic requirements and were anonymised at source. Cultures were 
established as described by Lewandowicz et al. (2000) and stored in liquid 
nitrogen until required.  
Thirteen GBM short-term cell cultures were utilised up to passage 20. The 
established GBM cell line, U251MG, passage 78-86, was provided by Dr Darrell 
Bigner, Duke University, USA (Bigner et al., 1981). A normal human astrocyte 
culture (NHA)(Lonza), passage 2-10, was used as a non-cancerous control. 
Details of cultures are provided in Table 2.1.  
2.1.2 Maintenance of cell cultures 
All cell culture work was completed within Biomat 2 sterile class II Laminar 
flow hood using Sarstedt tissue culture consumables. Culture vials were 
removed from liquid nitrogen and immediately placed into a 37oC water bath 
for 1 minute. The contents of the vial were transferred to a fresh 25ml 
universal tube and 2ml of 37oC media was add drop by drop to the tube. The 
tube was then centrifuged for 5 minutes at 1200xg. After confirming a visible 
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pellet had gathered the supernatant was aspirated. Fresh growth media was 
added to gently resuspend the pellet and then was transferred into a T25 
growth flask and placed in a Panasonic MCO-170AIC-PE IncuSafe carbon 
dioxide (CO2) Incubator at 37ºC (Panasonic UK). Fresh media was provided to 
growing cultures every 36 hours. Cells were passaged when confluent by 
washing with PBS (Life Technologies) followed by treatment with 3 ml trypsin 
(Sigma Aldrich, UK) for 5 min at 37 ºC to detach the adhered cells. Trypsin 
was inactivated by the addition of 10 ml culture media. After removing from 
the flask, the cell suspension was centrifuged at 1200xg for 5 min and cells 
resuspended in fresh media and sub-cultured into new tissue culture flasks 
using a split ratio of 1:3.  
For long-term storage of cells in liquid nitrogen, 1x106 cells were re-suspended 
in a 1ml mixture of 10% DMSO (Sigma Aldrich, MERCK, UK) and 90% FCS. 
The 1 ml solutions were transferred to cryovials and left overnight at -80ºC in 
a NALGENE® Mr. Frosty (Thermo Scientific, UK). After 12 hours, the cryovials 
were moved to liquid nitrogen for indefinite storage.  
2.1.3 Growth media 
NHA cultures were grown in ABM Basal Medium supplemented with AGM 
SingleQuot Kit Suppl. and Growth Factors (Lonza, UK). This proprietary cell 
growth medium solution contains 4.80% gentamicin sulphate to prevent 
microbial growth. NHA cultures were grown in vented flasks at 5% CO2 and 
stored in a standard pressure sealed incubator at 37oC.  
All other cultures were grown in HAMs F-10 supplemented with Australian 10% 
FCS (Gibco, UK) without antibiotics or anti-microbial agents. Cultures were 
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grown in non-vented flasks in a standard growth incubator under normoxic 
conditions. The F-10 media contained HEPES to maintain the optimum pH and 
removing the need to use a CO2 incubation unit.  
For experiments in which cells were grown in varying glucose levels, glucose-
free HAMs F-10 (PAN Biotech) supplemented with 10% FCS, HEPES and 
glucose to the desired levels (Sigma, UK). Appendix I contains a breakdown 
of the F-10 media formulations used for all experiments. 
2.1.4 Growth proliferation curves 
1x105 cells were seeded into 8 x T25 flasks and proliferation was measured 
over a 10-day time course. Readings were taken at 1, 2, 3, 5, 7, 9 and 11 
days. For time point, cells were trypsinised, collected and re-suspended in 
growth media before being counted using a version 1 Countess Cell counter 
(Thermo Fisher). Live cells were stained with trypan blue growth media mix 
(1:1) and then counted. The reading was the average of two separate readings 
and each completed growth curve was the average of three repeats.  
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Table. 2.1 Details and characterisations for all cell cultures. 1IN-Institute of Neurology; 2M = Male, 
F = Female; 3Age listed in years at diagnosis; 4L = Left, R = Right; 5The mutation status of the tumour 
protein gene P-53 characterised through sequencing (Potter et al., 2018); 6MGMT status identified by 
methylation specific PCR (Licchesi et al, 2009).  
 
 
 
 
Sample1 Sex2 
Age at 
diagnosis3 
Location4 TP-53 status5 
TP53 
deletion 
MGMT status6 
EGFR over 
representation 
IN859 F 72 R frontal Deletion Yes Methylated chr 7p 
IN1265 F 70 R occipital exon 5 codon 160-162 DEL GGCCAT - Unmethylated chr 7p 
IN1461 F 44 L Parietal Wild type - Unmethylated chr 7p 
IN1472 F 46 Unknown 
exon 9 codon 319 AAG>TAG, LYS> 
STOP 
Yes Unmethylated - 
IN1528 M 61 
R temporo-
parietal 
exon 8 codon 272 GTG>GAG, 
VAL>GLU 
Yes Methylated chr 7p 
IN1612 M 53 
R post-
temporal 
Aberrant Yes Unmethylated chr 7p 
IN1682 F 48 R parietal Wild type - - chr 7p 
IN1752 M 45 Unknown Wild type - - - 
IN1760 F 56 L temporal Wild type - 
Partial 
methylation 
chr 7p 
IN1951 M 30 R parietal Wild type - Unmethylated - 
IN1979 M 46 
L temporo-
parietal 
exon 8 codon 267 CGG>CCT, 
ARG>PRO 
Yes Unmethylated - 
IN2045 M 25 L frontal 
exon 6 codon 215 AGT>GGT, 
SER>GLY, exon 7 codon 248 
CGG>TGG, ARG>TRP 
- 
Partial 
methylation 
- 
IN2093 M 55 R frontal Wild type - Unmethylated - 
U251MG - - - 
exon 8 codon 273 CGT>CAT, 
ARG>HIS 
- 
Partial 
methylation chr 7p 
NHA N/A N/A N/A Wild type - Unmethylated - 
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2.2 Growth Inhibition Assays 
2.2.1 Drugs 
Metformin, phenformin, sodium oxamate, camptothecin and temozolomide 
were purchased from Sigma Aldrich. Sorafenib was purchased from Cambridge 
Bioscience, UK.  
2.2.2 Determination of ID50 growth inhibition and drug synergy 
Cells were seeded into a 96 well plate at 4000 cells per well (CPW) in 200µl 
growth media and incubated until exponential growth phase has been 
reached. Drugs were prepared to required concentrations and serial diluted 
with growth media in a separate 96 well plate. The media was aspirated and 
replaced with media containing appropriate concentrations of drugs before 
being returned to the incubator for 72 or 96 hours. Media was aspirated, and 
the cells fixed to the plate using 150µl TCA and placed at 4oC. After 1 hour, 
the plate was washed twice in water removing excess TCA. Viability of cells 
was then assessed using the sulforhodamine B (SRB) colorimetric assay 
(Vichai, 2006). Staining of the cells was completed by adding 100µl of 0.4% 
SRB (Sigma, Merck) suspended in 2% acetic acid (Sigma, Merck) to each well. 
The plate was left for 1 hour at room temperature before being washed twice 
with water. Plates were dried at 37oC for 1 hour before being analysed. Two 
hundred µl of 10mM Tris solution (Sigma, Merck) was added to each well and 
gently mixed for 5 minutes till all the SRB dye had re-entered suspension. 
Plates were read for absorbance in a GloMax®-Multi Microplate Reader 
(Promega) at a wavelength of 560nm. Each plate used eight concentrations 
of drug and two negative controls grouped in batches of 3 replicates. From 
the replicates, outliers could be removed, and average data generated.  
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2.2.3 Calculation of ID50 values  
Data points were analysed using GraphPad PRISM software using a 
log(inhibitor) vs. Response or a four-parameter logistic curve (4PL) algorithm. 
This method utilises all the data points against log molar dosages and assumes 
a, non-standard, variable slope as outlined in Fig. 2.1. From this ID50s value 
are output for each drug tested on the cultures. Groupings of data were 
analysed for significant difference of the means using an un-paired students 
t-test. 
 
 
 
Figure 2.1 – Mathematical model used for all analysis on graph pad prism. The 
method allows for variable analysis of the drug response yielding more accurate ID50s than 
seen on a standard curve model. 
2.2.4 ID50 flask setups for experiments  
All setups that utilised the ID50 setups seeded cells at the same concentration 
as tested on the 96 well plates. T25 flasks were seeded with 5ml at 20,000 
cells per ml and T75 flasks were seeded with 15 ml of cells at 100,000 cells 
per ml.  
 
 
 
Model 
Y= Bottom + (Top-Bottom) / 
(1+10^((LogID50-X)*Hillslope)) 
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2.2.5 Drug Synergy Assays 
For synergy analysis, cultures were treated with single or paired drug 
combinations. ID50 values calculated using cytotoxic SRB assay outlined in 
2.3.2. Doses for metformin were in the mM range. Figure 2.2 illustrates the 
layout of a combination SRB 96 well plate. The concentrations used in the 
combined drug wells were equimolar to the equivalent wells of the mono-drug 
treatment. ID50 values for each combination of the experiment were analysed 
using graph pad prism software. Drug synergy was determined by calculating 
a combination index (CI) using the Chou-Talay method (Chou., 2010). The full 
equation of this method is given in Figure 2.3. CI values < 1 and > 1 were 
considered to be synergistic and antagonistic, respectively. Values of 1 were 
defined as having an additive effect when used in combination. The further 
the CI deviated, in both directions, from 1 the stronger the net effect. Each 
synergy plate contained two replicates per combination and each plate was 
repeated three times.  
 
 
 
 
 
 
 
 70 
   
 
 
 
 
 
 
Figure 2.2 – Layout of 96 well plate for Chou Talay synergy assays. Each drug was 
assessed with two replicate data sets. Drugs were serially diluted along each row. Highest 
concentration was in column 2 and lowest in column 9. Columns 10 and 11 were used as 
control wells for untreated growth comparison. Metformin wells (Blue) dose ranged from 
80mM to 0.625mM. Drug concentrations used for each drug tested were selected based on 
the pre-assessed ID50 values for GBM cultures. Concentration used for the drug combination 
rows were kept in equimolar dosage with the mono treatment counterparts.  
 
 
 
 
 
 
 
 
METFORMIN 
METFORMIN + DRUG A 
 
DRUG A 
UNTREATED 
 71 
   
 
 
 
 
 
Figure 2.3 – Chou Talay synergy equation. The equation for working out the CI of each 
drug assessed with the Chou Talay synergy assay (Chou., 2010). Met Solo and A solo 
represent the ID50 values for metformin and the assessed drug when used as individual 
treatments. The ID50 values represent the sensitivity of the cell to that individual drug. Met 
combo and A combo represent the ID50 of the drugs when used together in an equimolar 
combination. The ID50 values represent the sensitivity to the drugs when used in combination. 
The equation divides the combination ID50 value by its individual treatment counterpart. The 
CI index is then generated from the values for each drugs response. The drugs must average 
a contribution to the total CI index of less than 0.5 each to be determined as achieving a 
synergistic response. A resulting CI index of less than 1 implies the combination of the drug 
produces a response greater than sum of the individual treatments.  
 
 
 
 
 
 72 
   
2.3 Assessment of glucose 
The concentrations of glucose in media was determined using by using a 
OneTouch Ultra diabetic glucose meter (OneTouch) and disposable 
measurement sticks. The accuracy of the device was assessed using reference 
standards created using glucose added to PBS and growth media. To assess 
the cellular use and uptake of glucose, cultures were grown in T25 flasks in 5 
ml of the desired media formulation. Every 24 hours 25µL of media was 
removed and added to a measurement stick. This was repeated till the time 
course was finished at 96 hours  
2.4 Flow cytometry 
All flow cytometry analysis was carried out using a BD Accuri C6 Plus cell 
analyser (BD Biosciences UK). All protocols were set to record 20,000 counts 
from the required gating. Cells were always run at a slow flow rate speed 
(14µl/min flow rate, 10µm samples core). This kept core stream size to a 
minimum, reduced the spread of the results and reduce the number of 
coincident events. Initial gating was set for each experiment using U251MG 
cells with and without camptothecin to induce apoptosis. Camptothecin was 
used at 100µM over a 72-hour period to induce a positive apoptotic control.  
2.4.1 Detection of apoptosis 
The BD Pharmingen Annexin V FITC Apoptosis Detection Kit I was used to 
assess early apoptosis and its progression over time. For each experiment, 
cells were measured every 24 hours over a 96-hour period. For each time 
point, 5 x103 cells were seeded into a T25 flask. To analyse the total cell 
population all media was collected from each flask to include any floating cells 
and any adherent cells were detached with trypsin. Harvested cells were then 
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washed twice with cold PBS before being resuspended in 1x Binding buffer at 
a concentration of 1x106 cells/ml. 100µl of this solution (1x105 cells) was 
transferred to a sterile 25 ml universal tube and 5µl of FITC Annexin V and 5µl 
of PI were added. The tube was gently vortexed and placed in the dark for 30 
minutes at room temperature. Finally, 400µl of 1X Binding Buffer was added 
to the tube. The cells were gently mixed and then placed into the flow 
cytometer. The setup and gating used for analysis was adapted from 
templated provided by BD Biosciences. The gating for the readings was aligned 
against the untreated control of each culture.  
2.4.2 Mitochondrial membrane potential 
BD MitoScreen (JC-1) Kit was used to assess the potential of the mitochondrial 
membrane (ΔΨ). Cells were grown in T25 flasks till the exponential growth 
phase was reached. Cells were then treated for 72 hours with drug or vehicle 
control, after which the growth media was collected, and trypsin was used to 
remove any remaining adherent cells from the flask. Cells were centrifuged at 
1200xg and supernatant aspirated. 5ml PBS was used to wash the cells before 
being centrifuged at 1200xg. The cells were resuspended in 500 µl of JC-1 
working solution and incubated for 15 min in a 37oC CO2 incubator. The cells 
were centrifuged at 1200xg and washed with 1x assay buffer before being 
analysed in a flow cytometer. The setup and gating used for analysis was 
adapted from templated provided by BD Biosciences. The gating for the 
readings was aligned against the untreated control of each culture. 
Camptothecin was used at 100µM over a 72-hour period to induce a positive 
apoptotic control. 
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2.4.3 Cell cycle  
Analysis of cell cycle was completed with propidium iodide stained ethanol 
fixed cells. Cells were grown in T25 flask and treated with metformin at 96-
hour ID50 values. After 96 hours of incubation the cells were trypsinised 
(approximately 1x106 cells) and placed in a 10ml sterile universal. Cells were 
centrifuged at 1200xg and supernatant aspirate out. Cells were the washed 
with 5ml PBS. After discarding the supernatant, the pellet was resuspended in 
200µl PBS. While being vortexed, 2 ml of 100% ice cold ethanol was added 
slowly in drops to the solution. This was to prevent clumping of the cells. Cells 
were then left overnight at -20oC. To the 10ml universal, 8ml of PBS was added 
and the tube was then centrifuged at 1600xg for 5 min. Ethanol fixed cells are 
more buoyant and required higher speeds to successfully pellet them. This cell 
pellet was then washed again with PBS removing any remaining ethanol. To 
the washed pellet 300µl of a PI mix (100µg/ml RNASE A, Propidium Iodide 
50µg/ml in PBS) was added to the cells. Cells were then incubated at room 
temperature for 15 minutes before being ran through the flow cytometer.  
Doublet cells, two cells in G1-phase being record as one event by the flow 
cytometer, were prevented from causing false G2/M positives by plotting FL2-
A versus FL2-H. This allowed for discrimination between G1 doublets and G2/M 
single cells and generation of suitable gating to remove them (Rafael, 2001). 
Gating groups were defined to separate out the stages of cell division (G0/G1, 
S, and G2/M) as given in Figure 2.7. A sub-G1 population was also created to 
analyse the level of DNA fragmentation and concentration of late apoptotic 
 75 
   
cells. (Darzynkiewicz and Zhao, 2014). Camptothecin was used at 100µM over 
a 72-hour period to induce an apoptotic control. 
 
 
 
 
 
 
Figure 2.4 Examples of flow cytometry cell cycle analysis. Diagrams represent cell 
cycle analysis results. The amount of propidium iodide staining detected on the FL-2A channel 
represents quantity of DNA present with the cell. Cells in G0/G1, green region, are cells in 
resting state with normal levels (n=2) of genetic material. As cells enter S-phase, pink region, 
DNA starts to replicate and FL-2A reading increases. Upon reaching G2/M phase, blue region, 
the cell possesses double the quantity of DNA (n=4). Upon dividing flow cytometer will detect 
the daughter cells as separate G0/G1 cells. An increase in the population of a phase may be 
indicative of cells arresting in cell cycle at that progression check point. A) A standard pattern 
for cell cycle analysis from a flow cytometer. The different regions are as follows: G0/G1 – 
Green, S – Pink, G2/M – Blue, Sub-G0/G1 – Red. The red horizontal line indicates the apoptotic 
cell cut off (sub-G0/G1, n<2). B) An example of apoptosis cells induced by camptothecin. Cells 
undergoing apoptosis have fragmented DNA. This is detected as low reading in the FL-2A 
channel and allows for the separation of apoptotic populations. 
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2.5 Caspase pathway analysis 
Caspase values were assessed using promega Caspase-Glo (Promega) assay. 
This assay cleaves the caspase-3/7 releasing a substrate for luciferase (amino 
luciferin). This leads on to a luciferase reaction which as a by-product will 
produce light that can be detected in a plate reader. The complete experiment 
is summarised as a flow diagram in Figure 2.8.  
Cells were grown simultaneously on two 96 well growth plates. One plate was 
fixed, stained and analysed using the SRB assay outlined in 2.3.1. 
Simultaneously, the second plate was exposed to 200 µl of Caspase-Glo mixed 
reagent. The plate was then put on a plate mixer for ten minutes followed by 
being incubated at room temperature in the dark for twenty minutes. The 
ensuing cell solution was transferred to a white walled 96 well plate and then 
luminesce was recorded on a Promega Glomax plate reader. Each measured 
value from the Caspase-Glo sample was then normalised against its respective 
sample from the SRB plate. This normalisation allows for a better 
representation of caspase 3/7 activity per cell. Camptothecin was used at 
100µM over a 72-hour period to induce a positive apoptotic control. 
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Figure 2.5 Flow diagram of Caspase-glo assay with normalisation. Standard caspase 
glo assay was augment with an SRB assay run alongside under identical treatment conditions. 
The addition of this extra simultaneous assay allowed for the normalisation of the luminesce 
from the caspase assay based on the number of viable cells. 
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2.6 miRNA analysis 
2.6.1 Database analysis 
Microarray expression and isoform data from the TCGA was downloaded and 
individual miRNAs were compared across a range of tumour types using MS 
Excel. Data was normalised against miR-17 used as a normal endogenous 
control (Davoren et al., 2008). 
2.6.2 Extraction of RNA 
Cells for miRNA extraction were seeded at of 4.8x104 cells per ml and grown 
in T75 flasks until the exponential growth phase was reached. Cells were then 
treated at the relative ID50 concentrations for metformin at 37oC for 96 hours 
before harvesting them for RNA extraction using a miRVANA RNA extraction 
kit according to the manufacturer’s instructions. Cell pellets were washed with 
PBS and transferred to a 1.5ml Eppendorf. After centrifugation and removal of 
supernatant, 450µl of Lysis/binding solution was added and the resulting 
solution was vortexed. To the homogenous lysate 45µl of miRNA homogenate 
Additive was added and the lysate was left on ice for 10 min. After this 450µl 
of Acid-Phenol: Chloroform and the tube was vortexed for sixty seconds to 
mix. The tube was then centrifuged for five minutes at ten thousand G at room 
temperature. The upper phase (aqueous) was transferred to a fresh tube with 
x1.25 the recovered total volume of 100% ethanol. The total lysate/ethanol 
mixture was placed into a filter cartridge tube, centrifuged for 15 seconds and 
the flow through discarded. 700µl of miRNA Wash solution 1 was added to the 
filter cartridge and centrifuges for 10 seconds. The flow through was discarded 
and this step was then repeated twice with 500µl of Wash solution 2/3. After 
the second wash step, the filter cartridge was spun for one minute at 
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maximum speed to remove any residual fluid. The filter cartridge was moved 
to a new collection tube and 100µL of pre-heated 100oC water was added. 
Collection tube with filter cartridge was then spun at maximum speed for 30 
seconds. Water in collection tube now contained total RNA from extraction. 
Filter cartridge was then discarded and the total RNA in collection tube was 
stored at -80oC until required. 
2.6.3. Assessment of total RNA 
Assessment of the quantity and quality of extracted genetic material was 
carried out on a NanoDrop 2000 spectrophotometer (Thermo Scientific, UK). 
This outputted the concentration of nucleic acids as ng/µl. This was equated 
using a modified Beer-Lambert, c = (A*ϵ)/b, it utilizes the concentration 
(c)(ng/µl), the absorbance (A) in Au (260 nm), the wavelength dependent 
extinction coefficient (ϵ) (ng-cm/µl) and pair length (b) (cm). The ratio 
between the genetic material (260nm) against precipitated proteins (280nm) 
and organic compounds/chaotropic salts (230nm) was used to assess quality 
of each sample. A260/280 ratios above 2 and 2.0-2.2 for A260/230 were 
deemed pure and useable for miRNA experiments. Quantification from 
Nanodrop was used to equalise all RNA samples used to a concentration of 
20ng/µl. 
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2.6.4 Stem Loop PCR  
Assessment of miRNA levels was carried out using specific stem loop primers 
as outlined by Chen et al. (2005). 
2.6.4.1 Stem loop primer design  
Information required for the design of stem loop primers was acquired from 
MiRBASE (http://www.mirbase.org) for use with the miRNA primer designer 
tool. This tool was developed by Fuliang Xie for the East Carolina University 
(Xie, 2015). Output from this tool would give the three primers required for 
each PCR (stem-loop RT, forward and reverse primers) and were purchased 
as custom DNA oligos from Sigma UK.  
2.6.4.2 Stem loop reverse transcription and PCR 
Reverse transcription of the miRNA was completed using a TaqMan MiRNA 
Reverse Transcription Kit (Thermo Fisher, UK), following manufacturer’s 
instructions. Stem loop cDNA was generated from the kit using a reaction 
volume of 20µl with 40ng of extracted total RNA and 10µM of Stem loop PCR 
primers (Sigma, UK). PCR of the miRNA samples was amplified for 30 cycles 
using specific primers in a reaction volume of 40µl contain 2mM dNTP (Sigma 
UK), 2.5 mM MgCl2 (Qiagen UK), 20μM of each forward and reverse miRNA 
primer (Sigma UK) and 1 unit of HotStarTaq DNA polymerase (Qiagen UK).  
2.6.4.3 Gel Electrophoresis 
Amplification products were separated on a 2% agarose electrophoresis gel 
(Themo fisher) in 1x TBE buffer (Geneflow), visualised with ethidium bromide 
(SIGMA, MERCK) and compared with a 50bp DNA ladder (Thermo Scientific). 
Gels were scanned using Gel DocTM EZ imager and analysed with Syngene 
Gel software.  
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2.6.5 Quantitative Real time PCR 
Q- PCR was carried out using TaqMan assays (Fisher Life Technologies UK) 
using an Applied Biosystems 7500 Fast Real-Time PCR system. The creation 
of the cDNA from total RNA was completed using TaqMan MiRNA Reverse 
Transcription Kit (Thermo Fisher, UK) as listed in 2.7.7 with the replacement 
of using 3µl of Taqman RT primer (Fisher Life Technologies UK). Data from 
PCR was used to work out expression fold change (2^-ΔΔCt) for all samples. 
Analysis For the normalisation of the results the snRNA U6 (RNU6B) was used 
as an endogenous housekeeping control. Selection of an endogenous control 
for miRNA analysis is not straightforward. There is a fair amount of conflicting 
research as to suitability of all choices (Occhipinti et al., 2016). Applied 
Biosystems recommend the use of U6 as a candidate control gene for use in 
miRNA data analysis (Applied Biosystems, 2011). However, Xiang et al. (2014) 
showed that in nasopharyngeal carcinoma samples that U6 showed variation 
between samples and that it was susceptible to decay after repeated freeze 
thaw cycles. In liver carcinoma, it has also been shown that there can be 
variation between the expression in normal tissue and carcinoma cells (Lou et 
al., 2015). Despite this though U6 has previously been used for miRNA 
normalisation in tumour analysis (Gee et al., 2011) and is still used in as a 
common choice for qRT-PCR normalisation (Chang et al., 2018; Lin et al.,2018; 
Manzine et al., 2018; Zhou et al., 2018) 
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2.7 Statistical tests and data processing 
For most experiments, a minimum of three biological repeats were created to 
allow for statistical analysis. This allowed for standard deviations on all data 
to be equated and t-tests to be carried on identifying the significance of the 
data. T-tests were carried out using graph pad web tool QuickCalcs. All graphs 
were created using Microsoft Excel Open office version 1701 (Build 
7766.2096). Error bars for all graphs display the standard error of the mean 
for each sample based on its replicates. Graph pad prism version 7.03 was 
used for all the calculations of ID50 values on all samples. Linear regression 
analysis was carried out using the data analysis module for Microsoft Excel. 
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Chapter 3 Results 
3.1 Growth characteristics and biguanide growth inhibition in 
GBM in vitro 
Metformin has been identified to have anti-tumour potential in cancer 
prevention and reduction of cancer severity (Heckman-Stoddard et al., 
2017). Initial experiments identified if this was identifiable in GBM. The 
experimental panel of 13 short term GBM cell cultures, 1 immortalised cell 
line (U251MG) and NHA were assessed initially for biguanide drug 
cytotoxicity. However, to provide optimal drug treatment during exponential 
growth of each culture, the doubling time of the entire panel had to be 
evaluated. This then allowed cytotoxic experiments to proceed to generate 
ID50 values for the culture panel.  
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Cultures ordered highest to lowest based off the doubling time. 1All cultures marked with a + indicate P53 
wild type. 2 Doubling time of the cultures taken in hours from initial seeding of culture flasks. All samples 
are averaged from three replicate time courses with two counts at every sample read. Doubling times 
worked out from the highest gradient of plotted growth curve during exponential growth phase. P53 wild 
type cultures possess relatively higher doubling times compared to those cells possessing mutations. 
3.1.1 Growth curves  
All cultures grew successful under relevant conditions as detailed in section 
2.1.4. Figure 3.1 shows growth curves for all cultures used. The doubling times 
of each culture measured from the highest gradient of the exponential phase, 
are listed in table 3.1. The doubling times for the GBM cells ranged from 24 
hours (U251MG) to 70 hours (IN2093). with a mean doubling time of 40 hours 
and a median of 42 hours. NHA, the normal cell control, had the second 
slowest observed doubling times.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Culture1 
Doubling time2 
(Hours) 
U251MG 24 
IN859 24 
IN1612 28 
IN1528 32 
IN1979 35 
IN2045 36 
IN1760+ 40 
IN1752+ 44 
IN1472 45 
IN1682+ 50 
IN1265 50 
IN1951+ 55 
IN1461+ 60 
NHA+ 63 
IN2093+ 70 
Table 3.1. Doubling time of culture panel 
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Fig 3.1 Graph displaying the growth curve data for all GBM cultures tested alongside NHA. 
Cultures seeded at day zero with 2x105 cells. Cultures were collected at eight-time points along time course. 
Data shown is averaged from three replicate time courses. Doubling times for cultures generated from the 
highest gradient on each time course during its exponential growth phase.   
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GBM cultures possessing a P53 mutation or deletion versus had significantly 
shorter doubling times compared to the P53 wild type cultures (P=0.0046).  
3.1.2 Growth inhibition  
3.1.2.1 Metformin 
All GBM cultures treated with metformin showed a cytotoxic response after 
more than three days of exposure. Table 3.2 lists the ID50 values for metformin 
treated cultures for 72h and 96h. ID50 values for cultures tested fell within a 
milli-molar scale (1-100mM). Following both 72h and 96h exposure, there was 
a very significant difference (P=0.0006, P=0.0024) in response to metformin 
based on P53 status. Cultures with P53 wild type were less sensitive to 
metformin and generally had higher ID50 values that P53 aberrant cultures. All 
P53 aberrant cultures, and two of the P53 wild type cultures, showed a 
significant reduction (p<0.05) in ID50 values after an additional 24 hours of 
drug treatment. At both time points, IN859 was the most sensitive culture with 
ID50 values below 10mM. NHA had a high tolerance of metformin; the ID50 
was the highest in all cultures tested at both 72 and 96 hours as expected for 
a non-tumour control. The percentage reduction in ID50 at 96 hours exposure 
compared to 72 hours varied between cultures with the lowest being IN1461(-
7%) and the highest being IN1528 (-59%). Figures 3.2a and 3.2b display the 
averaged results from the SRB growth inhibition assay. Complete SRB toxicity 
data for 72 and 96 hours metformin drug treatment can be found in 
Appendices 1 and 2 respectively.  
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Table 3.2 – ID50 values for all cultures treated with metformin.  
1 All cultures marked with a + indicate P53 wild type. 2 Metformin ID50 concentration. Standard deviation for each 
average is listed after each result (±). P53 sub groups are ordered lowest to highest based on the 96-hour metformin 
ID50. 3 Percentage reduction in the ID50 value of the culture going between the 72 and 96-hour time point. 4 P-value 
for the statistical difference between the means of the 72 and 96-hour metformin ID50 values. Level of significance is 
denoted with *.   
 
Culture 
reference1 
P53 Status 
Metformin 
ID50 72 hours 
(mM)2 
Metformin 
ID50 96 hours 
(mM)2 
Reduction in 
ID50  
72hr v. 96hr 
metformin 
treatment3 
P-value4 
IN859 Aberrant/Deletion 6.38 (±1.78) 4.52 (±0.6) -29% 0.0209* 
U251 MG Aberrant 11.44 (±2.35) 4.83 (±2.11) -58% 0.0223* 
IN1472 Aberrant 11.75 (±3.38) 5.38 (±0.26) -54% 0.0315* 
IN2045 Aberrant 12.11 (±4.38) 6.41 (±3.50) -47% 0.0405* 
IN1528 Aberrant 26.20 (±1.11) 10.78 (±0.42) -59% 0.0001*** 
IN1612 Aberrant 18.28 (±3.93) 10.82 (±3.73) -41% 0.0291* 
IN1265 Aberrant 20.22 (±3.74) 11.13 (±2.05) -45% 0.0209* 
IN1979 Aberrant 30.01 (±1.6) 25.66 (±3.84) -14% 0.0142* 
IN1760+ Wild Type 22.90 (±1.6) 11.59 (±5.05) -49% 0.0211* 
IN1682+ Wild Type 36.22 (±6.45) 24.87 (±5.41) -31% 0.0796 
IN1752+ Wild Type 48.93 (±9.83) 29.19 (±5.62) -40% 0.0393* 
IN1461+ Wild Type 61.13 (±4.7) 56.59 (±6.89) -7% 0.4001 
IN1951+ Wild Type 69.52 (±8.9) 57.33 (±4.26) -18% 0.0993 
IN2093+ Wild Type 69.29 (±14.57) 63.7 (±7.17) -8% 0.5829 
NHA+ Wild Type 90.95 (±14.39) 84.3 (±8.50) -7% 0.5285 
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Figure 3.2a – Graph showing SRB cytotoxicity assay results for culture panel at 72 hours 
metformin treatment. Percentage cell survival is measured by comparing each OD value against 
averaged OD value at control well (0mM metformin). Error bars display standard deviation averaged 
from 3 replicates. Serial dilution drug concentrations ranged from 100mM at highest to 0.78mM at 
lowest achieved through serial dilution. P53 wild type data points coloured white, NHA data points 
coloured black 
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Figure 3.2b – Graph showing SRB cytotoxicity assay results for culture panel at 96 hours 
metformin treatment. Percentage cell survival is measured by comparing each OD value against 
averaged OD value at control well (0mM metformin). Error bars display standard deviation averaged from 
3 replicates. Serial dilution drug concentrations ranged from 100mM at highest to 0.78mM at lowest 
achieved through serial dilution. P53 wild type data points coloured white, NHA data points coloured black 
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3.1.2.2 Retreatment of metformin  
Metformin is not metabolised in the human body and not known to accumulate 
in normal tissue (Bailey, 2017). However, to assess the features in GBM cells 
four GBM cultures were assessed for differences in ID50 values following 96-
hours exposure to metformin with daily replacement of growth media and drug 
compared to a single treatment at the start of the assay (Table 3.3). The four 
cultures utilized were the most sensitive to metformin treatment and with the 
lowest ID50 values of the panel. All four cultures showed a significant increase 
in ID50 value after daily retreatment with metformin. U251-MG exhibited the 
highest change in ID50 value with daily metformin dosage showing an increase 
of over 200% compared to single treatment. IN859 and IN1472 showed a 
highly statistically significant change in ID50 value with p values of 0.0051 and 
0.0026 respectively. Figures 3.3 shows the results of the retreatment 
experiments. U251MG and IN859 showed the largest increase in ID50 values. 
The two cultures also showed the lowest doubling time of the panel in Table 
3.1.  
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Table 3.3 – ID50 values for all cultures treated with metformin.  
All values are the average of three repeats that all are within the mM dose range. Standard deviation for 
each average is listed after each result (±).2Percentage change in theID50 value of the culture when 
compared against single dose time course. 3P-value for the statistical difference between the means of the 
ID50 single vs multiple treatments at 96 hr. Level of significance is denoted with *.   
 
Culture 
reference 
P53 Status 
Metformin 
ID50 96 
hours (mM)3 
Metformin 
ID50 daily 
retreatment 
(mM)1 
% Change in 
ID50 single vs 
multiple 
treatments at 
96 hr2 
P-value3 
U251MG Aberrant/Deletion 3.77(±1.5) 11.43(±2.08) +204% 0.0418* 
IN859 Aberrant 3.4(±1.48) 15.2(±5.3) +342% 0.0051** 
IN1472 Aberrant 4.77(±1.24) 12.2(±1.47) +155% 0.0026** 
IN2045 Aberrant 4.9(1.21±) 14.3(±4.47) +192% 0.00246* 
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Figure 3.3 – Graphs of 96-hour daily retreatment of metformin compared with solo treatment. All cultures 
demonstrated a significant increase (p>0.05) in metformin ID values when retreated with metformin. All cultures tested 
were P53aberrant cultures that had demonstrated sensitivity to metformin in 96-hour ID50 values as shown in table 
3.2. One treatment cultures were dosed with metformin at the start of the 96-hour time course and incubated. Multiple 
treatment cultures has growth media and metformin replaced every 24hrs.  
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3.1.2.3 Phenformin 
In addition to testing metformin, other biguanides have anti-cancer potential 
(Jiang et al., 2016). The biguanide phenformin has been discontinued for 
use as a treatment for type 2 diabetes but could still be repurposed to treat 
tumours if shown to be more effective than metformin (Pryor and Cabreiro, 
2015).  
All GBM cultures treated with phenformin showed a cytotoxic response after 3 
days of exposure. Table 3.4 lists the ID50 values for cultures treated with 
phenformin for 72 hours. The ID50 values for phenformin range of 5.74mM 
between 0.29mM (IN859) to 6.03mM (IN1760) at 6.03mM. There is no 
significant association between P53 status and response to phenformin 
(P=0.569). In addition, there is no clear relationship between ID50 values for 
metformin and phenformin after 72 hours treatment. Several of the cultures 
with relatively high metformin ID50 values, have relatively low phenformin ID50 
values, as illustrated in Figure 3.4. All phenformin ID50 values are a magnitude 
smaller than metformin ID50 values but still fall within the mM dose range. Due 
to time constraints and lack of availability of cells, NHA as a normal cell control 
was not able to be completed for the phenformin data set.  
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Table 3.4 – ID50 values for all cultures treated with phenformin.  
1Phenformin ID50 value of cultures. All values are the average of three repeats that all are within 
the mM dose range. Standard deviation for each average is listed after each result (±). P53 sub 
groups are ordered lowest to highest based on the 96-hour phenformin ID50. All cultures marked 
with a + indicate P53 wild type. 2P53 status of each culture was to group cultures together. 
Phenformin cytotoxicity graphs for all cultures can be found in Appendix 3.  
 
 
 
 
 
 
 
 
 
 
 
 
Culture reference P53 Status Phenformin ID50 72 hours (mM)1 
IN859 Aberrant 0.29(±0.06) 
IN2045 Aberrant 0.61(±0.19) 
IN1979 Aberrant 0.74(±0.13) 
IN1528 Aberrant 0.78(±0.35) 
U251 Aberrant 0.87(±0.41) 
IN1612 Aberrant 1.71(±1.73) 
IN1472 Aberrant 2.40(±0.45) 
IN1265 Aberrant 3.87(±3.32) 
IN1682+ Wild Type 0.82(±0.59) 
IN2093+ Wild Type 2.08(±0.65) 
IN1951+ Wild Type 2.43(±0.89) 
IN1461+ Wild Type 3.31(±1.61) 
IN1752+ Wild Type 3.83(±1.90) 
IN1760+ Wild Type 6.03(±0.51) 
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Figure 3.4 – Graph showing SRB cytotoxicity assay results for culture panel at 96 hours phenformin 
treatment. Percentage cell survival is measured by comparing each OD value against averaged OD value at 
control well (0mM metformin). Error bars display standard deviation averaged from 3 replicates. Serial dilution 
drug concentrations ranged from 25mM at highest to 0.19mM at lowest.  
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3.1.2.4 Overview of response of GBM cultures to metformin 
  
ID50 values were generated for all GBM cultures for both metformin and 
phenformin. A summary of ID50 values at the 72-hour time point for both drugs 
is given in Table 3.5. Phenformin ID50 values were lower than metformin ID50 
values in all GBM cultures. The average ID50 values were lower in P53 aberrant 
GBM cultures for both metformin and phenformin, but only metformin values 
showed a significant difference between cultures grouped by P53 status.   
 
 
 
 
 
 
 
 
Average metformin 
72-hour ID50 value 
(mM) 
Average phenformin 72-
hour ID50 value (mM) 
% change 
in drug ID50 
value 
All 
cultures 
33.31 (±22.05) 2.22 (±1.68) -93% 
P53 
Aberrant 
17.86 (±8.41) 1.48 (±1.28) -92% 
P53 Wild 
type 
cultures. 
51.33 (±18.93) 3.08 (±1.78) -94% 
Table 3.5 – Overview of metformin and phenformin ID50 values  
Metformin and phenformin ID50 values were within the mM dose range. P53 status is a significant 
indicator of metformin sensitivity with GBM cultures. P53 wild type cultures have a lower sensitivity to 
the cytotoxic effect of metformin. Phenformin ID50 values are on average an order of magnitude 
smaller than metformin ID50 values but show no relationship with metformin or P53 status. 
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3.1.3 Summary  
3.1.3.1 Growth curves 
Results on culture growth curves showed that P53 was a significant factor 
influencing cell doubling time. P53 is a tumour suppressor gene and activation 
of it has a negative impact on cell proliferation (Kaiser and Attardi, 2018). GBM 
cultures possessing an aberrant P53 would be expected to show higher rates 
of growth. The two cultures with the lowest doubling time are IN859 and 
U251MG (24 hours). A short term low passage culture would not usually be 
expected to grow as fast as a high passage, established, immortalised cell line 
and is indicative of the high heterogeneity present with GBM. IN2093 was the 
slowest growing culture with a doubling time of 70 hours, slower rate of 
proliferation than the NHA normal control with a doubling time of 60 hours. It 
would be expected that, NHA as a normal cell control, would be slower than 
all tumour cells. 
3.1.3.2 Metformin growth inhibition 
An inhibitory growth response to metformin was observed in all GBM cultures. 
A large range in ID50 values was observed in the GBM panel and this variance 
in metformin sensitivity in GBM was associated with cell-specific factors. P53 
was identified as a significant factor in metformin sensitivity of the GBM 
cultures. The role of P53 in response to metformin treatment varies in different 
types of cancer (Sun et al., 2016; Shimazu et al, 2017; Lee et al., 2018).  The 
results obtained in GBM cultures in the current study are similar to previously 
published data in colon cancer, in which P53 -/- xenografts showed higher 
susceptibility than P53+/+ to metformin treatment (Buzzai, 2007). The 
authors hypothesise that metformin treatment is forcing a metabolic 
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conversion that P53-/- are unable to withstand. Conversely in prostate and 
breast cancer, metformin has been to induce P53-dependent apoptosis (Sahra 
et al., 2010; Li et al., 2015; Tran et al., 2017). 
NHA showed the least growth inhibition after treatment with metformin and 
the highest ID50 value at both 72 (90.95mM ±14.39) and 96-hour (84.3mM 
±8.50) time points. The GBM cell culture with the most similar level of 
sensitivity was IN2093; however, the ID50 value at 96-hours was >20mM lower 
than that of NHA. The large difference in the cytotoxic sensitivity of normal 
cells compared to GBM cells indicates that metformin mechanism of action is 
related to cancer specific changes, possibly alterations in metabolism changes 
and the Warburg effect (Wahl and Venneti, 2018). 
Metformin dosages required to induce cell death were all in the mM range. 
This dosage is much higher than metformin levels detected in circulating 
plasma in vivo. Metformin levels reaching mM concentrations have been 
detected in health gut tissue (Bailey et al, 2008; Proctor et al, 2008)  
Daily reapplications of metformin were shown to decrease sensitivity to 
metformin in GBM cultures. The results given in Table 3.3 show an overall 
increase in the ID50 values of the four cultures tested. Due to fact that 
metformin is not metabolised (Hassan and Carlton, 2018), the reapplication of 
fresh drug daily made no impact on maintain metformin concentration and it 
is unlikely that metformin is accumulating in GBM cells.  However, the increase 
in growth can be attributed to the cells receiving fresh nutrients daily, thus 
removing this potentially limiting factor on growth in the wells. In addition, 
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when considering the rate at which the glucose would be expended by the 
cells (as shown in Figure 3.20), the reapplication of fresh media would 
normalise the concentration of glucose around 6mM/L. Wahdan-Alaswad et al. 
(2017), demonstrated that in breast cancer cells an increase in glucose media 
concentration reduced the efficacy of metformin.  Glucose concentration and 
the availability of resources are important factors that impact of cytotoxic 
effects by metformin. 
3.1.3.3 Phenformin growth inhibition 
Phenformin also induced cytotoxicity in GBM cultures. When compared to ID50 
values of metformin, phenformin ID50 values were an order of magnitude 
lower at near µM concentrations and this may be linked to the increased lipid 
solubility of phenformin (Schafer, 1983). This potentially would allow the drug 
to more readily cross cell and mitochondria membranes to affect mitochondria 
complex I (Wheaton, et al. 2014). The observed difference between metformin 
and phenformin highlights the need for further investigation into other drugs 
in the biguanide class as potential therapeutic agents. However, due to a high 
incidence of lactic acidosis phenformin is no longer a widely-used drug though 
it is still available in China, Brazil and Italy (Ching, 2008; Fimognari et al., 
2008).  To consider phenformin for repurposing as GBM therapy would require 
additional clinical trials and tests. Metformin is a licenced drug and is already 
being considered and tested in prostate cancer clinical trial as a repurposed 
therapeutic agent (Pryor and Cabreiro, 2015; Heckman-Stoddard et al., 2018). 
New investigations into novel biguanides and derivates could produce new 
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formulation that have improved cellular response (Markowicz-Piasecka et al., 
2018). 
3.2 Assessing drug synergy in GBM cultures 
Metformin would not be used as a monotherapy and the identification of 
other drugs it can work additively with will increase its likelihood of use in 
clinical trials (Aldea et al., 2014). Potential synergistic drug partners were 
assessed with metformin using the SRB assay to assess the combined 
treatment effect. Four drugs were assessed for combination therapy 
treatments. The culture panel utilised for 3.2 was reduced, due to the 
resource and time cost of maintaining active culture flasks for the entire 
panel. The reduced panel still contained variation in p53 status and cell 
doubling time.  
3.2.1 Synergy culture panel 
Eight cultures were utilized to assess the potential synergy of four drugs with 
metformin. The four drugs were disulfiram, TMZ, sodium oxamate and 
sorafenib. Drugs were chosen based on the pre-existing use for GBM or the 
promising potentials as GBM therapeutic agents.  TMZ is the front-line 
treatment for GBM (Messaoudi et al., 2015). Disulfiram and sorafenib have 
shown cytotoxic effects in GBM cell lines (Liu et al., 2012; Aldea et al., 
2014). Sodium oxamate has been shown to synergise with phenformin in 
GBM (Miskimins, et al. 2014). The panel of cultures comprised six P53 
mutant cultures and two P53 wild type cultures. Setup and analysis of the 
experiment was carried out as detailed in 2.3.5. Table 3.6 shows the 
comparative drug combinations used in relation to metformin.  
 103 
   
 
 
 
 
 
 
 
 
 
 
 
 
Drug1 Units 
Drug concentration3 
Highest 
 
Lowest Control4 
Metformin mM 80 40 20 10 5 2.5 1.25 0.63 0 
Disulfiram4 nM 1000 500 250 125 62.5 31.25 15.63 7.81 0 
Temozolomide µM 500 250 125 62.5 31.25 15.62 7.81 3.9 0 
Sodium Oxamate µM 160 80 40 20 10 5 2.5 1.25 0 
Sorafenib µM 80 40 20 10 5 2.5 1.25 0.63 0 
Table 3.6 – Drug concentrations used in synergy analysis with metformin.  
All drugs were utilized both individually and in equimolar doses with metformin. 1Drugs tested for synergy. All 
drugs tested for synergy analysis were dissolved in water. Drugs are ordered based on the concentration used in 
experiments. All experiments compared ID50 independently and combined with metformin.  2Drug concentration 
values used in the serial dilution to produce an 8-point concentration range for each drug. 3 Control values taken 
as an average of two wells per replicate. 4All disulfiram wells were supplemented with 10µM copper Chloride. 
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3.2.2 Synergy analysis using the Chou-Talay theorem 
Paired drug treatment for synergy analysis were assessed using the Cho-
talay theorem (Chou., 2010). This generates a combination index relative to 
the effectiveness of each drug when used as a mono therapy and when you 
in conjunction with the other. The complete equation is given in figure 3.2. 
3.2.2.1 Disulfiram  
Disulfiram was shown to have a cytotoxic effect on all cultures tested over a 
96-hour treatment period. In all treatments, disulfiram was supplemented with 
10µM copper chloride to enable the drug to function at maximum efficacy (Liu 
et al., 2014). Table 3.7 summarizes the ID50 values generated from 
combination analysis of disulfiram. The ID50 value for U251MG concurs with 
previously published results (Liu et al., 2012) and was the most sensitive of 
all the cultures to disulfiram. There was no significant association between P53 
status and response to disulfiram (p=0.0908). 
 
Culture reference P53 Status Disulfiram ID50 96 hours (nM)1 
U251MG Aberrant 164.53 (±14.31) 
IN859 Aberrant 195.3 (±48.59) 
IN1265 Aberrant 210 (±68.06) 
IN2045 Aberrant 227.2 (±20.77) 
IN1528 Aberrant 240.63 (±71.31) 
IN1979 Aberrant 276.13 (±65.87) 
IN1760+ Wild Type 260.4 (±61.4) 
IN1682+ Wild Type 298.6 (±18.04) 
 
 
 
Table 3.7 – ID50 values for disulfiram in GBM cultures 
1ID50 values for disulfiram at 96 hours when supplemented with 10µM copper chloride. Cultures 
ordered lowest ID50 to highest. No significant distinction due to P53 status was present in the panel. 
All cultures marked with a + indicate P53 wild type. P53 status of each culture used to group cultures 
together. 
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The concentration of disulfiram ranged from 7.81nM to 1000nM and was used 
both separately and in equimolar concentrations with metformin. Separate 
SRB assay data for the three treatments is given in Figure 3.6. Combination 
data for disulfiram and metformin is shown in Table 3.8. All cultures 
demonstrated a strong antagonistic result from the combination of disulfiram 
with metformin. The lowest of the average combination index was 1.31, 
observed in IN2045. Only IN1760 showed a synergistic response in one of its 
replicates, a CI index of 0.81. This is a strong synergistic value; however, this 
culture was also one with the highest standard deviation in its results. 
 
Culture 
reference 
P53 
Status 
Combination 
Index1 
Average Result2 
A B C 
U251MG Aberrant 1.26 1.27 1.40 1.40(±0.07) Antagonism 
IN859 Aberrant 1.55 1.32 1.55 1.47(±0.13) Antagonism 
IN1265 Aberrant 1.63 2.18 2.03 1.95(±0.28) Antagonism 
IN1528 Aberrant 1.49 1.25 1.74 1.49(±0.24) Antagonism 
IN1979 Aberrant 2.01 1.73 1.84 1.86(±0.14) Antagonism 
IN2045 Aberrant 1.30 1.19 1.43 1.31(±0.12) Antagonism 
IN1682+ Wild 
Type 
1.87 2.01 1.62 1.83(±0.20) Antagonism 
IN1760+ Wild 
Type 
1.52 0.81 1.95 1.42(±0.57) Antagonism 
 
 
 
 
 
Table 3.8 – Drug synergy analysis for disulfiram supplemented when combined in equimolar dosage 
with metformin.  
 
All cultures marked with a + indicate P53 wild type. P53 status of each culture used to group cultures 
together. 1Combination index result as a measure of synergy comparing each drug individually to an 
equimolar combination. Due to intragroup comparisons required each result shown separately 
2Overall result from synergy analysis based on average combination index result. All samples showed 
an antagonistic response to the drug combination. 
CI Index >1 – Antagonism (Red), CI Index = 1 – Additive (Orange), CI Index <1 = Synergy (Green).  
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All graphs in figure 3.6 display a lower dose response curve with metformin 
compared to disulfiram. The combination dose response curves show similar 
trends to the metformin curve. Chou-talay analysis requires a reduction in the 
combination treatment over one individual drug and the lack of this difference 
explains the antagonist results detailed in table 3.8. Additional graphs 
representing this drug synergy analysis for disulfiram with metformin can be 
found in appendix D. From this result, it is clear there is no increase in 
cytotoxicity in GBM cells from the addition of disulfiram to metformin.  
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Figure 3.6 – Graphs representing the combination synergy experiments of metformin 
alongside disulfiram.  All culture tested in solo and combination treatment in equimolar dosages in a 
96-hour period. Cultures that showed synergy marked with a ☨. Disulfiram results show higher ID50 curves 
than metformin. Combination curves of most graphs are similar to metformin treatment leading to 
antagonist results.  All cultures marked with a + indicate P53 wild type. 
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3.2.2.2 Temozolomide 
Temozolomide was shown to have a cytotoxic effect on all cultures tested over 
a 96-hour treatment period. TMZ is stable in acid pH but has a half-life of 
approximately 2 hours at pH7 (Brian et al., 1994; Patel et al., 2003). To 
account for the short half-life of temozolomide additional temozolomide was 
supplemented into the growth media daily. The media was not changed, and 
additional glucose was not provided to the cells. This was to prevent the 
increase in cell growth and reduced sensitivity of metformin that was shown 
in 3.1.3. MGMT status has been known to be a factor on the sensitivity of GBM 
in respect to the overall efficacy of temozolomide (Franceschi et al., 2018). 
Cultures with methylated MGMT genes should have an increased sensitivity to 
temozolomide (Tosoni et al., 2017; Bell et al., 2018). Table 3.9 summarizes 
the ID50 values generated from synergy analysis of temozolomide. When 
comparing the response to MGMT status there was no clear pattern to the ID50 
values for temozolomide. U251MG was the most sensitive to the temozolomide 
treatment with an ID50 of 116µM. P53 status of the culture showed no 
significant effect (P=0.1516). 
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Culture 
reference 
P53 Status MGMT status1 
Temozolomide 
ID50 96 hours 
(µM) 
U251MG Aberrant Methylated 116 (±0.63) 
IN1528 Aberrant Methylated 163.81 
(±64.60) 
IN1265 Aberrant Unmethylated 240.89 
(±86.24) 
IN1979 Aberrant Unmethylated 257.3 (±24.16) 
IN859 Aberrant Methylated 274.07 
(±69.85) 
IN2045 Aberrant Methylated 353.33 
(±34.77) 
IN1760+ Wild Type Methylated 336.8 (±38.97) 
IN1682+ Wild Type ND 337.33 
(±54.73) 
 
 
 
Combination data for temozolomide and metformin treatment was shown in 
Table 3.10. Three cultures showed a synergistic response to the drug 
combination (CI<1); U251MG, IN2045 and IN1760, all of which were MGMT 
methylated. No relationship was apparent between P53 status and TMZ 
synergy with metformin. MGMT status did not affect the synergism between 
TMZ and metformin. This result fits with the TMZ ID50 values not showing any 
significant relationship.   
 
 
 
Table 3.9 – ID50 values for TMZ in GBM cultures 
1MGMT methylation status of the culture.  ID50 values for temozolomide at 96 hours. Cultures ordered 
lowest ID50 to highest.  No significant distinction due to P53 status was present in the panel. All 
cultures marked with a + indicate P53 wild type. ND – Not determined. 1The methylation of the MGMT 
gene is a known factor in the sensitivity of tumour response to temozolomide 
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Culture 
reference 
P53 
Status 
MGMT 
status1 
Combination 
Index2 Average Result5 
A B C 
U251MG Aberrant Methylated 0.85 0.96 0.88 0.89(±0.05) Synergism 
IN859 Aberrant Methylated 1.7 1.55 1.57 1.61(±0.08) Antagonism 
IN1265 Aberrant Unmethylated 0.89 1.18 1.25 1.11(±0.19) Antagonism 
IN1528 Aberrant Methylated 1.41 1.38 1.04 1.28(±0.21) Antagonism 
IN1979 Aberrant Unmethylated 1.45 1.44 1.22 1.38(±0.13) Antagonism 
IN2045 Aberrant Methylated 0.95 1.05 0.77 0.93(±0.14) Synergism 
IN1682+ Wild Type ND 1.30 1.51 1.20 1.33(±0.15) Antagonism 
IN1760+ Wild Type Methylated 0.95 0.94 0.87 0.92(±0.04) Synergism 
 
 
 
 
 
The concentration of TMZ ranged from 3.9µM to 500µM and was used both 
separately and in equimolar concentrations with metformin. Separate SRB 
assay data for the three treatments is given in Figure 3.7. In cultures IN859 
and IN1265, the metformin dose response curve was below the combination 
treatment demonstrating an antagonist reaction increasing the ID50 value 
when used in combination. Additional graphs representing this drug synergy 
analysis for temozolomide with metformin can be found in Appendix E. The 
result here showed that there is possible synergy between metformin and 
temozolomide.  
Table 3.10 – Drug synergy analysis for temozolomide when combined in equimolar dosage with 
metformin.  
 
 
All cultures marked with a + indicate P53 wild type. P53 status of each culture was used to group cultures together. 
1MGMT methylation status of the culture. The methylation of the MGMT gene is a known factor in the sensitivity of 
tumour response to temozolomide 2Combination index result as a measure of synergy comparing each drug individually 
to an equimolar combination. Due to intragroup comparisons required each result shown separately 5Overall result 
from synergy analysis based on average combination index result. Three cultures showed a synergistic response and 
5 showed an antagonistic response. CI Index >1 – Antagonism (Red), CI Index = 1 – Additive (Orange), CI Index <1 
= Synergy (Green). ND – Not determined. 
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Figure 3.7 – Graphs representing the combination synergy experiments of metformin 
alongside temozolomide supplemented with copper chloride.  All cultures tested in solo and 
combination treatment in equimolar dosages in a 96-hour period. Cultures that showed synergy marked 
with a 
☨
. Temozolomide results show lower ID50 values than metformin. Combination curves of most 
graphs are similar to metformin treatment.  All cultures marked with a + indicate P53 wild type. 
☨ 
☨ 
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3.2.2.3 Sodium Oxamate 
Sodium oxamate was shown to have a cytotoxic effect on all cultures tested 
over a 96-hour treatment period. The ID50 values ranged from 57.18µM 
(IN2045) to 95.94µM (IN1760) and five out of the eight (5 of 8) ID50 values 
of the cultures tested were between the highest two concentration points. 
IN2045 was the most sensitive to sodium oxamate treatment with an ID50 of 
57.18µM There was no clear relationship between P53 status and sodium 
oxamate ID50 value (p=0.1816). ID50 sodium oxamate is listed in table 3.11. 
Culture 
reference 
P53 Status Sodium Oxamate ID50 96 hours 
(µM)1 
IN2045 Aberrant 57.18 (±25.99) 
IN859 Aberrant 63.27 (±14.04) 
IN1265 Aberrant 66.87 (±27.81) 
IN1528 Aberrant 81.68 (±14.49) 
U251MG Aberrant 85.27 (±18.88) 
IN1979 Aberrant 91.81(±27.88) 
IN1682+ Wild Type 84.81 (±33.5) 
IN1760+ Wild Type 95.94 (±27.76) 
 
 
Combination data for sodium oxamate and metformin treatment is shown in 
Table 3.12. Only one culture showed a synergistic response with the drug 
combination of sodium oxamate and metformin, U251MG. All the short-term 
GBM cultures showed an overall antagonistic response. There was a 
synergistic response in one replicate of IN1979 treatment (CI=0.93) but the 
averaged data produced a CI of 1.18. This was the lowest result in all the 
short-term cultures. The concentration of sodium oxamate ranged from 
1.25µmM to 160µM and was used both separately and in equimolar 
Table 3.11 – ID50 values for sodium oxamate in GBM cultures 
 
 
All cultures marked with a + indicate P53 wild type. P53 status of each culture used to group cultures together. 
1ID50 values for sodium oxamate at 96 hours. Cultures ordered lowest ID50 to highest. No significant distinction 
due to P53 status was present in the panel.  
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concentrations with metformin. Separate SRB assay data for the three 
treatments is given in Figure 3.8. 
 
Culture 
reference 
P53 
Status 
Combination 
Index1 
Average Result2 
A B C 
U251MG Aberrant 0.64 0.76 0.79 0.73(±0.08) Synergism 
IN859 Aberrant 1.29 1.24 1.86 1.46(±0.34) Antagonism 
IN1265 Aberrant 1.86 1.69 1.66 1.73(±0.11) Antagonism 
IN1528 Aberrant 1.54 1.11 1.37 1.34(±0.22) Antagonism 
IN1979 Aberrant 1.40 0.93 1.20 1.18(±0.24) Antagonism 
IN2045 Aberrant 1.68 1.49 0.96 1.38(±0.37) Antagonism 
IN1682+ Wild 
Type 
1.95 1.33 1.08 1.45(±0.45) Antagonism 
IN1760+ Wild 
Type 
1.43 1.10 1.34 1.29(±0.17) Antagonism 
 
 
 
 
Additional graphs representing this drug synergy analysis for sodium oxamate 
with metformin can be found in Appendix F. Apart from the result from 
U251MG sodium oxamate there seems to be no benefit from the combination 
of sodium oxamate and metformin. U251MG strong synergy may be indicative 
of a factor unique to that culture that is not present within short term cultures.  
 
 
 
Table 3.12 – Drug synergy analysis for sodium oxamate when combined in equimolar dosage 
with metformin.  
 
All cultures marked with a + indicate P53 wild type. P53 status of each culture used to group cultures together. 
1Combination index result as a measure of synergy comparing each drug individually to an equimolar 
combination. Due to intragroup comparisons required each result shown separately 2Overall result from synergy 
analysis based on average combination index result. One culture, U251, showed a synergistic response from 
the drug combination. All short-term cultures showed antagonism. 
CI Index >1 – Antagonism (Red), CI Index = 1 – Additive (Orange), CI Index <1 = Synergy (Green).  
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Figure 3.8 – Graphs representing the combination synergy experiments of metformin 
alongside sodium oxamate.  All cultures tested in solo and combination treatment in equimolar dosages 
in a 96-hour period. Cultures that showed synergy marked with a 
☨
. Sodium oxamate showed synergy in 
U251MG but no other cultures tested. In all other cultures metformin mono treatment had the lowest ID50 
values. All cultures marked with a + indicate P53 wild type. 
☨ 
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3.2.2.4 Sorafenib 
Sorafenib was shown to have a cytotoxic effect on all cultures tested over a 
96-hour treatment period. There was no clear pattern between P53 status and 
sorafenib ID50 value (P=0.5889). IN1979 was shown to be the most sensitive 
to sorafenib with an ID50 value of 18.47µM. All the ID50 for the cultures tested 
is listed in table 3.13.  
Culture reference P53 Status Sorafenib ID50 96 hours 
(µM)1 
IN1979 Aberrant 18.47 (±6.67) 
IN1528 Aberrant 21.56 (±5.77) 
IN2045 Aberrant 26.25 (±19.3) 
IN859 Aberrant 33.36 (±7.76) 
IN1265 Aberrant 36.06 (±12.87) 
U251MG Aberrant 42.83 (±23.49) 
IN1682+ Wild Type 26.01 (±13.86) 
IN1760+ Wild Type 28.28 (±2.97) 
 
 
When used in combination, all the cultures tested had a synergistic response. 
The culture with the lowest CI was IN1265. This result may stem from its 
sorafenib ID50 value, which was the highest of aberrant cultures tested. 
IN2045 had the highest CI of any culture and this is due to a variation in its 
replicates. Due to its CI index remaining around 1 it showed a synergistic, 
additive and antagonistic response to the drug combination. P53 status did 
not show a link to the drug combination of sorafenib and metformin. The 
concentration of sorafenib ranged from 0.63µM to 80µM and was used both 
separately and in equimolar concentrations with metformin. Separate SRB 
assay data for the three treatments is given in Figure 3.9. 
Table 3.13 – ID50 values for sorafenib in GBM cultures 
 
 
All cultures marked with a + indicate P53 wild type. P53 status of each culture used to group cultures together. 
1ID50 values for sorafenib at 96 hours. Cultures ordered lowest ID50 to highest. No significant distinction due 
to P53 status was present in the panel.  
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Culture 
reference 
P53 
Status 
Combination 
Index1 
Average Result2 
A B C 
U251 Aberrant 0.97 0.98 0.90 0.90(±0.4) Synergism 
IN859 Aberrant 0.86 0.87 0.96 0.90(±0.06) Synergism 
IN1265 Aberrant 0.40 0.49 0.26 0.45(±0.06) Synergism 
IN1528 Aberrant 0.94 0.85 0.81 0.87(±0.06) Synergism 
IN1979 Aberrant 0.93 0.99 0.94 0.95(±0.03) Synergism 
IN2045 Aberrant 1.0 0.76 1.10 0.96(±0.17) Synergism 
IN1682+ Wild 
Type 
0.91 0.90 0.64 0.82(±0.15) Synergism 
IN1760+ Wild 
Type 
0.69 0.78 0.77 0.75(±0.05) Synergism 
 
 
 
 
In all graphs, there is a visible separation of the dose response curves for the 
combination treatment against the mono drug treatments. Additional graphs 
representing this drug synergy analysis for sodium oxamate with metformin 
can be found in appendix G.  
 
 
 
 
 
 
Table 3.14 – Drug synergy analysis for sorafenib when combined in equimolar dosage with 
metformin. 
  
All cultures marked with a + indicate P53 wild type. P53 status of each culture used to group cultures together. 
1Combination index result as a measure of synergy comparing each drug individually to an equimolar 
combination. Due to intragroup comparisons required each result shown separately 2Overall result from synergy 
analysis based on average combination index result. CI Index >1 – Antagonism (Red), CI Index = 1 – Additive 
(Orange), CI Index <1 = Synergy (Green). IN1265 C result was anomalous and removed averaged data. 
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Figure 3.9 – Graphs representing the combination synergy experiments of metformin alongside 
sorafenib.  All culture tested in solo and combination treatment in equimolar dosages in a 96-hour period. Results 
that showed synergy marked with a #. All cultures showed strong synergy this is identifiable by the separation of 
the combination dosage response from the mono treatment results. 1All cultures marked with a + indicate P53 wild 
type. 
# # 
# # 
# # 
# 
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3.2.3 Synergy Time course 
Sorafenib was the only drug tested that demonstrated a synergistic response 
with metformin in all GBM cultures as shown in Table 3.14. To further evaluate 
this synergy, a time course experiment was conducted using the SRB assay. 
This allowed for examination of the synergistic effect at fixed concentration 
combinations over time. A standard dosage of 10mM metformin was used for 
all cultures across the time course combinations. The cultures chosen were 
U251MG, IN859, IN1528 and IN2045. All cultures are P53 mutant or deletions 
and the cultures have been shown to be sensitive to metformin with ID50 
values after 96 hours treatment of 4.52mM, 4.83mM, 6.41mM and 10.82mM 
for (U251MG, IN859, IN2045 and IN1528), respectively. Sorafenib was treated 
at 10µM and 20µM both in solo and in combination with 10mM metformin. The 
sorafenib ID50 values for the cultures were all above this range 21.56 µM, 
26.25 µM, 33.36 µM and 42.83 µM (IN1528, IN2045, IN859 and U251MG). 
Graphical representations of the experiments can be seen in Figure 3.10a and 
Figure 3.10b. From the results, the time course responses follow three main 
groups. In all cultures the strongest response was the combination of 
metformin and 20µM sorafenib. For U251MG sorafenib at 10µM had a low 
effect on the cells. IN859 had a similar 96-hour time point for 10µM sorafenib 
but the drug showed a greater effect across the time course. U251MG, IN859 
and IN1528 showed a similar response for sorafenib at 20µM and both 
metformin combinations. IN2045 showed a stronger a stronger response from 
sorafenib at 20µM than combination of 10µM sorafenib and metformin. 
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Figure 3.10a – Drug synergy analysis time course of metformin and sorafenib. Metformin and 
sorafenib were tested in solo and in combination over a 96-hour time course. Figure A shows U251MG and 
IN859. OD values were obtained every 24 over the time course. Error bars show the standard deviation of 
the replicate samples used.  
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Figure 3.10b – Drug synergy analysis time course of metformin and sorafenib. Metformin and 
sorafenib were tested in solo and in combination over a 96-hour time course. Figure B shows IN1528 and 
IN2045. OD values were obtained every 24 over the time course. Error bars show the standard deviation 
of the replicate samples used.  
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3.2.4 Summary 
3.2.4.1 Drug Synergy 
Three of the drugs tested, TMZ, sodium oxamate and disulfiram, showed 
synergy in at least one culture. Disulfiram showed no synergy in any culture. 
The most effective combination was a synergistic effect when paired with 
sorafenib. This is in line with the response glioma stem cells reported by Aldea, 
et al, 2014. They hypothesized that the synergy was due to the separate target 
pathways of the two drugs working together to impact overall cell survival. 
The metformin affecting the cell through AKT/mTOR pathway and the 
sorafenib through RAF/MAPK, are two important cell signalling cascades with 
important roles in cell proliferation that have been reported as often 
dysregulated in GBM (Cheng et al., 2009; Gao et al., 2013). Aldea et al. (2014) 
hypothesised that there is interplay between member proteins of the pathways 
to act as a redundancy in case of tyrosine kinase inhibition and reduction in 
MAPK signalling. The failure of sorafenib to provide an advantage in GBM 
clinical trials was suggest as an example for this (Hainsworth et al., 2010; 
Peereboom et al., 2013). The strong synergistic response may also be due to 
the method metformin inhibit the mTOR pathway. Most inhibition of mTOR 
happens through activation of adenosine monophosphate- AMPK (Ben Sahra 
et al., 2011). However, metformin is able to directly impact the mTOR pathway 
through increase mTORs affinity to bind with its regulatory associated protein, 
RAPTOR (Liu et al., 2014). This increased affinity can be seen in the synergy 
time courses. Compared with sorafenib as a single treatment the combination 
of metformin and sorafenib could produce a larger inhibitory response than 
seen individually.       
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Sodium oxamate has been shown to synergise with phenformin in Miskimins, 
et al. 2014. This study utilized a range of cultures including breast, colon, lung, 
prostate, tonsil cancer as well as melanoma. In the GBM cultures tested only 
U251MG showed synergy, the rest of the culture panel all showed strong 
antagonism. One common factor between the two studies is the use of 
established cell lines. The cultures utilised by Miskimins, et al. 2014 were 
purchased from the American Type Culture Collection and there is no mention 
of the passage range used. It is possible that this response is linked to a 
change developed within cell lines. Oxamate acts through inhibition of LDH to 
reduce the conversion of pyruvate and stop the build-up of lactic acid in cell 
cystol (Zhai et al., 2013). For cancer cells in vivo, lactic acidosis is common in 
the tumour microenvironment (Gatenby and Gillies, 2004). This state has been 
theorised to be used by the cancer cells to mitigate the immune response by 
allowing them to modulate the micro-environment pH through lactic acid 
secretion (Choi, et al. 2013). Utilisation of lactic acid in this way may be an 
attribute lost in the immortal cell lines, as it no longer suffers from the same 
target immune response as a selection pressure. This may explain the 
synergistic response only seen in U251MG.  
Disulfiram showed no beneficial effect when combined with metformin. All 
cultures yielded an antagonistic result when the two drugs were used together 
in the presence of copper. In OSCC cells, the presence of metformin was 
shown to increase the tumour inhibiting properties of disulfiram and increase 
the concentration of copper in cytosol (Jivan et al 2015). Disulfiram has also 
already been shown to be a cytotoxic agent for GBM cell cultures (Liu, et al. 
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2012). Cellular response to metformin has been shown to be tumour-type 
dependent with variations in mechanisms and path -ways used (Babcook et 
al., 2014; Adeberg et al., 2017; Lindqvist et al., 2018). The lack of a synergy 
result shown here could possibly be due to variations between GBM and OSCC.  
There was variation in the response of GBM cultures to treatment with 
temozolomide and metformin. Three of the eight cultures showed a synergistic 
response, U251MG (CI=0.89), IN2045 (CI=0.93) and IN1760 (CI=0.92). 
There does not seem any reason why the three cultures showed a synergistic 
response and the rest strong antagonism. There was no clear factor to identify 
why the three cultures showed a synergistic response in comparison to the 
strong antagonism present in the remaining five cultures. When separated as 
a group the three share no common factor that sets them apart from the rest 
of the panel. All other cultures showed a strong antagonism in the drug 
combination (CI>1.1). Of the three cultures that showed synergism the 
strongest result was in U251MG (CI=0.89), the other two cultures had a 
combination index less than 0.1 from the separation point. The Chou-Talay 
method is relatively strict in its identification when separating synergy and 
antagonism. However additive effects are harder to identity under this 
method. Though the U251MG result is a synergistic response it could be that 
the other two cultures are showing an additive effect of the two drugs. 
Examining the separate ID50s we see that both 1760 and 2045 have TMZ 
values of greater than 330µM. The Metformin ID50s of the cultures are towards 
the lower end of the panel range, 11.59mM and 6.41mM. This difference of 
high TMZ ID50 and relatively low metformin ID50 could be the reason for the 
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additive effect seen here. U251 was the highest sensitivity to TMZ and second 
highest sensitivity to metformin this culture may be behaving differently due 
to genetic and metabolic differences of being a long-term cell culture (Torsvik, 
et al. 2014). IN1682 also possessed a TMZ ID50 in excess of 330µM however 
its metformin ID50 was higher (24.86mM).  
The last factor to consider is the structure and half-life of TMZ. Rate of decay 
of TMZ to its intermediary form MITC is pH dependent and can become stable 
under acidic conditions (Baker, et al. 1999; Lopes, et al. 2013). Although fresh 
TMZ was added to cultures daily, the media was not changed, and acidic 
conditions may have been produced towards the end of the time course 
experiment. A variation between the pH of the cell culture media may lead to 
the difference in response to TMZ identified here. Measurement of pH changes 
in culture media across the time course would be an important factor to record 
for future studies 
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3.3 Glucose  
Metformins use as a diabetic therapy reduces blood sugar levels and 
increases glucose uptake (Bailey, 2017). Results from 3.1.2.2 showed that 
GBM cultures benefitted from daily supplemental glucose and displayed 
reduced efficacy for metformin. To assess metformins effect on non-
supplemented glucose levels in growth media it was measured over a time 
course.  A reduced culture panel of six GBM and NHA was used due to 
limited resources and time.  
3.3.1 Assessment of glucose in culture media 
Assessment of glucose levels in growth media was done through adaptation 
of a diabetic blood glucose meter. Growth media is not the intended 
measurement medium for the device. Glucose standards with a range of 
different concentrations were generated in F10 media supplemented with FCS 
and PBS (as a comparative control) and assessed with the glucose meter and 
the results are listed in Table 3.15 and Figure 3.7. In both PBS and F-10, the 
glucose meter was able to detect the increases in glucose concentration. At 
higher glucose concentrations (>5.5mM), there was an overestimation of the 
amount of glucose in the tested sample. However, this was not seen to be 
significant (P=0.0802) deviation from the expected trend. The device was 
shown to be limited as it was insufficiently sensitive to detect glucose at 
concentrations below 1.0mM.  
 
 
 126 
   
 
Concentration 
Glucose added to solution 
(mM) 
Measured glucose quantity 
in PBS (mM) 
Measured glucose quantity 
in Pan F-10 supplement 
with FCS (mM) 
0.00 ER4 ER4 (±) 
1.0 Lo1 Lo (±) 
1.5 1.5 (±0.2) 1.6 (±0.2) 
2.0 2.2 (±0.4) 2.4 (±0.2) 
3.0 3.0 (±0.2) 3.2 (±0.2) 
4.0 3.9 (±0.2) 4.4 (±0.2) 
5.0 5.4 (±0.7) 5.4 (±0.3) 
6.0 6.6 (±0.5) 7.0 (±0.8) 
10.0 10.3 (±1.1) 11.1 (±0.6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lo relates to the reading on the display when any sample with less than 1.0mM glucose 
was samples.  Any sample with a greater concentration of glucose could be detected and 
get an output reading from the machine. ER4 was what the machine displayed when given 
each medium with no supplementary glucose. 
Table 3.15 – Glucose measurements from PBS and F-10 
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The results displayed in Table 3.1 showed low standard deviations and 
indicates the suitability of the glucose meter for accurately measuring glucose 
values in cell media. It also demonstrates that the limit of detection for 
measuring glucose was 1.0mM glucose.  
 
Figure 3.11 – Measured Glucose reading from defined control standards. A range of 
glucose standards diluted in PBS and pans F-10 measured by a diabetic blood glucose meter. 
Expected value represents the concentration of glucose added to the solution deviations from 
this line represent inaccuracy in the devices reading. 
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3.3.2 Measurement of media glucose over time  
To assess the uptake of glucose by cells undergoing metformin treatment and 
to measure the effect of glucose on metformin sensitivity, GBM cultures were 
treated with the ID50 value of metformin in T25 flasks.  Untreated control cells 
were grown in parallel and measurements of glucose were taken at 24-hour 
intervals. For this six GBM cell cultures and NHA were used. NHA was used to 
add a non-cancerous control. Two of the cultures, IN760 and IN1682 are both 
P53 wild type cultures sensitive to metformin.  Four of the cultures U251MG, 
IN859, IN1979 and IN2045 are all P53 aberrant cultures. P53 wild type 
cultures showed the greatest sensitivity to metformin the four cultures 
selected have ID50 values that cover the range of observer aberrant cultures. 
Of the aberrant cultures IN859 has the lowest metformin ID50 (4.52mM) and 
IN1979 has the highest (25.66mM).  
The results of all the time course experiments are shown in Figure 3.12. All 
cultures displayed a similar pattern of glucose depletion over time. Glucose 
was depleted faster in metformin-treated samples compared to untreated 
controls, regardless of whether cells were grown in media supplemented with 
6mM or 3mM glucose. All cultures tested with 3mM glucose and metformin 
expended glucoses to unmeasurable levels within 72 hours. 
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 Figure 3.12 – Measurements of availability of glucose in growth media over time. Cultures 
started at 3mM or 6 mM glucose. Cultures were treated with metformin for 96 hours and compared 
against a vehicle control. All cultures showed decreasing levels of glucose over the time course.  
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3.3.3 Effects of low glucose concentrations on response to 
metformin treatment 
Five GBM patient derived short-term cultures were used to investigate the 
effect of low glucose conditions on the sensitivity of cultures to metformin. 
This smaller cohort of cultures was representative of the panel containing two 
P53 wild type short term cultures (IN1682 and IN1760), three P53 aberrant 
short-term cultures (IN859, IN1979 and IN2045), one P53 aberrant 
established cell line (U2351MG) and NHA as a normal cell control. The cultures 
were used for all investigations of potential mechanisms of cell death induced 
by metformin in Section 3.4. GBM cells were grown in Pan F-10 supplemented 
with 3mM glucose and treated with metformin for 96 hours. Results were 
compared against ID50 values from standard F-10 growth media (6mM 
glucose) as described in Table 3.2. To confirm the suitability of the Pan F-10 
formulation, the ID50 values of metformin in Pan F-10 supplemented with 6 
mM glucose was also assessed. This data is summarised in Table 3.16. All GBM 
cell cultures demonstrated a reduction ID50 values when the glucose 
concentration of the media was lowered to 3mM. Three cultures showed 
significant reductions in the ID50 values, U251MG, IN859 and IN1979. The only 
remaining P53 mutant, IN2045, showed the largest reduction in ID50 value (-
62%) but due to high standard deviation this result was not significant. 
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Culture 
ID50 values 
PAN1 + 3mM 
Glucose 
PAN1 + 6mM 
Glucose 
% Change 
in ID502 
P-value Gibco (6mM)3 
U251MG 2.3 (±1.15) 5.2 (±3.65) -53% 0.0336* 4.83 (±2.11) 
IN859 1.8 (±1.09) 4.01 (±4.21) -61% 0.0189* 4.52(±0.6) 
IN1979 18.6(±1.22) 28.51 (±4.9) -27% 0.0396* 25.66 (±3.84) 
IN2045 2.41 (±3.2) 5.23 (±2.64) -62% 0.1244 6.41 (±3.5) 
IN1682 19.3 (±1.5) 26.7 (±2.54) -22% 0.0396 24.87 (±5.41) 
IN1760 8.05(±1.2) 14.8 (±3.97) -31% 0.1244 11.59 (±5.05) 
NHA 78.3(±7.63)  -7% 0.5285 84.3 (±8.50) 
 
 
 
3.3.4 Summary  
The glucose values detected by the glucose meter in Pan F-10 varied slightly 
from the expected standard but the difference was not statistically significant 
(P=0.0802). However, the glucose meter has a limit of detection for measuring 
low concentrations of glucose (<1mM).  Measurements of glucose over the 
96-hour time course showed an increase in the depletion rate of glucose when 
cells were grown in the presence of metformin at ID50 concentrations. In 
U251MG, IN859 and IN1760, at the 72 and 96-hour readings, metformin 
caused a reduction in glucose concentration to levels 24-hours earlier than 
glucose readings measured by the untreated sample. The mechanism 
responsible for this depletion is unclear, although this observation is consistent 
with the original 1956 name of metformin; glucophage (Bailey, et al. 2004). 
This reduction in media glucose concentration may be due to metformin 
 Table 3.16 Metformin ID50 values for GBM cells grown in low glucose conditions 
(3mM) 
1Pan F-10 formulation contains no glucose. 2Changes in ID50 value when comparing Pan+3mM 
glucose with Gibco F-10 (6mM) 3Results for standard Gibco F-10growth media found in table 
3.2.  
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increasing the cellular uptake of glucose (Sinnett-Smith et al. 2014; Saisho, 
2015; Niccoli, et al., 2016). 
3.4 Mechanisms of cell death induced by metformin 
Metformins mechanism of anti-tumour action are still not fully elucidated 
(Chae et al., 2016). It has been identified to inhibit complex I on the election 
transport chain (Jiang et al., 2016). The use of mechanisms has been shown 
to diverge based on the type cancer; the inhibition of mTOR through AMPK 
activation has been shown to be a dependency for tumour inhibition in 
several cancers and independent in other (Liu et al., 2014). Identifying 
specific mechanism and pathways through which metformin acts on GBM is 
an important factor to assess its potential use as a cancer therapy. This was 
assessed through use of flow cytometry and functional assays.  
3.4.1 Cell cultures 
Five GBM patient-derived short-term cultures were used to investigate 
mechanisms through which metformin induces cytotoxicity. This cohort was 
augmented with the GBM cell line U251MG and NHA as a non-cancerous 
control.  A summary of the features of the cultures is given in Table 3.17. This 
smaller cohort was selected to maintain the range and diversity of the original 
panel whilst enabling greater depth and focus of the study. IN859 and IN2045 
represented mutant P53 cultures. Cultures IN1682 and IN1760 are both P53 
wild types. U251MG is a P53 mutant used as a cell line comparative control 
and NHA was used as a non-cancerous control. The cells are also 
representative of the larger panel regarding metformin sensitivity and doubling 
time. 
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Culture P53 Status1 MGMT status Doubling time2 Metformin ID503 
U251MG Aberrant Partial methylation 24 4.83 (±2.11) 
IN859 Aberrant Methylation 24 4.52 (±0.6) 
IN2045 Aberrant Partial methylation 36 6.41 (±3.5) 
IN1682 Wild type - 50 24.87 (±5.41) 
IN 1760 Wild type Partial methylation 40 11.59 (±5.05) 
NHA Wild type Unmethylated 63 84.3 (±8.50) 
 
 
3.4.2 Induction of apoptosis 
Apoptosis was assessed by cellular staining with Annexin V and 7-AAD followed 
by flow cytometric analysis. For this technique, apoptosis was determined by 
tracking progression of cell populations through three predefined gated 
quadrants and an example of this progression can be seen in Figure 3.13. 
Separation by quadrants allows for division of the cell population based upon 
positive binding of appropriate fluorophores. The lower left quadrant 
represents live cells with a negative binding for both chemicals. The lower 
right quadrant indicates positive binding of annexin V to phospholipid 
phosphatidylserine. This protein, normally held facing the cytosolic (inner) of 
the cell membrane, is important for extracellular signalling in apoptotic 
pathways (Segawa and Shigekazu, 2015). The proteins become exposed as 
an early indicator for cellular apoptosis (Koopman et al., 1994). However, once 
the cell enters the later stages of cell death, the cell membrane inevitably 
becomes permeable allowing the annexin V to diffuse into the cystol and reach 
the internal membrane. The second dye, 7-AAD, is used to distinguish 
between healthy cells and dead cells. 7AAD is a DNA binding agent that 
1The mutation status of P-53; 2Doubling time in hours; 3ID50 of drugs after 96 hours treatment 
given in mM concentrations  
 
Table 3.17 List of characteristics for tumours selected for flow cytometry analysis 
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intercalates between cytosine and guanine bases (Xiucai et al., 1991; Philpott 
et al., 1996). However, it is unable to normally bypass the cellular membrane. 
This defines 7-AAD negative cells as possessing a functional membrane and 
7-AAD positive cells (upper two quadrants) possessing damaged cellular 
membranes. 
Early apoptosis would then be identified by binding of annexin V, resulting in 
an increase in the FL2 channel. An increase in FL3 indicates that 7-AAD-A can 
cross into the cell and that the cellular membrane has been compromised, 
equivalent to late stage cell death. To confirm apoptosis, the cells must be 
measured over time a course to detect shifts in the cell populations as shown 
in Figure 3.13.  The technique is unable to define the mechanism of cell death 
once the cells reach the upper right quadrant. In the later stages of necrosis, 
autophagy and apoptosis, the membrane has the same permeability and 
hence, this method is unable to distinguish the different cells. The possible 
outcomes from flow cytometric analysis are summarised in Table. 3.18 
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A 
 
B 
 
C 
 
 Figure 3.13 Identification of apoptosis across a time course through flow 
cytometry. A: Untreated samples showing a strong population in the bottom left quadrant. B: 
Samples treated with camptothecin for 72 hours. A new population in the bottom right 
apoptotic quadrant indicates binding of annexin V with no damage to permeability of cell 
membrane. This is a strong positive detection of apoptosis. C: Camptothecin treated cells at 96 
hours. Population has shifted into the top right dead quadrant. Cells are confirmed as dead as 
membrane has become permeable and 7-AAD is able stain DNA. 
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Analysis of cell membranes for apoptotic markers was completed over a 96-
hour time course. Readings were taken at intervals of 24 hours for a period of 
96 hours for all samples. Cultures were treated at the ID50 value for metformin 
and growth media containing either high (6mM) or low (3mM) concentrations 
of glucose and compared with an untreated control (using water as a vehicle). 
For all cultures, 72 hours treatment with 100µM camptothecin was used as a 
positive control for induction of apoptosis. Figure 3.14 shows a comparison of 
an apoptotic positive result with an untreated control. Figure 3.15a and 3.15b 
show an example of a completed apoptotic time course. 
 
 
 
 
 
 
Quadrant Label Annexin V (FL2) 
7-AAD 
(FL1) 
Lower left Live cells Negative Negative 
Lower right Apoptotic cells Positive Negative 
Upper right Dead cells Positive Positive 
Upper left Permeable membrane/Necrotic cells Negative Positive 
Table 3.18 Interpretation of binding of the different fluorochromes to measure 
apoptosis  
 
Describes the potential outcomes from flow cytometry analysis of apoptosis 
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A) Untreated  
 
 
B) Treated 
 
 
 
 
 Figure 3.14. Apoptosis was induced in U251MG using 100µM camptothecin over a 
96-hour period. A) Untreated control cells. Limited positive binding of annexin V. B) 
Camptothecin induced apoptosis. Large population in bottom right quadrant. Dead cell 
population also increased. Coloration in graph indicates quadrant. Blue – Live cells, Green – 
apoptotic cells, Red – Dead cells. 
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 Figure 3.15a 96-hour apoptotic time course of IN2045 treated with metformin in 6mM 
culture media. A) Untreated samples. Minimal variation in the live cell population over the time 
course. No increase in apoptosis. B) ID50 metformin treated samples. After 72 hours of metformin 
treatment dead cell population rises rapidly. No sign of generation of apoptotic population. Coloration in 
graph indicates quadrant. Blue – Live cells, Green – apoptotic cells, Red – Dead cells. 
A) Untreated 
B) Treated 
6mM Glucose 
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 Figure 3.15b 96-hour apoptotic time course of IN2045 treated with metformin in 3mM 
culture media. A) Untreated samples. Minimal variation in the live cell population over the time course. 
No increase in apoptosis. B) ID50 metformin treated samples. After 72 hours of metformin treatment 
dead cell population rises rapidly. No sign of generation of apoptotic population. Coloration in graph 
indicates quadrant. Blue – Live cells, Green – apoptotic cells, Red – Dead cells. 
A) Untreated B) Treated 
3mM Glucose 
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Figure 3.15a shows that when IN2045 cells are grown in media containing 
6mM glucose, metformin induced cell death appears after 72 hours of drug 
treatment. No apoptotic sub-population is detected across the time course. In 
the progression from 72 to 96 hours, the dead population increased above 
30% although there was no increase in annexin V uptake. At the 96-hour time 
point a population is present in the upper left region. This quadrant indicates 
binding of 7-AAD without positive binding of annexin V and is indicative of 
possible necrotic cell death. Figure 3.15b shows a 96-hour time course of 
IN2045 grown in media containing 3mM glucose and the ID50 concentration 
of metformin. There was no induction of apoptosis or increase in cell death in 
untreated cultures. However, in the metformin treated cells, a large dead cell 
population was evident after 48 hours. Across the time course there was no 
increase in the apoptotic population but progression of cells from lower left 
quadrant directly to upper right quadrant.  The live cell population was 
reduced to a minority after 72 hours. In comparison to the camptothecin 
induced positive control illustrated given in Figure 3.14, the population of cells 
in Figures 3.15a and 3.15b transition from a live state to death without 
progressing through the apoptotic quadrant.  Figures 3.16, 3.17, 3.18, 3.19, 
3.20 and 3.21 show data at different time points for each culture time course 
with different treatment types. Across all time courses there was no clear 
progression of cells through the three quadrants (Live cells --> Apoptotic cells 
--> Dead cells). No significant (p<0.05) change in the apoptotic quadrant was 
observed in any of the treatment conditions. However, all GBM cultures 
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showed significant population differences in the live and dead cells populations 
after 96 hours of treatment with metformin. NHA showed significant changes 
in both 6mM and 3mM live population but not in either dead population. 
Additional apoptotic time course for all cultures found in Appendix H.  
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 Figure 3.16a Apoptotic time courses for U251MG over 96 hours. A) Time course 
results. Coloured segments show % of cell population gated at each time point. Colours 
represent gating: Green – live cells, Orange – Apoptotic cells, Red – Dead cells, Black – 
Necrotic cells B) p-value results for statistical comparisons of each untreated and treated time 
point. Each level of statistical significance is denoted with a *.  
Apoptotic cells Dead cells Necrotic cells Live cells 
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U251MG            
6mM 
Glucose 
Untreated     
6mM 
Glucose 
Treated     
% 0hr 24hr 48hr 72hr 96hr % 0hr 24hr 48hr 72hr 96hr 
Live cells 88.46 90.5 94.8 91.63 91.8 Live cells 83.73 68 81.36 82.8 28.76 
Apoptotic 
cells 
6.73 5 3.1 4.46 2 
Apoptotic 
cells 
8.73 14.5 5.1 4.1 2.13 
Dead cells 3.96 2.5 1.16 3.266 3.43 Dead cells 6.56 13.2 10.7 9.7 33.7 
Necrotic 
cells 
0.83 1.8 0.4 0.6 2.8 
Necrotic 
cells 
1.2 3.4 2.16 3.33 36.06 
3mM 
Glucose 
Untreated     
3mM 
Glucose 
Treated     
% 0hr 24hr 48hr 72hr 96hr % 0hr 24hr 48hr 72hr 96hr 
Live cells 73.9 71.6 78.13 76.3 90.8 Live cells 85.43 75.16 77.16 22.13 6.6 
Apoptotic 
cells 
12.4 12.46 12.23 11.1 5.26 
Apoptotic 
cells 
8.4 11.63 10 4.167 25.03 
Dead cells 11.5 14.96 8.167 10.87 2.6 Dead cells 5.4 9.86 9.1 46.1 56.6 
Necrotic 
cells 
2.16 0.9 1.433 1.767 1.33 
Necrotic 
cells 
0.8 3.3 3.73 27.6 11.8 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.16b Apoptotic time course figures for U251MG over 96 hours. Averaged numerical 
data for apoptotic time course. Cells grown in 3mM or 6mM glucose growth media were treated with 
or without metformin. Populations were measured every 24 hours by flow cytometry to assess levels 
of apoptosis.  Values represent the percentage of the total population that fell within each gated 
quadrant. Colours represent gating: Green – live cells, Orange – Apoptotic cells, Red – Dead cells, 
White – Necrotic cells. 
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B 
 Figure 3.17a Apoptotic time courses for IN859 over 96 hours. A) Time course results. 
Coloured segments show % of cell population gated at each time point. Colours represent 
gating: Green – live cells, Orange – Apoptotic cells, Red – Dead cells, Black – Necrotic cells B) 
p-value results for statistical comparisons of each untreated and treated time point. Each level 
of statistical significance is denoted with a *. 
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IN859            
6mM 
Glucose 
Untreated     
6mM 
Glucose 
Treated     
% 0hr 24hr 48hr 72hr 96hr % 0hr 24hr 48hr 72hr 96hr 
Live cells 95.2 84.2 90.7 87.6 73.5 Live cells 86.4 80.5 88.6 73.2 7.2 
Apoptotic 
cells 
3 11.6 7 8.4 17.1 
Apoptotic 
cells 
7.4 12.5 8.7 10.7 6.4 
Dead cells 1.4 3.8 1.8 3.6 8.3 Dead cells 4.2 6.5 2.3 15.4 70.6 
Necrotic 
cells 
0.4 0.4 0.5 0.4 1.1 
Necrotic 
cells 
0.4 0.4 0.3 0.6 15.7 
3mM 
Glucose 
Untreated     
3mM 
Glucose 
Treated     
% 0hr 24hr 48hr 72hr 96hr % 0hr 24hr 48hr 72hr 96hr 
Live cells 85.3 85.4 81.1 79.2 71.7 Live cells 89.8 75.9 75.7 50.2 1.3 
Apoptotic 
cells 
8.9 7.6 12.1 12.3 19.1 
Apoptotic 
cells 
7.2 15.8 18.7 19.2 13.5 
Dead cells 5.9 6.1 5.6 6.9 8 Dead cells 2.1 7.7 5.2 29.7 82.7 
Necrotic 
cells 
0.5 0.8 1 1.4 1.1 
Necrotic 
cells 
0.7 0.4 0.2 0.8 2.4 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.17b Apoptotic time course figures for IN859 over 96 hours. Averaged numerical 
data for apoptotic time course. Cells grown in 3mM or 6mM glucose growth media were treated 
with or without metformin. Populations were measured every 24 hours by flow cytometry to 
assess levels of apoptosis.  Values represent the percentage of the total population that fell within 
each gated quadrant. Colours represent gating: Green – live cells, Orange – Apoptotic cells, Red 
– Dead cells, White – Necrotic cells. 
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 Figure 3.18a Apoptotic time courses for IN2045 over 96 hours. A) Time 
course results. Coloured segments show % of cell population gated at each time point. 
Colours represent gating: Green – live cells, Orange – Apoptotic cells, Red – Dead cells, 
Black – Necrotic cells B) p-value results for statistical comparisons of each untreated 
and treated time point. Each level of statistical significance is denoted with a *. 
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IN2045            
6mM 
Glucose 
Untreated     
6mM 
Glucose 
Treated     
% 0hr 24hr 48hr 72hr 96hr % 0hr 24hr 48hr 72hr 96hr 
Live cells 88.7 92.2 84.7 86 84.1 Live cells 88 87.1 83.9 56.3 18.5 
Apoptotic 
cells 
6.8 4.8 10.4 8.2 7.4 
Apoptotic 
cells 
8.1 5.8 11.1 12.4 10.4 
Dead cells 3.5 1.7 4.2 4.7 7.1 Dead cells 3.4 5.5 4.2 24.1 51.3 
Necrotic 
cells 
0.9 1.1 0.6 0.9 1.2 
Necrotic 
cells 
0.4 1.5 0.7 7.1 19.7 
3mM 
Glucose 
Untreated     
3mM 
Glucose 
Treated     
% 0hr 24hr 48hr 72hr 96hr % 0hr 24hr 48hr 72hr 96hr 
Live cells 87.3 86.7 80.9 82 83.3 Live cells 87.5 85.9 59 24.1 20.9 
Apoptotic 
cells 
7.6 7.1 9.4 10.4 6.7 
Apoptotic 
cells 
8.1 5.3 12.6 14.6 12.5 
Dead cells 3.8 5 8.8 6.8 8 Dead cells 3.8 7.2 22.2 52.1 52.4 
Necrotic 
cells 
1.2 1.1 0.8 0.6 2 
Necrotic 
cells 
0.5 1.6 6 9 14.1 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.18b Apoptotic time course figures for IN2045 over 96 hours. Averaged 
numerical data for apoptotic time course. Cells grown in 3mM or 6mM glucose growth media were 
treated with or without metformin. Populations were measured every 24 hours by flow cytometry 
to assess levels of apoptosis.  Values represent the percentage of the total population that fell 
within each gated quadrant. Colours represent gating: Green – live cells, Orange – Apoptotic cells, 
Red – Dead cells, White – Necrotic cells. 
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 Figure 3.19a Apoptotic time courses for IN1682 over 96 hours. A) Time course 
results. Coloured segments show % of cell population gated at each time point. Colours 
represent gating: Green – live cells, Orange – Apoptotic cells, Red – Dead cells, Black – 
Necrotic cells B) p-value results for statistical comparisons of each untreated and treated 
time point. Each level of statistical significance is denoted with a *. 
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IN1682            
6mM 
Glucose 
Untreated     
6mM 
Glucose 
Treated     
% 0hr 24hr 48hr 72hr 96hr % 0hr 24hr 48hr 72hr 96hr 
Live cells 89.2 86.5 83.7 90 91.5 Live cells 89 88.4 81 78.7 52.8 
Apoptotic 
cells 
6.4 8.3 10.8 5.6 5.4 
Apoptotic 
cells 
6 7.7 9.8 10.3 11.5 
Dead cells 2.1 3.8 4.2 2.6 2 Dead cells 3.5 2.2 6.6 7.7 30.8 
Necrotic 
cells 
2.1 1.3 1.2 1.7 0.9 
Necrotic 
cells 
1.5 1.6 2.6 3.1 4.7 
3mM 
Glucose 
Untreated     
3mM 
Glucose 
Treated     
% 0hr 24hr 48hr 72hr 96hr % 0hr 24hr 48hr 72hr 96hr 
Live cells 87.5 90 80.5 85.2 89.2 Live cells 90.3 85.4 82.9 59.8 25.3 
Apoptotic 
cells 
7.6 4.1 7.5 7.4 5.6 
Apoptotic 
cells 
4.9 7.2 7.6 11.3 19.5 
Dead cells 3.3 4.5 10.1 6.1 4.2 Dead cells 3.8 6.4 5.8 23.9 47.4 
Necrotic 
cells 
1.4 1 1.8 1.1 0.9 
Necrotic 
cells 
0.9 0.9 3.5 4.8 7.6 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.19b Apoptotic time course figures for IN1682 over 96 hours. Averaged 
numerical data for apoptotic time course. Cells grown in 3mM or 6mM glucose growth media were 
treated with or without metformin. Populations were measured every 24 hours by flow cytometry 
to assess levels of apoptosis.  Values represent the percentage of the total population that fell 
within each gated quadrant. Colours represent gating: Green – live cells, Orange – Apoptotic cells, 
Red – Dead cells, White – Necrotic cells. 
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 Figure 3.20a Apoptotic time courses for IN1760 over 96 hours. A) Time course 
results. Coloured segments show % of cell population gated at each time point. Colours 
represent gating: Green – live cells, Orange – Apoptotic cells, Red – Dead cells, Black – 
Necrotic cells B) p-value results for statistical comparisons of each untreated and treated 
time point. Each level of statistical significance is denoted with a *. 
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IN1760            
6mM 
Glucose 
Untreated     
6mM 
Glucose 
Treated     
% 0hr 24hr 48hr 72hr 96hr % 0hr 24hr 48hr 72hr 96hr 
Live cells 94.3 91.1 93 85.6 93.8 Live cells 91.8 85 90.7 84.5 39.2 
Apoptotic 
cells 
3.7 6.6 2.8 5.8 3.3 
Apoptotic 
cells 
4.5 9.5 5.1 9.2 6.7 
Dead cells 1.1 1.8 3.3 7.9 2.2 Dead cells 3.1 5 3.4 5.5 40.9 
Necrotic 
cells 
0.8 0.4 0.8 0.5 0.6 
Necrotic 
cells 
0.5 0.3 0.7 0.6 13.1 
3mM 
Glucose 
Untreated     
3mM 
Glucose 
Treated     
% 0hr 24hr 48hr 72hr 96hr % 0hr 24hr 48hr 72hr 96hr 
Live cells 94.2 91.8 91.7 87.3 93.3 Live cells 92 90.8 81.4 37.9 28.4 
Apoptotic 
cells 
3.6 4.7 4.8 6.2 4.1 
Apoptotic 
cells 
3.7 5.1 6.8 10 8 
Dead cells 1.3 3 2.9 5.7 2 Dead cells 3.7 3.5 9.2 42.8 52.6 
Necrotic 
cells 
0.6 0.5 0.4 0.6 0.6 
Necrotic 
cells 
0.4 0.4 2.5 9.2 10.9 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.20b Apoptotic time course figures for IN1760 over 96 hours. Averaged 
numerical data for apoptotic time course. Cells grown in 3mM or 6mM glucose growth media were 
treated with or without metformin. Populations were measured every 24 hours by flow cytometry 
to assess levels of apoptosis.  Values represent the percentage of the total population that fell 
within each gated quadrant. Colours represent gating: Green – live cells, Orange – Apoptotic cells, 
Red – Dead cells, White – Necrotic cells. 
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 Figure 3.21a Apoptotic time courses for NHA over 96 hours. A) Time course 
results. Coloured segments show % of cell population gated at each time point. Colours 
represent gating: Green – live cells, Orange – Apoptotic cells, Red – Dead cells, Black – 
Necrotic cells B) p-value results for statistical comparisons of each untreated and treated 
time point. Each level of statistical significance is denoted with a *. 
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NHA            
6mM 
Glucose 
Untreated     
6mM 
Glucose 
Treated     
% 0hr 24hr 48hr 72hr 96hr % 0hr 24hr 48hr 72hr 96hr 
Live cells 84.9 84.1 87.1 90.6 88.3 Live cells 86.6 84.3 82.5 75.8 67.9 
Apoptotic 
cells 
10.4 11.8 6.6 4.4 6.4 
Apoptotic 
cells 
8.6 8.7 8.1 11.6 9.1 
Dead cells 3.8 2.9 5.5 2.8 4.3 Dead cells 3.6 5 7.5 9.9 22 
Necrotic 
cells 
0.8 1.1 0.6 0.7 0.8 
Necrotic 
cells 
1 1.8 1.8 2.5 2.6 
3mM 
Glucose 
Untreated     
3mM 
Glucose 
Treated     
% 0hr 24hr 48hr 72hr 96hr % 0hr 24hr 48hr 72hr 96hr 
Live cells 86.1 89.7 87.8 90.9 86.2 Live cells 89.7 88.38 84.9 80.1 62.5 
Apoptotic 
cells 
8.4 3.9 4.9 3.9 6.6 
Apoptotic 
cells 
5.6 3.9 7.4 7.5 10.5 
Dead cells 3.8 5.5 5.23 3.8 5.9 Dead cells 3.7 6.4 6.4 10.9 24.6 
Necrotic 
cells 
1.5 0.9 1.96 1.6 1.1 
Necrotic 
cells 
0.8 1.16 1.1 1.4 2.4 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.21b Apoptotic time course figures for NHA over 96 hours. Averaged numerical 
data for apoptotic time course. Cells grown in 3mM or 6mM glucose growth media were treated 
with or without metformin. Populations were measured every 24 hours by flow cytometry to assess 
levels of apoptosis.  Values represent the percentage of the total population that fell within each 
gated quadrant. Colours represent gating: Green – live cells, Orange – Apoptotic cells, Red – Dead 
cells, White – Necrotic cells. 
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There were significant changes in the live population of metformin- treated 
U251MG cells at four-time points at 6 mM glucose (0, 24, 48 and 72 hours) 
and 3 points for 3mM glucose (0, 72 and 96 hours) (Figure 3.16). The changes 
at 72 hours and 96 hours are consistent with a decrease in live populations 
observed in other GBM cultures; however only, IN1760 also showed a similar 
change in live populations at 24 hours. the 24-hour time point, U251MG, 
IN2045 and NHA showed a significant increase in the dead cell population that 
did not persist to the next data point. Though all cultures showed significant 
decreases in live cells and increases in dead cell populations at the 96hour 
time point, IN859 showed this trend at 72 hours for 6 mM glucose and both 
IN1760 and IN2045 showed the same significant changes at 72 hours for 3mM 
glucose. Table 3.19 detailed the statistical average of each time course. 
Metformin treated NHA at 6mM glucose was the only time course that had a 
significant result (72h). All other time courses showed no significant changes 
in population level averaged across the time course.   
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Results of paired t-test for cultures apoptotic time courses. Compares the statistical average of each treated 
time course against the untreated control. Results showing statistical significance denoted by *. Cultures 
marked with a + are P53 wild type.  Results identified only NHA having a statistically significant change 
in necrotic cells. 
 
Table 3.19 Results of paired t-test for cultures apoptotic time courses.  
Time course p-values 6mM glucose Untreated - Treated 
 U251MG IN859 IN2045 IN1682+ IN1760+ NHA+ 
Live cells 0.1017 0.1879 0.1789 0.2433 0.2682 0.1535 
Apoptotic Cells 0.29 0.9275 0.1594 0.3086 0.1989 0.5037 
Dead cells 0.0684 0.2442 0.1879 0.2607 0.3377 0.1487 
Necrotic Cells 0.2788 0.3703 0.2424 0.1627 0.3958 0.0193* 
       
Time course p-values 3mM glucose Untreated - Treated 
 U251MG IN859 IN2045 IN1682+ IN1760+ NHA+ 
Live cells 0.2567 0.1733 0.1018 0.2328 0.1253 0.2145 
Apoptotic Cells 0.9358 0.3467 0.1521 0.2682 0.062 0.3201 
Dead cells 0.265 0.2659 0.102 0.245 0.1318 0.1891 
Necrotic Cells 0.1794 0.8731 0.0993 0.1541 0.1368 0.9057 
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3.4.3 Comparison of glucose levels to apoptotic time course 
Glucose concentration has been shown to impact the sensitivity of cancer cells 
to metformin (Zordoky et al., 2014). Data from glucose levels from Figure 3.12 
were aligned with the results of the apoptotic time course. Figures 3.22a and 
3.22b display the overlay of the time course results of glucose concentration 
and metformin-induced cell death.  Linear regression was used to assess the 
possible relationship between the amount of available media glucose and the 
percentage cell death. 
Significant increases in the population of dead cells were seen in all the GBM 
cultures grown in media containing 3mM compared to 6mM glucose (p<0.05). 
Two of the short-term cultures with TP53 aberrations, IN859 and IN2045, 
showed highly significant increases (p<0.005). However, significant increases 
in dead cells were not observed in any of the cultures grown in media 
containing at 6m, indicating that lower glucose levels significantly increase 
metformins toxicity. NHA showed no significant relationship between cell 
death and glucose concentrations, indicating that the increased sensitivity and 
cytotoxic effect identified in the 3mM time course is cancer-cell specific.  
The results of this analysis show that the availability of glucose and the 
metabolism of cancer cells have a significant factor in the mechanism of 
metformin-induced cell death. 
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Figure 3.22a Results of glucose and cell death comparison P53 aberrant cultures. 
Comparison analysis of glucose levels across time course compared with cell survival values 
taken from flow cytometry analysis for cultures U251MG, IN859 and IN1682. Flow cytometry 
values given as a percentage of population gated as dead cells. Glucose values measured in 
mM to two S.F.  
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Figure 3.22a Results of glucose and cell death comparison P53 wild type cultures. 
Comparison analysis of glucose levels across time course compared with cell survival values 
taken from flow cytometry analysis for cultures IN1760, IN2045 and NHA. Flow cytometry 
values given as a percentage of population gated as dead cells. Glucose values measured in 
mM to two S.F. 
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3.4.4 Mitochondria potential  
Analysis of mitochondrial membranes was completed to determine whether 
the mitochondria play an important role in the mechanisms of metformin 
cytotoxicity (Choi and Lim, 2014; Wheaton et al., 2014) Active measurement 
of mitochondrial membrane potential is affected by several factors and 
accurate assessment of the membrane can be completed with flow cytometry 
(Darzynkiewicz et al. 2001). JC-1 is a membrane-permeable lipophilic cationic 
fluorochrome able to penetrate cellular and mitochondria membranes 
(Cossarizza et al., 1993). This feature allows its emission spectra to vary based 
on its relative concentration within cells and provide a reflection of ΔΨ. At low 
concentrations, JC-1 forms into monomers and at high concentrations it is able 
to aggregate into larger structures. This variation in behaviour enables the 
emission profile to be separated. When healthy cells are exposed to JC-1 it is 
taken up into the cell as monomers but is driven to accumulate with the 
mitochondria due to the polarized ΔΨ. Once enough JC-1 has penetrated the 
mitochondrial membrane, it begins to accumulate and form aggregates. 
If the ΔΨ is depolarised JC-1 is unable to penetrate the mitochondria and 
remains as monomers in the cytoplasm of the cell. JC-1, in both forms, appears 
on the FL-1 (green) channel; however, the formation of aggregates creates a 
shift in the red emission which can be measured on FL-2 (red). By gating the 
cells using the parameters, it is possible to separate the monomer and 
aggregate populations and measure any changes in ΔΨ as shown in Figure 
3.23a. 
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Figure 3.23a Flow cytometry gating for the separation of JC-1. Flow cytometry gating to 
separate monomer and aggregate populations of JC-1 in GBM cells. The red gate (A) selects for 
aggregate JC-1 populations that occur within the mitochondrial matrix. Populations in this gate have 
a polarised mitochondrial membrane that allows the JC-1 monomers to pass into the mitochondria, 
increase in concentration and form aggregates. The green gate (B) selects for monomer JC-1 
populations that occur in the cytoplasm of cells. Populations in this gate have a de-polarised 
mitochondrial membrane that blocks JC-1 monomers entering the mitochondria. Monomers remain in 
the cytoplasm of the cells and do not form aggregates.  
ΔΨ Polarised membrane 
JC-1 aggregate gate 
ΔΨ De-polarised membrane 
JC-1 monomer JC-1 gate 
A 
B 
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Five GBM cultures and NHA were assessed by flow cytometry for depolarisation 
of the mitochondrial membrane potential. Cells were treated with metformin 
for 96 hours with the ID50 concentrations in media containing 6mM glucose. 
Cells were analysed at 72-hour time point before the full completion of the 
cytotoxic time course. 
Examples of mitochondrial depolarisation after 72 hours of 100µM 
camptothecin treatment are given in Figure 3.23b. Post-camptothecin 
treatment, the population of cells shifts to a higher reading on the FL1 channel. 
Positive depolarisation was defined by shifts from red P4 gate to green P5 
gate.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23b Depolarisation of the mitochondrial membrane by camptothecin. U251 MG 
cells were treated with 100µM camptothecin for 72 hours. Readings assessed based on FL1-A vs FL2-
A readings. Apoptosis results in depolarisation of ΔΨ, shift in the FL1-A and reduction in FL2. Flow 
cytometry gating for depolarisation based on BD Biosciences template and adapted to GBM cultures 
based on repeat camptothecin treatments.  Lower green gating (P5) shows JC-1 monomers unable to 
enter mitochondrial membrane, upper red gating (P4) shows the red shifted aggregated JC1 
accumulating inside the mitochondria.  
A: Untreated 
Healthy polarised 
membrane 
 
B: Treated 
Unhealthy de-polarised 
membrane 
Treatment time 
72 hours 
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U T 
1 
U251MG 
U T 
1 
IN859 
U T 
1 
IN2045 
Figure 3.24a. Measurement of mitochondrial membrane potential in P53 
aberrant cultures. Red U-Untreated cultures, T-Cultures treated with metformin at 96 
ID50 value.   Lower green gating (P5) shows JC-1 monomers unable to enter 
mitochondrial membrane, upper red gating (P4) shows the red shifted aggregated JC1 
accumulating inside the mitochondria. 
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U T 
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IN1682
+ 
U T 
1 
IN1760
+ 
U T 
1 
NHA+ 
Figure 3.24b. Measurement of mitochondrial membrane potential in P53 wild 
type cultures. Red U-Untreated cultures, T-Cultures treated with metformin at 96 ID50 
value.   Lower green gating (P5) shows JC-1 monomers unable to enter mitochondrial 
membrane, upper red gating (P4) shows the red shifted aggregated JC1 accumulating 
inside the mitochondria. Cultures marked with a + are P53 wild type. 
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Results for all cultures are given in table 3.21. There were significant 
reductions in all JC-1 aggregate populations and significant increases in 
monomer population for all cultures. This shows that metformin had a 
significant effect on depolarising the mitochondrial membrane. There was no 
statistical difference between cultures based on P53 status. Levels of 
monomers in untreated samples varied between cell cultures. The lowest 
monomer levels were seen in U251 17.50% (±1.51) and the highest values 
were seen in NHA 44.03% (±0.42).  The lowest response was seen in IN1682 
for which post treatment monomer values averaged to 55%. Examples of 
results for each culture are given in Figure 3.24a and Figure 3.24b. The 
experiments were not repeated under 3mM glucose conditions due to the 
strong positive response detected in mitochondrial membrane depolarisation 
for cells grown in media containing 6mM glucose. Results indicate significant 
depolarisation of the mitochondrial membrane occurs after 72 hours of 
metformin treatment at ID50 values at 96 hours.  The cytotoxic effect of 
metformin can have an impact on the membrane and functions of 
mitochondria regardless of P53 status. 
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 U T 
Aggregate1 Monomer2 Aggregate1 Monomer2 
U251MG*** 81.83 (±1.56) 17.5 (±1.51) 1.4 (±0.2) 98.36 (±0.15) 
IN859*** 69.43 (±2.11) 28.5 (±2.15) 4.2 (±0.56) 93.03 (±0.55) 
IN2045** 60.06 (±6.11) 36.06 (±3.18) 1.1 (±0.89) 97.13 (±1.96) 
IN1682+*** 78.86 (±2.31) 19.9 (±2.34) 37.93 (±5.33) 55.6 (±4.87) 
IN1760+*** 65.66 (±1.5) 32.5 (±1.56) 4.133 (±0.78) 95.16 (±0.85) 
NHA+*** 53.56 (±0.45) 44.03 (±0.42) 3.1 (±0.4) 94.93 (±0.42) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.20 Mitochondrial membrane potential depolarisation assessments 
 
Results of assessments of mitochondrial membrane across all cultures. Each level of statistical 
significance denoted by *. Cultures marked with a + are P53 wild type. 1Aggregate result represents 
JC-1 crossing the mitochondrial membrane and accumulating within. 2Monomer results represent 
JC-1 accumulating in the cytoplasm of cells and remaining in a monomer form.  
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3.4.5 Cell cycle 
Cell cycle analysis was carried out in five GBM cultures and NHA at 96 hours 
treatment with ID50 concentrations of metformin. Positive controls for 
apoptosis were created using 100µM camptothecin at 96 hours treatment 
which successfully generated sub-G1 populations and examples of induction 
of apoptosis and DNA fragmentation are given in Figure 3.25.  
Cell cycle analysis is shown in Figures 3.26a and 3.26b and Tables 3.22 and 
3.23. Five out of the six GBM cultures showed significant increases in G2/M 
population (Table 3.23). The P53 aberrant cultures all showed increases above 
12% and the P53 wild-type IN1760 has a 7.7% (±3.8) increase in G2/M. 
IN1682 showed a non-significant increase of 4.2% (±8.3). All cultures 
demonstrated a reduction in G0/G1 populations, U251MG and IN1760 showed 
significant reductions in this population. The only culture to show a significant 
change in S-phase was U251MG with an increase of 6.5% (±0.3). All other 
cultures showed an increasing trend in S phase population; however, it was a 
non-significant result. IN2045 was the only culture to show a significant 
change in sub-G0/G1. The culture showed a significant decrease in the 
apoptotic population; however, this result was an average reduction of 0.7% 
(±0.2). U251MG proved most sensitive to cell cycle changes as it was the only 
culture to show a significant change in all its cell cycle stages. The experiments 
were not repeated under 3mM glucose conditions due to the positive cell cycle 
arrest observed in G2/M phase of cell cycle for cells grown in media containing 
6mM glucose.  
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The results demonstrate that metformin treatment influences cell cycle 
progression through arrest at the G2/M step. The status of P53 was not a 
factor in observed cell cycle response, IN1682 had a weak response and 
limited G2/M arrest. There was no significant increase in apoptotic population 
in any culture tested. This would indicate no fragmentation of DNA has 
occurred in the cultures. G0/G1 populations were not significantly affected in 
most populations and only a small non-significant increase was seen in S-
phase in all short-term cultures, suggesting that the impact on cell cycle does 
not affect the checkpoints for either of the stages. 
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Figure 3.25 Camptothecin induced apoptotic positive cell cycle analysis. Cultures treated with 
100µM camptothecin for 96 hours. Cultures measured after remove doublet cells. Apoptosis results in 
degradation of DNA producing stained fragments with low FL2 values. Apoptotic region labelled V1-L, 
normal cell cycle region labelled V1-R. Variation was observed between cells populations apoptotic 
presentation:  A) U251MG – Wide peak that connects to G0/G1 population. B) IN1760 – Distinct sub 
population in sub-G0/G1 region separate from G0/G. C) IN859 – Wide population with no distinct peak. 
Populations coloured based on cell cycle stage: Red – Sub-G0/G1, Green – G0/G1, Pink – S-phase, Blue – 
G2/M.  
A B C 
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G0/G1 S G2/M Apoptosis1 
U T U T U T U T 
U251MG 
73.7 
(±6) 
55.1 
(±2) 
2.3 
(±0.2) 
8.9 
(±0.2) 
23.3 
(±5.7) 
35.7 
(±2.2) 
0.7 
(±0.3) 
0.4 
(±0.1) 
IN859 
66.2 
(±6.1) 
52.2 
(±7.8) 
7.1 
(±1.1) 
8.6 
(±1.1) 
25.5 
(±6.5) 
38.0 
(±5.9) 
1.2 
(±0.5) 
1.2 
(±1.0) 
IN2045 
70.8 
(±3.9) 
53.3 
(±4.4) 
6.2 
(±2.4) 
12.2 
(±2.4) 
21.8 
(±5.3) 
34.0 
(±5.1) 
1.2 
(±0.1) 
0.5 
(±0.2) 
IN1682+ 
66.4 
(±2.8) 
58.7 
(±3.9) 
10.6 
(±2.1) 
14.1 
(±2.1) 
20.3 
(±5.2) 
24.4 
(±3.1) 
2.8 
(±0.9) 
2.7 
(±1.3) 
IN1760+ 
83.6 
(±1.1) 
73.3 
(±4.7) 
3.2 
(±0.4) 
4.8 
(±0.4) 
8.1 
(±1.1) 
15.8 
(±0.9) 
5.1 
(±0.4) 
6.1 
(±0.2) 
NHA+ 
63.3 
(±1.1) 
58.1 
(±8) 
9.6 
(±1.5) 
12.2 
(±2.1) 
25.0 
(±0.6) 
25.1 
(±4.2) 
2.1 
(±1.0) 
4.5 
(±1.7) 
 
 
 
 
 
 G0/G1 S G2/M Apoptosis1 
U251MG -18.6% (±4.9) * +6.5% (±0.3) ** +12.4% (±4.4) * -0.4% (±0.3) 
IN859 -14% (±7.5) +1.5% (±4.6) +12.5% (±3.3) * 0% (±0.9) 
IN2045 -17.6% (±7.1) +6.0% (±2.5) +12.2% (±4.8) * -0.7% (±0.2) * 
IN1682+ -7.6% (±6.4) +3.5% (±5.2) +4.2% (±8.3) -0.1% (±2.3) 
IN1760+ -10.3% (±3.9) *  +1.7% (±3.8)  +7.7 (±0.3) * +1.0% (±0.5)  
NHA+ -5.2% (±7.1) +2.7% (±6.9) +0.1% (±4.7) +2.4% (±2.5) 
 
 
 
 
Table 3.21 Cell cycle assessments  
Results of cell cycle analysis of cultures after metformin. 1Apoptosis value represent 
sub-G0/G1 populations. U- Untreated, T- Treated with metformin 96-hour ID50 value 
for 96 hours.   
Table 3.22 Change in cell cycle populations   
Percentage changes in each cell population after 96-hours at ID50 metformin treatment. 
1Apoptosis value represent sub-G0/G1 populations. Each level of statistical significance 
denoted by *. Cultures marked with a + are P53 wild type.   
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U T 
U T IN859 
U T IN2045 
U251MG 
Figure 3.26a Cell cycle analysis in P53 aberrant cultures.  Cell cycle flow cytometry results of GBM 
cells, untreated (U) or treated (T) with ID50 metformin. DNA of cells stained with propidium iodide and 
measured on FL2-A. Gating of cell cycle stages based off untreated GBM sample. Populations coloured 
based on cell cycle stage: Red – Sub-G0/G1, Green – G0/G1, Pink – S-phase, Blue – G2/M. Increase in 
G2/M values of all GBM cultures indicative of G2/M cell cycle arrest.    
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IN1682+ U T 
U T IN1760+ 
U T NHA+ 
Figure 3.26b Cell cycle analysis in P53 wild types cultures.  Cell cycle flow cytometry results of 
GBM cells, untreated (U) or treated (T) with ID50 metformin. DNA of cells stained with propidium iodide 
and measured on FL2-A. Gating of cell cycle stages based off untreated GBM sample. Populations coloured 
based on cell cycle stage: Red – Sub-G0/G1, Green – G0/G1, Pink – S-phase, Blue – G2/M. Increase in 
G2/M values of all GBM cultures indicative of G2/M cell cycle arrest.    
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3.4.6 Caspase  
Caspase 3/7 analysis was carried out on six cultures treated with 96-hour ID50 
concentrations of metformin. Levels of caspase activity and SRB uptake were 
measured at 72 and 96 hours of drug treatment and normalised. A positive 
control for apoptosis was generated using 100µM camptothecin.  
The normalised results show no significant change in caspase 3/7 readings in 
GBM cultures at all time points and glucose measurements. NHA showed a 
significant decrease in caspase activity at 96-hour time points in both glucose 
concentrations. There was no trend in the changes of caspase activity after 
metformin treatment at any time point in GBM culture. P53 status of culture 
showed no difference in the observed response. Changes in relative light units 
(RLU) can be attributed to normal variation in generation of results.   No 
metformin treated culture generated a RLU of above 5x105 under any 
treatment conditions. Camptothecin (100µM) proved a strong positive control 
at inducing caspase activity in all cultures tested. The caspase activity detected 
for the camptothecin control exceeded an order of magnitude in all samples 
producing RLU values from 2x106 up to 3.7x106.    
Results indicate that metformin does not affect caspase 3/7 activity at 72 or 
96 hours of treatment in any GBM cultures. The RLU levels displayed by 
camptothecin show a strong increase in caspase apoptotic activity. This shows 
that the mechanism of cell death, following metformin treatment, in GBM 
appears to be independent of an increase of caspase 3/7 activity and this is 
not dependent on the P53 status of the cell. 
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P- Values for metformin treat cells in caspase 3/7 assay 
 
3mM Glucose 72 
hours 
3mM Glucose 96 
hours 
6mM glucose 72 
hours 
6mM Glucose 96 
Hours 
U251MG 0.0592 0.0631 0.0721 0.0821 
IN859 0.3817 0.2314 0.0811 0.624 
IN12045 0.0871 0.0645 0.7456 0.5741 
IN1682+ 0.7521 0.3645 0.4572 0.6521 
IN1760+ 0.4761 0.9821 0.3451 0.9451 
NHA+ 0.141 0.0495* 0.0789 0.0412* 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.23 Significance values for caspase 3/7 assay  
Comparative p-value results for all changes in RLU from caspase 3/7 assay treated 
with ID50 metformin. Increasing levels of significance are marked with *.  Cultures marked 
with a + are P53 wild type. 
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Figure 3.27a Caspase 3/7 assay results for U251MG. Results of measuring activity levels 
of caspase 3/7 in U251MG treated with 96-hour ID50 metformin with respect to glucose 
concentration. Readings taken at 72 and 96 hours. Normalised caspase value measured in 
relative light units normalised by an SRB control. 100µM camptothecin used to induce positive 
apoptosis. Value of camptothecin displayed are from 96-hour time point. Significant results 
marked with a * for each level of significance. 
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Figure 3.27b Caspase 3/7 assay results for IN859. Results of measuring activity levels of 
caspase 3/7 in IN859 treated with 96-hour ID50 metformin with respect to glucose 
concentration. Readings taken at 72 and 96 hours. Normalised caspase value measured in 
relative light units normalised by an SRB control. 100µM camptothecin used to induce positive 
apoptosis. Value of camptothecin displayed are from 96-hour time point. Significant results 
marked with a * for each level of significance. 
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Figure 3.27c Caspase 3/7 assay results for IN2045. Results of measuring activity levels 
of caspase 3/7 in IN2045 treated with 96-hour ID50 metformin with respect to glucose 
concentration. Readings taken at 72 and 96 hours. Normalised caspase value measured in 
relative light units normalised by an SRB control. 100µM camptothecin used to induce positive 
apoptosis. Value of camptothecin displayed are from 96-hour time point. Significant results 
marked with a * for each level of significance. 
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Figure 3.27d Caspase 3/7 assay results for IN1682. Results of measuring activity levels of 
caspase 3/7 in IN1682 treated with 96-hour ID50 metformin with respect to glucose concentration. 
Readings taken at 72 and 96 hours. Normalised caspase value measured in relative light units 
normalised by an SRB control. 100µM camptothecin used to induce positive apoptosis. Value of 
camptothecin displayed are from 96-hour time point. Cultures marked with a + are P53 wild type. 
Significant results marked with a * for each level of significance. 
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Figure 3.27e Caspase 3/7 assay results for IN1760. Results of measuring activity levels of 
caspase 3/7 in IN1760 treated with 96-hour ID50 metformin with respect to glucose concentration. 
Readings taken at 72 and 96 hours. Normalised caspase value measured in relative light units 
normalised by an SRB control. 100µM camptothecin used to induce positive apoptosis. Value of 
camptothecin displayed are from 96-hour time point. Cultures marked with a + are P53 wild type. 
Significant results marked with a * for each level of significance. 
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Figure 3.27f Caspase 3/7 assay results for NHA. Results of measuring activity levels of 
caspase 3/7 in NHA treated with 96-hour ID50 metformin with respect to glucose concentration. 
Readings taken at 72 and 96 hours. Normalised caspase value measured in relative light units 
normalised by an SRB control. 100µM camptothecin used to induce positive apoptosis. Value of 
camptothecin displayed are from 96-hour time point. Cultures marked with a + are P53 wild type. 
Significant results marked with a * for each level of significance. 
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3.4.7 Summary 
3.4.7.1 Apoptosis 
Overall, the combined experiments show very little evidence in favour of a 
caspase dependent apoptotic pathway as the main mechanism of cell death in 
GBM from metformin treatment. 
Results from the apoptotic time course showed that most of the cell death 
occurred at the 72 and 96-hour time points. This means that during the first 
48 hours of exposure, metformin exerted little effect on the cells. Metformin 
is not metabolised within the human body, it is excreted in the same format it 
enters cells (Bailey, 2017; Hassan and Carlton, 2018).  Metformin has been 
shown to be stable at physiological pH (Markowicz-Piasecka et al., 2018) so 
over this period is unlikely to be broken down and concentrations should be 
maintained.  Therefore, the lack of effect on the cells indicates that another 
mechanism may be mediating the cellular response to metformin. Levels of 
cell death in NHA were lower than the 50% that an ID50 dose should have 
generated. This discrepancy could be due to experimental differences with the 
SRB assay. The SRB assay is a measure of uptake of SRB into fixed cellular 
membranes (Skehan et al., 1990). The ID50 values generated include 
reductions in proliferation in addition to measurement of cytotoxic effects, 
whereas the apoptotic flow cytometry assessment measure cell death only 
(Telford et al., 1992). This may imply that metformin is mainly impacting NHA 
through reductions in proliferation. Cell cycle experiments demonstrated no 
Sub-G0 stained DNA, indicative of apoptotic cells (Pierre et al., 2014) (Chen 
et al., 2009). Instead a significant increase in G2/M region of all cultures 
indicates G2/M cell cycle arrest. 
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Induction of caspase was not observed in any culture. Caspase 3/7 are primary 
effectors at the end of the apoptotic caspase pathway, and hence the lack of 
a strong signal in any of the test cultures indicates that the metformin 
mediated response is independent of the caspase pathway. Though not 
common, caspase-independent pathways for cell death do occur in glioma 
(Du, et al. 2016). Cell death can also occur independently of caspase through 
necrosis or autophagy (Kitanaka and Kuchino, 1999; Kroemer and Martin, 
2005). Metformin has been associated with induction of autophagy (Tomic et 
al., 2011; Jivan et al., 2017). The results given here indicate that mechanism 
of action for metformin in GBM is unlikely to function through caspase-
mediated apoptosis. 
3.4.7.2 Response to Metformin vs Glucose uptake 
The data from the apoptotic time course shows that the majority of cell death 
occurred after 72 hours of exposure to metformin. The results of the 
regression analysis showed a significant relationship between glucose 
concentration and cell death was present in all the GBM culture time course 
experiments when cells were grown in media containing 3mM glucose. 
However, this relationship was not shown to be significant when cells were 
grown in media containing 6mM glucose. This shows that the metformin-
mediated cell death is mediated by low/zero glucose conditions. For all 
cultures, the initial 3mM concentration of glucose in growth media was 
reduced to 1mM glucose by 72 hours.  The cultures showed the highest values 
for cell death over the time course. The NHA culture was the only cell culture 
not to show a significant relationship between the change in glucose 
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concentration and cell death. Cell death was still detected, and glucose levels 
were also declining in the NHA cultures, so the lack of significance indicates 
that this is a cancer-specific relationship. 
It has been previously shown by Zhuang et al. (2014) that sensitivity of cancer 
cells to metformin was modulated by the amount of glucose present within 
the growth media as higher glucose concentrations reduced the efficacy of 
metformin and had a protective effect on the cells. Once glucose levels were 
lowered, metformin-induced cell death increased due to a reduction in 
metformin-stimulated glycolysis. The comparison of the apoptotic time course 
data against the glucose values from section 3.4.3 has shown a similar 
response with the majority of cell death appearing once the glucose level drops 
to below 1.1mM. Reducing the starting glucose also showed a significant 
relationship in all GBM cultures.  
Due to metformin observed effect of reducing blood glucose levels, it original 
name was glucophage, “the eater of glucose” (Fujioka et al., 2005).  This has 
since been corroborated with the effect of metformin treatment inducing 
cellular uptake of surrounding glucose (Koffert et al., 2017). 
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3.4.7.3 Mitochondrial membrane 
Depolarisation of the mitochondrial membrane was induced by metformin 
treatment. Metformin has been shown to impact mitochondria through 
inhibition of complex 1 of the mitochondria l respiratory chain (Owen et al., 
2000). In all GBM cultures, high levels of depolarisation were demonstrated, 
and this will impact metabolism within the cell and may lead to cell senescence 
(Ziegler et al., 2015). Mitochondrial membrane depolarisation sometimes is a 
sign of apoptosis (Gyulkhandanyan et al., 2015). This can lead to release of 
cytochrome C and activation of caspase apoptosis (Chen et al., 2015). 
However, the caspase 3/7 assay showed no increase in activity, limiting the 
potential of this pathway being mediated by metformin. An alternative 
mechanism of action was proposed by Wheaton (2014). In a study using 
293FT embryonal kidney cells, metformin impacted cell tumorigenesis through 
inhibition of mitochondrial complex I, causing a reduction in mitochondrial 
activity and cellular respiration. The depolarisation of the mitochondrial 
membrane demonstrated here could indicate that the mechanism of action of 
metformin within the cell is targeting the mitochondria and downstream 
effectors. 
3.4.7.4 G2/M Cell cycle arrest 
Cell cycle analysis showed a significant increase in G2/M phase post metformin 
treatment in four out of the five GBM cultures. The only one that did not 
demonstrate a significant increase was IN1682.  This increase indicates that 
cells are arrested at this division check-point. This form of cell cycle arrest 
maybe indicative of DNA damage (Cho et al., 2013) and damage to mitotic 
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spindle prevent progression the spindle assembly checkpoint (Fendzhi et 
al.,1998; Maria et al., 2004). 
Arrest at this checkpoint has been identified by Adeburg et al. (2017) who 
demonstrated in two GBM cell lines (Ln18, tP53 mutant and LN229, tP53 
mutant) that mM doses of metformin could induce G2/M arrest after 72 hours 
treatment. Cell cycle arrest at this pre-mitosis checkpoint from metformin 
treatment has also been observed in several other tumour types. In a 
colorectal cancer cell line (HCT116) metformin was shown to cause an 
accumulation of tumour cells in the G2/M phase and delayed DNA repair cause 
by ionizing radiation exposure (Jeong et al., 2015). This cell cycle arrest was 
seen in both cultures but more significantly in HCT116 P53-/- samples. G2/M 
has also been detected in drug-resistant leukaemia cells (Rodríguez-Lirio et 
al., 2015). In epithelial ovarian cancer, two cell lines (OVCAR-3, OVCAR-4) 
showed cell cycle arrest in the S and G2/M phases after 72 hours of metformin 
treatment. 
In contrast, metformin has also been seen to halt cells at the G0/G1 
checkpoint. In oesophageal squamous cell carcinoma, metformin caused 
G0/G1 arrest in a P53 dependent manner (Cai et al., 2015). In glioma studies, 
metformin was shown to induce cell cycle arrest in G0/G1 phase, however this 
was only seen in the C6 rat glioma cell line (Isakovic et al., 2007). This is the 
opposite of the results from this study. However, they also reported that 
significant levels of cell death were not induced by metformin treatment 
possibly due to the lower dosage of metformin used (5mM) and the differences 
between short term cultures and the C6 glioma cell line.  
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U251MG showed a significant increase in its S phase cell population post-
metformin treatment, the only culture in which such a response was observed. 
Cell cycle arrest in S phase would be advantageous in drug treatment due to 
sensitising the cells to chemotherapy and radiotherapy DNA damage (Wang 
et al., 2008). However, only U251MG showed a significant change, indicating 
this to be a feature gained by the cell line during long-term in vitro culture. 
Though primarily a response to DNA damage, the G2/M check point is affected 
by other factors including mitochondria. Due to the high energy demand, the 
G2/M cell cycle check point is partly coordinated by mitochondria metabolism 
(Wang et al., 2014). The mitochondria can also cause G2/M arrest through 
inhibition of the mitochondrial fission protein DRP1 (Qian et al., 2012). This 
protein has been shown to be reduced and inhibited in metformin-treated 
endothelial cells leading to reduced mitochondrial fission in an AMPK 
dependent manner (Wang et al., 2017). This work demonstrated that 
metformin does impact mitochondria in GBM with depolarisation of the 
mitochondrial membrane. Measurement of DRP1 in GBM cultures might 
indicate metformin is impacting G2/M arrest through this mechanism.   
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3.5 Metformins impact on miRNA expression 
Pulito et al. (2014) examined the role of metformin in reprogramming the 
metabolism of cancer cells, potentially, through an interplay with miRNA 
expression. A literature review highlighted nine miRNAs (miR-26a, miR-33a, 
miR-140, miR-142, miR-192, miR-200, miR-205 miR-222 and let-7c) that were 
modulated by metformin treatment and had relevant known targets in cancer 
These miRNAs are summarised in Table 3.25. The metformin miRNA cancer 
targets have been identified from studies of several cancers including breast, 
lung and pancreatic but also included the effect of metformin on circulating 
miRNAs in diabetic patients. 
3.5.1 TCGA miRNA GBM expression   
To assess the relevance of the metformin miRNA targets in GBM, data on 
miRNA expression was taken from the TCGA database and analysed for 
normalised expression. The TCGA contained five sets of miRNA microarray 
expression data for GBMs. The full array output files were restricted but miRNA 
count data was obtained. This data contained information on the reads of each 
miRNA and, was normalised by reads per million miRNAs mapped. To account 
for variation between the arrays, the output value for each miRNA was 
normalised against the value of miR-16; a commonly used miRNA reference 
control (Davoren et al., 2008). The relative expression of each miRNA, per 
million RNA was then mapped and is given in Figure 3.28.  
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miRNA 
Change in 
expression 
Target 
Known target in 
cancer1 
Reference 
miR-140-5p 
Down 
regulated 
Circulating 
miRNA in 
diabetic patients 
ADAM10 Kai Y et al., 2014 
TGFBR1; FGF9 Yang H et al., 2013 
DNMT1 Takata A et al., 2013 
HDAC4 Song B et al., 2009  
miR-222 
Down 
regulated 
Lung cancer, 
Circulating 
miRNA in 
diabetic patients 
MGMT Quintavalle C et al., 2013 
p27 le Sage C et al., 2007 
ADIPOR1 Hwang MS et al., 2013 
DKK2 Li Q et al., 2013 
ADAM17 Xu K et al., 2012  
PTPu Quintavalle C et al., 2012 
PTEN, p57 
Garofalo M et al., 2009; Wang Y et 
al., 2013 
miR-142-3p 
Up 
regulation 
Circulating 
miRNA in 
diabetic patients 
ADCY9 Huang B et al., 2009  
miR-192 
Up 
regulation 
Pancreatic 
cancer 
ZEB2 Wang B et al., 2010  
Bcl2 VEGFA Geng L et al., 2013  
let-7c 
Up 
regulation 
Pancreatic 
cancer 
RAS Johnson SM et al., 2005  
TRIB2 Wang PY et al., 2013 
Bcl-xL Cui SY et al., 2013  
ITGB3 MAP4K3 Zhao B et al., 2014  
MYC Nadiminty N et al., 2012  
MMP11 PBX3 Han HB et al., 2012  
miR-26a 
Up 
regulation 
Breast cancer, 
Pancreatic 
cancer 
EZH2 Lu J et al., 2011  
HMGA2 Palmieri D et al., 2012 
miR-200 
family 
Up 
regulation 
Murine 
embryonic 
fibroblasts 
ZEB1 Park SM et al., 2008  
ZEB2 Gregory PA et al., 2008  
SLUG Liu YN et al., 2013  
E2F3 Feng B et al., 2012  
SIRT1 Eades G et al., 2011  
miR-205 
Up 
regulation 
Lung cancer, 
Murine 
embryonic 
fibroblasts 
LRP1 Song H, Bu G, 2009  
ZEB1 ZEB2 Gregory PA et al., 2008 
PTEN Greene SB et al., 2010  
ERBB3 Wu H et al., 2009 
miR-33a 
Up 
regulation 
Breast Cancer 
MYC Blandino et al., 2012  
TWIST Zhou Y et al., 2014  
PIM-1 Thomas M et al., 2012  
 
Table 3.24 miRNA targets of metformin 
Data on identified miRNA targets of metformin treatment. 1Known target 
gene of miRNA in cancer. Adapted from Pulito et al. (2014). 
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Out of the nine miRNAs assessed, let-7c and miR-140 showed 10 times the 
expression levels of miR-16. Three miRNAs (miR-142, miR-192 and miR-26) 
showed similar or slightly raised expression values and four miRNA showed 
lower levels of expression.  
3.5.2 Qualitative assessment of miRNA expression 
Five short-term GBM cultures and the established GBM cell line U251MG were 
used to analyse the impact of metformin on miRNA expression. NHA was 
included as a control to assess relative expression of each miRNA in GBM 
cultures. This smaller cohort was representative of the larger culture panel, 
containing two P53 wild type GBM cultures and three P53 mutant cultures. All 
cultures were treated with ID50 values of metformin for 96 hours as given in 
table 3.2. After extraction and quantification, stem loop miRNA PCR was 
conducted on 100ng of total RNA. Amplification was successful for 4 of the 
miRNAs analysed as shown in Figure 3.29.  All other cultures showed no band 
Figure 3.28 GBM normalised expression levels of miRNA targeted by metformin. GBM 
miRNA array expression data from five data files stored on the TCGA. Number of miRNA reads was 
mapped per million miRNAs read and then normalised against miR-16. miRNA samples with more than 
one version had all version averaged before normalisation. 
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for expression in either untreated or treated well for all repeats tested. It is 
unclear if this was from lack of expression in miRNA or an unsuccessful primer 
design. Two miRNA showed upregulation in metformin treated samples; miR-
222 showed upregulation in five cultures (IN859, IN1979, IN1682, IN1760 and 
NHA) and miR-192 showed upregulation in four cultures (U251MG, IN1979, 
IN2045 and NHA). miR-140 showed upregulation in metformin treated sample 
of two cultures (IN1760 and NHA). Let-7c showed down regulation in the 
metformin treated samples of two cultures (IN2045 and NHA) and 
upregulation in two cultures (U251MG and IN1760). However qualitative 
results lacked an endogenous housekeeping control, due to lack of successful 
miR-16 PCR result and so results need to be quantitively analysed to assess 
absolute changes in expression.  
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Figure 3.29 miRNA stem loop PCR results.  GBM cultures and NHA results of stem loop 
PCR. Images shown are of samples showing positive band in either well. Results are paired by 
treatment type. U – Untreated control, T- Treated with metformin at 96-hour ID50. Cultures 
marked with a + and coloured grey are P53 wild type samples. Paired samples with a * indicate 
samples with visible change in intensity of band after metformin treatment. 
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3.5.3 Quantitative assessment of miRNA expression 
The seven cell cultures (U251MG, IN859, IN1979, IN2045, IN1682, IN1760 
and NHA) used in Section 3.5.1 were analysed by real time quantitative PCR. 
From the total RNA samples extracted in 3.5.1, 100ng per sample was used 
for Q-PCR. As an endogenous control, the non-coding small nuclear RNA U6 
was used (Lange et al., 2017). Each culture was analysed twice. Initially, the 
fold-change in miRNA expression between untreated GBM and untreated NHA 
results was determined. The fold-change in expression following treatment 
with ID50 concentrations of metformin for 96 hours treatment was also 
assessed. Values for fold change were measured by 2^-ΔΔCt. 
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3.5.3.1 miR-222  
All GBM cultures showed lower expression of miR-222 compared to NHA as 
shown in Figure 3.30. U251MG and IN2045 showed the highest expression 
levels at approximately a 0.4-fold change of NHA expression and expression 
was lowest in IN859 (0.02 fold). This low level of expression for miR-222 is 
consistent with the analysis of TCGA data described in Section 3.5.1 implies 
that miR-222 has expression levels in GBM lower than seen in normal tissue.   
 
 
 
 
 
 
 
 
Metformin treatment had a varied effect on the culture panel as shown in 
Figure 3.31. Five cultures showed a reduction in fold change after metformin 
treatment. Two P53 aberrant short-term cultures, IN859 and IN1979, showed 
increase in fold change greater than 1.5. The two cultures had the lowest 
expression relative to NHA. Even with this change in expression both cultures 
will still be lower than NHA. NHA also showed a reduction in miR-222 
Figure 3.30 Expression fold change of miR-222 - GBM relative to NHA.  Real 
time PCR analysis of miR-222 in GBM cultures. Fold change has been normalised against 
average expression level of miR-222 in NHA.   Cultures marked with a + are P53 wild 
type. All GBM cultures showed fold change values less than one, indicating a reduction 
in miR-222 expression in the GBM samples compared to NHA.   
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expression with metformin treatment. The results indicate that metformin has 
a culture specific impact on miRNA-222 and its expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.31 Expression fold change miR-222 post ID50 metformin treatment.  Real time 
PCR analysis of miR-222 in GBM cultures and NHA treated with 96-hour ID50 metformin concentration. 
Fold change has been normalised against average expression level of miR-222 in an untreated cell 
culture. Cultures marked with a + are P53 wild type. Two GBM cultures (IN859 and IN1979) showed 
fold change values greater than one, indicating an increase in miR-222 expression in the GBM samples 
after metformin treatment. Four GBM cultures (U251MG, IN2045, IN1682 and IN1760) and NHA 
showed fold change values less than one, indicating a decrease in miR-222 expression in the culture 
samples after metformin treatment. 
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3.5.3.2 miR-192 
Only two GBM cultures showed higher expression of miR-192 than NHA, the 
P53 mutant cultures IN1979 and IN2045. All other cultures expressed lower 
levels of miR-192 as shown in Figure 3.32. The low relative levels of miR-192 
expression are in line with the analysis of TCGA data.  In IN1979, expression, 
was x4.8 higher than NHA although this result did show the highest standard 
deviation of all the cultures. This result indicates that miR-192 has lower levels 
of expression in most GBM cultures when compared to normal tissue.  
 
 
 
 
 
 
 
 
 
 
 
All cultures tested showed an increase in expression of mir-192 after 
metformin treatment as shown in Figure 3.33. Three cultures showed a fold 
 Figure 3.32 Expression fold change of miR-192 - GBM relative to NHA.  Real time 
PCR analysis of miR-192 in GBM cultures. Fold change has been normalised against average 
expression level of miR-192 in NHA.   Cultures marked with a + are P53 wild type. Two GBM 
cultures (IN1979 and IN2045) showed fold change values greater than one, indicating an 
increase in miR-192 expression in the GBM samples compared to NHA.  Four GBM cultures 
(U251MG, IN859, IN1682 and IN1760) showed fold change values less than one, indicating a 
reduction in miR-192 expression in the GBM samples compared to NHA.   
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change greater than 10, IN1760, IN1682 and IN859. IN1682 possessed the 
greatest increase with a fold change of 39. Both IN1682 and IN859 were 
among the smallest expression relative to NHA. The larger fold change 
exhibited by the samples may be explained by the initial low expression of 
miR-192 relative to NHA. The remaining cultures showed small increases with 
IN2045 only having a fold change of 3.3. NHA showed a fold change of 4.4 in 
line with the rest of the panel.  
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Figure 3.33 Expression fold change miR-192 post ID50 metformin treatment.  Real time 
PCR analysis of miR-192 in GBM cultures and NHA treated with 96-hour ID50 metformin 
concentration. Fold change has been normalised against average expression level of miR-192 in 
an untreated cell culture. Cultures marked with a + are P53 wild type. All GBM cultures and NHA 
showed fold change values greater than one, indicating an increase in miR-192 expression in the 
culture samples after metformin treatment.  
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3.5.3.3 miR-140 
All but one culture showed lower expression of miR-140 when compared with 
NHA as shown in Figure 3.34. In the remaining culture, IN1682, expression 
was 5.3-fold higher than in NHA. In contrast, the TCGA data analysis showed 
that miR-140 is expressed in GBM samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.34 Expression fold change of miR-140 - GBM relative to NHA.  Real time 
PCR analysis of miR-140 in GBM cultures. Fold change has been normalised against 
average expression level of miR-140 in NHA.   Cultures marked with a + are P53 wild type. 
One GBM culture (IN1682) showed fold change values greater than one, indicating an 
increase in miR-140 expression in the GBM sample compared to NHA.  Five GBM cultures 
(U251MG, IN859, IN1979, IN2045, and IN1760) showed fold change values less than one, 
indicating a reduction in miR-140 expression in the GBM samples compared to NHA.   
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Metformin treatment increased the expression level of miR-140 in all cultures 
as shown in Figure 3.35 The greatest increase of >20 fold was observed in 
IN859. This culture possessed a negligible level of expression when compared 
with untreated NHA and hence, its larger fold change increase may be due to 
its low initial starting value. NHA did show a fold change of 1.4, this is nearly 
identical to the result for IN2045. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.35 Expression fold change miR-140 post ID50 metformin treatment.  Real time PCR 
analysis of miR-140 in GBM cultures and NHA treated with 96-hour ID50 metformin concentration. Fold 
change has been normalised against average expression level of miR-140 in an untreated cell culture. 
Cultures marked with a + are P53 wild type. All GBM cultures and NHA showed fold change values 
greater than one, indicating an increase in miR-140 expression in the culture samples after metformin 
treatment. 
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3.5.3.4 Let-7c 
Expression of Let-7c in GBM cultures were varied, as shown in Figure 3.36. 
Four cultures showed lower expression than NHA with fold change values less 
than 1 and two cultures, IN859 and IN2045, had fold change values below 
0.15. Two cultures showed higher expression of Let-7c than NHA with, 
U251MG and IN1760 having fold change values of 1.24 and 1.8, respectively. 
The TCGA data analysis in Figure 3.28 showed, that relative to the other assed 
miRNA, let-7c had a higher expression level than average. The results when 
measured against NHA would imply most GBMs have lower levels of expression 
than normal cells. All three of the P53 mutant cultures had a fold change less 
than 1, including two cultures with very low expression.  
 
 
 
 
 
 
 
 
 
 
Figure 3.36 Expression fold change of Let-7c - GBM relative to NHA.  Real time PCR analysis 
of let-7c in GBM cultures. Fold change has been normalised against average expression level of let-
7c in NHA.   Cultures marked with a + are P53 wild type. Two GBM cultures (U251MG and IN1760) 
showed fold change values greater than one, indicating an increase in let-7c expression in the GBM 
sampled compared to NHA.  Four GBM cultures showed fold change values less than one (IN859, 
IN1979, IN2045, and IN1682), indicating a reduction in let-7c expression in the GBM samples 
compared to NHA.   
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Expression of let-7c increased after metformin treatment in all GBM cultures 
as shown in Figure 3.37. Four of the cultures had fold changes > 2. U251MG 
has a fold change of 1.1 which was the lowest of all the GBM cultures. NHA 
showed a reduction in let-7c expression level after metformin treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.37 Expression fold change let-7c post ID50 metformin treatment.  Real time PCR 
analysis of let-7c in GBM cultures and NHA treated with 96-hour ID50 metformin concentration. Fold 
change has been normalised against average expression level of let-7c in an untreated cell culture. 
Cultures marked with a + are P53 wild type. All GBM cultures showed fold change values greater 
than one, indicating an increase in let-7c expression in the GBM samples after metformin treatment. 
NHA showed a fold change value less than one, indicating a decrease in let-7c expression in NHA 
after metformin treatment. 
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3.5.4 P53 status and miRNA 
Analysis of P53 status with regard to miRNA expression is shown in Table 3.26. 
This analysis separates the six GBM cultures based on P53 status and assesses 
if there is a significant difference in expression based on the cultures P53 
status.  In all of the miRNA analysis conducted none showed any significant 
difference when analysed in relation to P53 status. An overview of the results 
and this analysis shows the P53 is not a defining factor for determining miRNA 
expression with regard to normal tissue. It is also not a determinant for 
differential expression of the miRNAs investigated after metformin treatment.   
 
3.5.4 Summary  
The TCGA data showed that most of the known metformin miRNA targets have 
low relative expression levels in GBM. Only miR-140 and let-7c showed large 
increase in quantity of miRNA compared with miR-16. Stem loop PCR was able 
to detect several expressed miRNAs in GBM samples and detect changes in 
expression. However, the lack of an endogenous control to compare the result 
against reduces the usefulness of the technique. Q-PCR combined with U6 as 
an endogenous control produced reliable data for all miRNA tested, all of which 
showed a change in expression after metformin treatment. 
 
p-Value 
miRNA expression compared with 
NHA 
miRNA expression after 
metformin treatment 
miR-222 0.8869 0.5944 
miR-192 0.4872 0.2015 
miR-140 0.1829 0.8927 
Let-7c 
0.2482 
 
0.3077 
Table 3.25 Analysis of P53 status with regard to miRNA expression  
 
Results of un paired t-test to compare the difference in means of P53 sub groups.  
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Although the initial levels of expression were low, metformin reduced miR-222 
expression levels in 5 of the cultures. The remaining two had low levels of 
expression, below 0.2 with respect to NHA so with the resultant increase the 
cultures will still have minimal amounts of miR222. Although miR-222 is an 
important miRNA for growth and cardiac repair (Liu et al., 2015), it has been 
reported to have implications in a range of cancers. A function of miR-222 is 
as a regulator of p27kip1, the cell cycle regulator and tumour suppressor. It 
has been reported that in glioma, high expression of miR-222 is linked with 
suppression of p27kip1 (le sage et al., 2007) In lung cancer, metformin has 
been shown to reduce proliferation through inhibiting miR-222 and thus 
preventing it from inducing cell growth and cell cycle progression (Wang et 
al., 2013). In breast cancer, the miR-222 promotes tumour aggressiveness 
and metastasis (Shah and Calin, 2011). It functions as key factor in melanoma 
development and dissemination while being propagated through exosomes 
(Felicetti et al., 2016). However, the role is cancer specific, as miR-222 has 
been identified as a tumour suppressor in prostate cancer (Fuse et al., 2012). 
In diabetic patients, miR222 can act to accelerate cell proliferation and has 
found to be upregulated. The factors are alleviated in type 2 diabetics through 
metformin treatment (Coleman et al., 2013). Although low levels of miR-222 
were present in all cultures tested, it has strong tumour promoting properties 
and metformin may have part of its anti-tumour action through suppression 
of this miRNA.    
miR-192 expression levels in both the TCGA data analysis and GBM cultures 
was relatively low, although expression was elevated in one samples, IN1979. 
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The role of miR-192 has been identified as a tumour suppressor in a range of 
cancers. For renal cell carcinoma, miR-192 has been identified as functioning 
as part of a microRNA network, working alongside miR-193 and miR-215 to 
supress cell migration and invasion (Khella et al., 2013). This is similar to other 
studies linking miR-192 and miR-215 to a P53-dependent up-regulation 
induced by genotoxic stress (Georges et al., 2008). However, in the current 
study, there was no significant association between expression and P53 status. 
It has been reported that miR-192 is a key regulator of transcription factors 
EGR1 and HOXB9 which control tumour angiogenesis (Kondetimmanahalli et 
al., 2018). In colon cancer, overexpression of miR-192 inhibits metastatic 
colonization and sensitisizes cells to stress induced apoptosis (Geng et al., 
2014). However, miR-192 has conversely been negatively linked to cancer as 
well.  In renal and ovarian cancers, low expression of miR-192 has been linked 
to poor clinical outcome (Kondetimmanahalli et al., 2018). All cultures showed 
some upregulation of miR-192 with some showing large increases in 
expression after metformin treatment. The upregulation of miR-192 could be 
aiding metformins anti-tumour potential.   
miR-140 showed very low levels of expression in all cultures except IN1682 
that showed a 5-fold increase over NHA cells. This high-level expression is not 
significantly linked to P53 status as IN1760 had a fold change of 0.39. This 
low level of expression in cultures and cell lines relatively to normal controls 
has also been reported in ovarian cancer (Lan et al., 2015). This work also 
reported the role of miR-140 as a tumour suppressor. Overexpression in 
hepatocellular carcinoma inhibited proliferation and induced apoptosis. miR-
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140 has also been linked with regulation of the Wnt signalling pathway (Barter 
et al., 2015). In gliomas, miR-140-5p targets HOXA11-AS at 3’-UTR. HOXA11-
AS has been linked with poor patient prognosis and shorter survival (Yan et 
al., 2017). In colorectal cancer, it has been shown to be strongly associated 
with better survival through targeting of smad2 metastatic phenotype 
promotor (Zhai et al., 2015). 
Let-7c expression varied between GBM cultures. However, all the tumour 
cultures responded to metformin treatment with increased expression of Let-
7c.  Let-7c was also the only miRNA tested that showed a reduction in NHA, 
an inverse of the response seen in all of the GBM samples.  
In cholangiocarcinoma, let-7c has been identified as a tumour suppressor 
reducing mamo sphere generation (Lin et al., 2015). Let-7c also plays a role 
in chemo-resistance in bladder cancer, with decreased let-7c expression 
leading to reduced patient response (Vinal et al., 2016). In glioma, let-7c has 
been linked to enforcing progression differentiation within the cell, reducing 
stem-like qualities (Degrauwe et al., 2016). The mRNA binding factor IMP2 
binds to miRNA recognition elements and prevents let-7c silencing. This would 
be consistent with the low to similar expression when compared with NHA. 
The upregulation from metformin treatment may lead to silencing of let-7c 
target genes. Phenformin has also been shown to increase let-7c expression 
in GBM cultures (Jiang et al., 2015). Let-7c appears to have a tumour 
suppressor role in several cancers. Metformin may cause part of its cytotoxic 
and tumour supressing effects through this increase in miRNA expression.  
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The results here show that metformin has an impact on similar miRNAs to 
other cancer types as outlined by Pulito et al. (2014). GBM cultures did show 
a varied expression of miRNAs between cultures that was not linked to P53 
status. Metformin may exert some of its cytotoxic effect in GBM cultures 
through regulation of miRNA with tumour populations. 
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CHAPTER 4 
Final discussion and conclusions 
 
 
 
 
 
 
 
 
 
 
 206 
   
Chapter 4 - Final discussion and conclusions 
4.1 Discussion 
4.1.1 Metformin and P53  
Sensitivity to metformin was shown to be significantly linked to P53 
aberrations. Cultures possessing P53 mutations and deletions had significantly 
lower ID50 values than P53 wild type cultures. The relationship between P53 
and metformin has been demonstrated in a range of cancers. However, the 
inverse of this relationship, requiring the activation of P53 for sensitivity to 
metformin treatment has been observed in breast, hepatocellular, Hodgkin 
lymphoma, prostate, melanoma, and lung cancer (Ben Sahra et al., 2010; 
Cerezo et al., 2013; Do et al., 2014; Gu et al., 2015; Li et al., 2015; Sun et al., 
2016; Shimazu et al., 2017). In colorectal and uterine serous carcinoma, the 
effects of metformin were demonstrated to be P53 independent (Sarfstein et 
al., 2013; Abu el Maaty et al., 2017). Buzzai et al., (2007) demonstrated that 
P53 aberrant colon cancer cell lines had increased sensitivity to metformin 
over P53 wild type cell lines. They reported that under metformin induced 
cellular stress; wild type cells, but not aberrant cells, had an enhanced rate of 
glycolysis and reduced proliferation to increase cell survival. This was backed 
up by a study showing P53 wild type had a role in protecting metabolically 
impaired cells under the effects of glucose and nutrient limitation (Jones et 
al., 2005). The importance of nutrient deprivation was shown with the 
significant relationship of glucose concentration to cell death, as given in 3.4.3 
and demonstrated in cancer and breast cell lines (Menendez et al., 2012; 
Birsoy et al., 2014). This implies that GBM with a P53 mutation has potentially 
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higher sensitivity to metformin due to lack of metabolic control during glucose 
depravation.   
4.1.2 Synergistic response of Temozolomide and Sorafenib 
4.1.2.1 TMZ 
A synergy between metformin and TMZ in GBM has been demonstrated 
before. Yu et al. (2015) reported that treating the U251MG and U87MG cell 
lines with metformin and TMZ has a significant effect on inhibiting 
proliferation, inducing apoptosis and reduced gliosphere formation. This work 
demonstrated the same synergistic response in U251MG. However, variation 
was present within the short term GBM cultures. Only two of the seven cultures 
showed a synergistic response. The response was not linked to P53 status or 
MGMT methylation. Further characterisation of the cultures is needed before 
a relationship can be identified to explain the synergy results observed.   TMZ 
has been shown to induce apoptosis in GBM through activation of AMPK 
upregulating and activating P53 (Zhang et al. 2010). AMPK is a metabolic 
kinase, important in regulation of metabolism and proliferation of cells 
(Mihaylova and Shaw, 2011). The effects of AMPK activation have been shown 
to be augmented by, AMPK independent, AMPK agonists such as metformin 
(Liu et al., 2014). The AMPK agonists act indirectly through metabolic stress 
to cause further physiological AMPK activation. This net increase of AMPK 
further sensitises cells to TMZ (Yu et al., 2015).  
In addition to this, metformin also impacts AKT as part of the mTOR pathway 
(Mahvash et al., 2010). AKT activation and upregulation of the mTOR pathway 
is a common alteration in tumours and leads to increased cell proliferation and 
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survival (Alfonso et al., 2005; Sharma et al., 2015).  Inhibition of AKT has 
been demonstrated to enhance the cytotoxicity of TMZ (Chen et al., 2012). 
TMZ upregulates AKT however this is counteracted through metformin induced 
inhibition of AKT and the mTOR pathway (Yu et al., 2015). This synergism of 
the two drugs leads to increased TMZ sensitivity in GBM cultures.  
Lee et al. (2018) demonstrated using the cell lines U87MG, U251MG and A172 
that in addition to the effects on AMPK and AKT, a metformin TMZ combination 
decreases expression of fatty acid synthase (FASN). Cancers with high FASN 
activity have increased proliferation (Swinnen et al., 2002). In gliomas 
increased FASN activity has been correlated with WHO tumour grade (Grube 
et al., 2014). The use of FASN inhibitors was linked to reduction in cell viability 
and survival (Yasumoto et al., 2016).  
4.1.2.2 Sorafenib 
Sorafenib was shown to have a strong synergistic relation to metformin. All 
cultures showed an overall synergistic response to combination with only one 
culture (IN2045) showing some variation in its replicate results. As discussed 
in 3.2.4.1 the mechanism of synergy possibly stems from the dual pathway 
inhibition of the drug combination. Metformin impacting the cells through 
AMPK/AKT/mTOR and sorafenib impacting through RAF/MAPK (Aldea et al., 
2014). This joint effect of the pathways has been considered as an important 
therapeutic target for cancer cells (Chappell et al., 2011; Asati et al., 2016). 
The dual action of this drug has been hypothesised in hepatocellular carcinoma 
and is given in figure 4.1. 
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Figure 4.1 Proposed mechanism of metformin and sorafenib combination in 
hepatocellular carcinoma. When used in combination on hepatocellular carcinoma, metformin 
promotes activation of reactive oxygen species and upregulated AMPK causing mTORC1 inhibition. 
This is supported by sorafenib inhibiting mTORC2 by an unknown inhibitory mechanism. The co-
operation of these two drugs regulation on both mTOR complexes may promote autophagy. (Ling et 
al., 2016) 
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The pathways are commonly dysregulated in cancer and the effects of the 
inhibition have been observed in other cancers (Steelman et al, 2011).  
Molhoek et al. (2005) demonstrated a similar synergistic inhibition of the two 
pathways in human melanoma with B-Raf inhibitor and mTOR inhibitor 
rapamycin. Wang et al. (2008) demonstrated sorafenib combined with 
rapamycin had a synergistic response at inhibiting hepatocellular carcinoma in 
murine models. The simultaneous inhibition of these pathways impacts several 
downstream factors including apoptotic, proliferative and differentiation 
pathways (Vivek et al., 2016). The results also demonstrate the importance of 
combination therapies and the use in the treatment of cancers. Several clinical 
trials have assessed sorafenib for use on GBM and showed moderate to no 
effect on progression free survival (Hainsworth et al., 2010; Hegi et al., 2011; 
Peereboom et al., 2013). The addition of metformin creating a dual pathway 
synergistic combination treatment may prove more effective.  
4.1.3 Metformin mechanism of cell death  
The summary of the results of section 3.4 indicate no sign of induced apoptosis 
from metformin treatment. Apoptotic time course analysis showed no 
significant changes in phospholipid membrane prior to cell death. Caspase 3/7 
levels showed no significant changes in activity post metformin treatment and 
assessed sub-G0/G1 populations showed no increase in cell cycle analysis. 
Mitochondrial membrane was depolarised in all cultures; however, this process 
can be independent of apoptosis and independent of caspase activation 
(Dussmann et al., 2003; Ly et al., 2003). P53 did not have a significant impact 
on any apoptosis related cell death analysis.   
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Metformin may act through another mechanism of cell death, both autophagy 
and necrosis have been linked to metformin. One study linked metformin and 
simvastatin treatment to receptor-interacting protein kinases (Ripk) 
dependent necrosis (Babcook et al., 2014). However, only U251MG, IN2045 
and NHA showed significant changes in necrotic cell populations and was not 
consistent across the time course. All other cultures showed no significant 
change in necrotic cells, instead showing significant dead cells. Autophagy is 
another mechanism linked to metformin treatment. Autophagy can become 
triggered in response to cellular stress and increases in cellular metabolic 
demands (Zhineng et al., 2011). Metformin can induce autophagy flux through 
regulation of AMPK (Zhang et al., 2017). Sesen et al. (2015) demonstrated in 
GBM cell lines (U87MG and U251MG) metformin induced autophagy. 
Therefore, autophagy is a possible candidate alternative mechanism through 
which metformin induces cell death in GBM short term cultures.  
A significant relationship between media glucose concentration and cell death 
over time was demonstrated in 3.4.3. Glucose deprivation has been 
highlighted as an important factor in metformins cancer cell lethality (Birsoy 
et al., 2014). Menendez et al. (2012) demonstrated that glucose concentration 
has a protecting effect on metformin induced cell death in breast cancer cells. 
Dosages of glucose of 10Mmo/L resulted in low levels of cell death and cell 
cycle arrest in G0/G1 phase, glucose depletion lead to increases in cell death. 
After 96-hours of metformin treatment, GBM cells under glucose starvation 
showed G2/M arrest and high levels of cell death.   
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4.1.4 Metformin G2/M cell cycle arrest 
Metformin induced G2/M cell cycle arrest in four of the five GBM cultures 
tested. IN1682 showed a non-significant increase in G2/M phase.  Metformin 
has been shown to impact cells through G2/M arrest in GBM cell lines and 
other cancer types (Jeong et al., 2015; Rodríguez-Lirio et al., 2015; Adeburg 
et al., 2017). Progression of the cell through cell cycle is managed by 
regulatory proteins called cyclin dependent kinases (CDK) that interact with 
cyclin proteins (Hydbring et al., 2016). The G2/M phase transition is managed 
by CDK1 with cyclin A and progression through mitosis is managed by CDK1 
with cyclin B (Vermeulen et al., 2003). Lee et al. (2016) demonstrated that 
treatment with metformin in lung cancer cell lines correlated with 
downregulation of CDK1/cyclin B leading to cell cycle arrest. In human salivary 
adenocarcinoma cell lines, showed G2 cell cycle arrest due to decreased 
expression in CDK1 after 48 hours of 4mM metformin treatment (Guo et al., 
2015). The activation of CDK1/cyclin B complex is required in the progression 
of cell cycle from G2 to the mitotic M phase (Choi et al., 2011). Measurement 
of CDK1/cyclin B and cyclin A may indicate if metformin utilises this mechanism 
to induce G2/M cell cycle arrest in GBM.   
4.1.5 Metformin impact on miRNA expression 
Metformin was shown to have an impact on the expression of four miRNA 
(miR-140, miR-192, miR-222 and let-7c). The miRNAs were outlined as known 
metformin cancer targets in Pulito et al. (2014). Five of the nine known 
metformin influenced miRNAs were not able to be detected in GBM cultures 
(miR-26a, miR-33a, miR-142, miR-200 and miR-205). Due to miRNAs abilities 
on post transcriptional regulation of mRNA, the dysregulation of pathways can 
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have a strong contribution to the tumour development, progression and 
therapeutic response (Iorio and Croce, 2012). MiRNA also have beneficial roles 
as diagnostic and prognostic biomarkers of cancer (Brown et al., 2017). 
Metformins impact on reducing miR-222 expression could counteract 
proliferation and invasion (le sage et al., 2007, Wang et al., 2013). miR-192 
has been outlined as a tumour suppressor and metformin was demonstrated 
to cause upregulation (Khella et al., 2013). miR-140 has been identified as a 
tumour suppressor and metformin treatment showed upregulation (Yan et al., 
2017). Metformins impact on miR-192 and miR-140 could counteract tumour 
growth. Let-7c is a tumour suppressor that enforces cell progression and 
differentiation regulation, the miRNA showed upregulation from metformin 
treatment (Degrauwe et al., 2016).  The results may indicate that metformins 
mechanism of action within, the inhibition of GBM cultures, is through 
modulation of miRNA expression.   
The differential expression of miRNA is being used to identify molecular 
subtypes within GBMS (Verzola et al., 2018). This would enable improved 
molecular diagnosis and the generation of targeted therapeutics. In two of the 
miRNA analysed (miR-192 and miR-140) there was an outlier with differential 
expression to the rest of the GBM cultures. In miR-192, IN1979 showed 
increased expression and in miR-140, IN1682 showed an increased expression 
profile. The observed difference is not explained through P53 status of the 
culture and may indicate molecular subtypes (Godlewski et al., 2017).   
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4.2 Conclusion 
This study showed the effect of metformin on a panel of short term GBM cell 
cultures. This unique group of cultures showed large variety in the response 
to metformin. The importance of this highlights the current over reliance in 
using immortal GBM cell lines and implies the possibility of generating results 
not representative of real GBM tumours.    
Metformin cytotoxically kills GBM cells but sensitivity varies and is significantly 
modulated by P53 status and the availability of glucose in the media. 
Phenformin also showed a significant link between P53 and metformin 
sensitivity but at a magnitude lower in dosage. This highlights the possibility 
of other analogues or formulations of metformin having an even greater 
response. Phenformin is a discontinued drug, however the strong response 
shown here does suggest that other biguanides may possess strong anti-
tumour properties. An obstacle in the application of other stronger biguanides 
will be overcoming the inherit negative side effects of biguanide drug use, that 
may need to be designed out to improve efficacy.   
Glucose mediated metformin sensitivity was seen in all GBM cultures tested. 
The availability of glucose is an important factor when assessing the potential 
of metformin in vivo. Understanding the role of glucose, other metabolites and 
micro environment on GBM sensitivity to metformin will help understand and 
utilize biguanides as a treatment.  
Metformin showed good synergy with sorafenib, this pairing should be further 
tested to see if it can be carried forward to clinical trials.  Metformin also 
showed some synergy with TMZ. Further characterisation will allow for the 
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possible identification of this metformin induced TMZ sensitive molecular sub 
group. Increasing GBM sensitivity to TMZ may be beneficial for some patients 
when used as part of combined therapy.  
We are progressing towards a new medical paradigm with personalised 
medical care, where treatment will be planned based on tumour molecular 
abnormality profile rather than tissue type or anatomical origin (Jackson et al., 
2015). The significant difference seen in P53 aberrant cells clearly highlights 
that a sub-set of GBM tumours might be advisably treated with metformin.  
The lack of detectable apoptotic cell death is also a novel result in GBM cell 
cultures. Reported cancer cells response to metformin varies between cancer 
type. This work identifies a non-caspase dependent, non-apoptotic cell death 
metformin response mediated by G2/M cell cycle arrest and mitochondria 
membrane depolarisation.  
4.2.1 Limitations 
There are several limitations inherent to this study and its techniques used.  
The use of short term cultures was a strong feature of the study as it provided 
a more representative model of original GBM tumours. However, the panel of 
short term cultures needed to be further characterised, genetically and 
epigenetically, to make full use of the variety present within the panel. This 
would also enable a more complete understanding of the variation in cellular 
response and identify potential treatment sub-groups.   
Short term cultures are more labour intensive compared to culturing immortal 
cells lines. This led to smaller groups of cultures being used for some 
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experiments. Due to the large variations in the culture doubling times it 
became a logistical problem to maintain many different short-term cultures, 
while also increasing the volume of each for experimental work.  This issue 
could be alleviated by more efficient planning and work flow structuring. 
Completing all required experiments on smaller batches of similar cultures 
would unify experimental setups and treatment times.    
Availability of biguanides for complete testing of metformin analogues was 
another limitation. The inability to source the drugs hindered expanding the 
scope of the work to the entire biguanide drug class.  
Measurements of glucose levels within the culture media is an area of study 
not commonly assessed but the results demonstrated here are limited by the 
equipment used. The repurposed diabetic meter was shown to yield results 
similar to the glucose standards tested, however it did not have the ability to 
measure glucose levels below 1mM. The acquisition of a custom designed 
measurement tool would enable a greater level of reliability and accuracy in 
glucose measurement.  
Analysis of cell death pathways was limited in the amount of techniques and 
avenues assessed. The analysis of apoptotic and cell cycle pathways needs 
examination at multiple points to definitively realise the complete mechanism 
of action utilised. In addition, the study did not assess necrosis or autophagy 
as possible mechanisms of metformin-based cell death. Analysis into these 
areas of work was outlined to be completed using western blotting and flow 
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cytometry. Problems arouse in the calibration of these techniques and no 
results were able to be reliably generated within the time frame of the work.  
The results of miRNA expression analysis did identify changes attributed to 
metformin treatment, however due to the nature of the technique only a small 
number of miRNA were assessed. Realtime PCR gives accurate expression 
level analysis, but it is a time and resource intensive technique with a low 
volume of throughput. The inclusion of miRNA micro-arrays would further the 
scope of analysis beyond individual miRNA samples to all expression changes 
for each GBM culture. 
4.3 Further study  
This study has identified metformin has potential use as a GBM treatment and 
worth further investigation. There are several directions this research could 
take. 
Metformin has a strong cytotoxic and metabolic effect on the cells, identifying 
the underlying mechanism of action utilized by metformin in GBM will help to 
identify potential partners and analogues. Western blotting and further flow 
cytometry would allow for this functional pathway analysis and should be the 
main start point of future research.  
Targets and areas of interaction of metformin within the cell are not well 
understood. Due to metformins lack of breakdown within normal tissue, it 
should be possible to utilize low dosage fluorescently labelled metformin to 
assess where metformin accumulates with GBM cells (Ferrera et al., 2012). 
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Follow up analysis using confocal microscopy could then generate 3D models 
to better visualise the results.  
Due to its already existing use, metformin could easily be repurposed and 
approved for other treatments if shown to be effaceable. However new 
derivates of metformin may prove to have superior anti-cancer attributes and 
open new avenues for drug development (Lam et al., 2018). Collaborating 
with other institutes to produce and test new chemicals would be a possible 
avenue of investigation but may be difficult to set up.  
Glucose starvation conditions showed to be a significant factor in GBM 
sensitivity. Further analysis into availability of glucose and other metabolites 
could aid in improving GBM drug sensitivity. This may indicate that the use of 
calorie restrictive diets, for example ketogenic diets, will benefit patients and 
aid in improving outcomes. The fate of glucose in metformin treated cells will 
also aid in understanding the mechanisms that are utilised. Pathway analysis 
through use of 13C-glucose labelling would allow for measurement of any kerb 
cycle and metabolic abnormalities (D’Alessandro et al., 2015).  
The improvement of cell culture modelling could be expanded on, primarily 
experimenting with different media types and different environmental 
conditions. The use of 3-D modelling and neuro spheres are the next step to 
closing the gap between scientific model and authentic growth conditions 
(Kaluzova et al., 2015). 
Hypoxia is a major factor that is not accommodated in the majority of cell 
culture work. The immense pressure and hyper-competitive densely packed 
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conditions present within a tumour are not represented by standard growth 
flasks and have effects on tumour proliferation (Mahase et al., 2017). Growing 
all cultures within hypoxic incubators, and examined only in hypoxic work 
stations, would allow for experiments to be conducted under hypoxic 
conditions.   
Metformin was demonstrated to affect the miRNA expression in GBM. Full 
analysis of all genomic miRNA through micro-arrays would generate a 
complete picture of metformins total effect on the miRNA expression profile 
for GBM.   
The results of this work have shown that metformins mechanism of cell death 
within GBM appears to be non-caspase non-apoptotic and utilises other factors 
including availability of glucose and miRNAs. This shows that the scope of 
metformins action has a wide affect over the GBM metabolism and has 
potential inter-play between several factors.  
The development of novel and repurposed treatments for GBM is a long and 
arduous process that has no guarantees of future success. The importance of 
this field of research will also likely grow over a time. If metformin, a derivate 
of metformin or another biguanide can prove to increase our understanding 
of GBM and cancer metabolism then its potential should not be overlooked.        
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Appendix A -Metformin treatment 72 Hour Individual graphs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A1 72 Hour SRB cytotoxicity assays for metformin. Result of SRB 
assay used to determine ID50 of metformin at 72 hours. P – Passage of the culture. 
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Appendix A2 72 Hour SRB cytotoxicity assays for metformin. Result of SRB 
assay used to determine ID50 of metformin at 72 hours. P – Passage of the culture. 
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Appendix A3 72 Hour SRB cytotoxicity assays for metformin. Result of SRB 
assay used to determine ID50 of metformin at 72 hours. P – Passage of the culture. 
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Appendix A4 72 Hour SRB cytotoxicity assays for metformin. Result of SRB assay 
used to determine ID50 of metformin at 72 hours. P – Passage of the culture. 
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Appendix A5 72 Hour SRB cytotoxicity assays for metformin. Result of SRB assay 
used to determine ID50 of metformin at 72 hours. P – Passage of the culture. 
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Appendix B -Metformin treatment 96 Hour Individual graphs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix B1 96 Hour SRB cytotoxicity assays for metformin. Result of SRB 
assay used to determine ID50 of metformin at 96 hours. P – Passage of the culture. 
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Appendix B2 96 Hour SRB cytotoxicity assays for metformin. Result of SRB 
assay used to determine ID50 of metformin at 96 hours. P – Passage of the culture. 
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Appendix B3 96 Hour SRB cytotoxicity assays for metformin. Result of SRB assay 
used to determine ID50 of metformin at 96 hours. P – Passage of the culture. 
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Appendix B4 96 Hour SRB cytotoxicity assays for metformin. Result of SRB assay 
used to determine ID50 of metformin at 96 hours. P – Passage of the culture. 
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Appendix B5 96 Hour SRB cytotoxicity assays for metformin. Result of SRB assay used 
to determine ID50 of metformin at 96 hours. P – Passage of the culture. 
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Appendix C -Phenformin treatment 72 Hour Individual graphs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix C1 72 Hour SRB cytotoxicity assays for phenformin. Result of SRB assay 
used to determine ID50 of phenformin at 72 hours. P – Passage of the culture. 
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Appendix C2 72 Hour SRB cytotoxicity assays for phenformin. Result of SRB assay 
used to determine ID50 of phenformin at 72 hours. P – Passage of the culture. 
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Appendix C3 72 Hour SRB cytotoxicity assays for phenformin. Result of SRB assay used 
to determine ID50 of phenformin at 72 hours. P – Passage of the culture. 
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Appendix C4 72 Hour SRB cytotoxicity assays for phenformin. Result of SRB assay 
used to determine ID50 of phenformin at 72 hours. P – Passage of the culture. 
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Appendix C5 72 Hour SRB cytotoxicity assays for phenformin. Result of SRB assay used to 
determine ID50 of phenformin at 72 hours. P – Passage of the culture. 
 
 236 
   
Appendix 4 - Disulfiram drug combination graphs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix D1 – Graphs representing the combination synergy experiments of metformin alongside disulfiram.  
All culture tested in solo and combination treatment in equimolar dosages in a 96-hour period. Cultures that showed synergy 
marked with a 
☨
. Disulfiram results show higher ID50 curves than metformin. Combination curves of most graphs are similar 
to metformin treatment leading to antagonist results.  All cultures marked with a + and shaded grey indicate P53 wild type. 
☨ 
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Appendix D2 – Graphs representing the combination synergy experiments of metformin alongside 
disulfiram.  All culture tested in solo and combination treatment in equimolar dosages in a 96-hour period. Cultures that 
showed synergy marked with a 
☨
. Disulfiram results show higher ID50 curves than metformin. Combination curves of 
most graphs are similar to metformin treatment leading to antagonist results.  All cultures marked with a + and shaded 
grey indicate P53 wild type. 
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Appendix E1 – Graphs representing the combination synergy experiments of metformin alongside 
temozolomide supplemented with copper chloride.  All culture tested in solo and combination treatment in 
equimolar dosages in a 96-hour period. Cultures that showed synergy marked with a 
☨
. Temozolomide results show lower 
ID50 curves than metformin. Combination curves of most graphs are similar to metformin treatment.  All cultures marked 
with a + and shaded grey indicate P53 wild type. 
☨ 
☨ 
☨ 
☨ 
Appendix E - Temozolomide drug combination graphs 
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Appendix E2 – Graphs representing the combination synergy experiments of metformin alongside 
temozolomide supplemented with copper chloride.  All culture tested in solo and combination treatment in 
equimolar dosages in a 96-hour period. Cultures that showed synergy marked with a 
☨
. Temozolomide results show 
lower ID50 curves than metformin. Combination curves of most graphs are similar to metformin treatment.  All 
cultures marked with a + and shaded grey indicate P53 wild type. 
☨ 
☨ 
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Appendix F1 – Graphs representing the combination synergy experiments of metformin 
alongside sodium oxamate.  All culture tested in solo and combination treatment in equimolar dosages 
in a 96-hour period. Cultures that showed synergy marked with a 
☨
. Sodium oxamate showed synergy in 
U251MG but no other cultures tested. In all other cultures metformin mono treatment had the lowest ID50 
values. All cultures marked with a + and shaded grey indicate P53 wild type. 
☨ 
☨ 
Appendix F - Sodium Oxamate drug combination graphs 
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Appendix F2 – Graphs representing the combination synergy experiments of metformin 
alongside sodium oxamate.  All culture tested in solo and combination treatment in equimolar 
dosages in a 96-hour period. Cultures that showed synergy marked with a 
☨
. Sodium oxamate showed 
synergy in U251MG but no other cultures tested. In all other cultures metformin mono treatment had 
the lowest ID50 values. All cultures marked with a + and shaded grey indicate P53 wild type. 
☨ 
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Appendix G1 – Graphs representing the combination synergy experiments of metformin alongside 
sorafenib.  All culture tested in solo and combination treatment in equimolar dosages in a 96-hour period. Cultures that 
showed synergy marked with a 
☨. All cultures showed strong synergy this is identifiable by the separation of the 
combination dosage response from the mono treatment results. 1All cultures marked with a + and shaded grey indicate 
P53 wild type. O marks a culture with an additive effect.  
O 
☨ ☨ 
☨ ☨ 
☨ 
☨ ☨ 
Appendix G - Sorafenib drug combination graphs 
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Appendix G2 – Graphs representing the combination synergy experiments of metformin alongside 
sorafenib.  All culture tested in solo and combination treatment in equimolar dosages in a 96-hour period. 
Cultures that showed synergy marked with a 
☨. All cultures showed strong synergy this is identifiable by the 
separation of the combination dosage response from the mono treatment results. 1All cultures marked with a + 
and shaded grey indicate P53 wild type. O marks a culture with an additive effect. 
☨ 
☨ 
☨ 
☨ 
☨ 
☨ 
☨ 
☨ 
 244 
   
Appendix H - Apoptotic time course results 
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Appendix H1 i 96-hour apoptotic time course of U251MG treated with metformin in 6mM 
culture media. A) Untreated samples. Minimal variation in the live cell population over the time 
course. No increase in apoptosis. B) ID50 metformin treated samples. Blue – Live cells, Green – 
apoptotic cells, Red – Dead cells. 
U251MG 
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Appendix H1 ii 96-hour apoptotic time course of U251MG treated with metformin in 3mM 
culture media. A) Untreated samples. Minimal variation in the live cell population over the time 
course. No increase in apoptosis. B) ID50 metformin treated samples. Blue – Live cells, Green – 
apoptotic cells, Red – Dead cells. 
U251MG 
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Appendix H2 i 96-hour apoptotic time course of IN859 treated with metformin in 6mM 
culture media. A) Untreated samples. Minimal variation in the live cell population over the time 
course. No increase in apoptosis. B) ID50 metformin treated samples. Blue – Live cells, Green – 
apoptotic cells, Red – Dead cells. 
IN859 
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Appendix H2 ii 96-hour apoptotic time course of IN859 treated with metformin in 
3mM culture media. A) Untreated samples. Minimal variation in the live cell population over 
the time course. No increase in apoptosis. B) ID50 metformin treated samples. Blue – Live cells, 
Green – apoptotic cells, Red – Dead cells. 
IN859 
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Appendix H3 i 96-hour apoptotic time course of IN1682 treated with metformin 
in 6mM culture media. A) Untreated samples. Minimal variation in the live cell 
population over the time course. No increase in apoptosis. B) ID50 metformin treated 
samples. Blue – Live cells, Green – apoptotic cells, Red – Dead cells. 
IN1682+ 
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Appendix H3 ii 96-hour apoptotic time course of IN1682 treated with metformin in 
3mM culture media. A) Untreated samples. Minimal variation in the live cell population over 
the time course. No increase in apoptosis. B) ID50 metformin treated samples. Blue – Live 
cells, Green – apoptotic cells, Red – Dead cells. 
IN1682+ 
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Appendix H4 i 96-hour apoptotic time course of IN1760 treated with metformin in 
6mM culture media. A) Untreated samples. Minimal variation in the live cell population over 
the time course. No increase in apoptosis. B) ID50 metformin treated samples. Blue – Live 
cells, Green – apoptotic cells, Red – Dead cells. 
IN1760+ 
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Appendix H4 ii 96-hour apoptotic time course of IN1760 treated with metformin in 
3mM culture media. A) Untreated samples. Minimal variation in the live cell population over 
the time course. No increase in apoptosis. B) ID50 metformin treated samples. Blue – Live cells, 
Green – apoptotic cells, Red – Dead cells. 
IN1760+ 
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Appendix H5 i 96-hour apoptotic time course of NHA treated with metformin in 6mM 
culture media. A) Untreated samples. Minimal variation in the live cell population over the time 
course. No increase in apoptosis. B) ID50 metformin treated samples. Blue – Live cells, Green – 
apoptotic cells, Red – Dead cells. 
NHA+ 
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Appendix H5 ii 96-hour apoptotic time course of NHA treated with metformin in 3mM 
culture media. A) Untreated samples. Minimal variation in the live cell population over the 
time course. No increase in apoptosis. B) ID50 metformin treated samples. Blue – Live cells, 
Green – apoptotic cells, Red – Dead cells. 
NHA+ 
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Appendix I - F-10 Growth media formulations used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix I1 Formulation of F-10 from Gibco Life Technologies. Standard 
formulation of F-10 used for culturing of all cultures.  
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Appendix I2 Formulation of F-10 from PAN Biotech. 
Formulation of F-10 used for all glucose experiments. PAN F-10 was 
supplemented with Glucose from Sigma UK.  
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